

The Standard Documents of tender to specialist Sectors Buying the Medicine

Contracting Entity: Ministry of Health / Environment / The State Company For Marketing Drugs Medical Appliances (kimadia)

Project Reference/Tender: Contract For The Supply of medicine will arranged on the recent balancfe
The Project Name/Tender: Med / 3 / 2020
Title of the Task: buying the medicine
Date: issued in date(day)... 9 / 2 / 2020.



The Standard Documents of tender to specialist Sectors

General Tender Buying the Medicine

Tender:Med /3 /2020 Reference Tender: recent Iraqi Federal Budget Date: 9 / 2 /2020



Invitation for Bids (IFB)

Tender: General Tender to Buying the Medicine

Tender No.: Med/ 3 /2020 on the recent Iraqi Federal Budget

IFB Number: 3

1. The Ministry of Health / Environment / The State Company For Marketing Drug AND Medical Appliances (kimadia

)invites the a bidders qualified to present the tenders that sealed & signer for contracting on supplying of medicine 2. will be adoption measures of public bidding in the process of tender where allowed to take part of all bidders from countries eligible legally as specified in the document of bidding.

3.Interested eligible bidders may obtain further information's from Ministry of Health / Environment / The State Company For Marketing Drug and Medical Appliances (kimadia)/**Drug Media Department& the Public Relations**- 5th floor ,position of MOH(Ministry of Health),E-mail (<u>dg@kimadia.iq</u>) &Kimadia website is(<u>WWW.kimadia.iq</u>) and inspect the bidding documents at the address given below from (8:30 AM) to (2:30 PM) at Baghdad time.

4.Bidders must meet the requirements of qualifications including: the legal, technical and financial requirements as mentioned in Bidding Document. A margin of preference for the pharmaceutical will be adopted from suppliers/ national factoriesgoods. Additional details shall be specified in the Bidding Documents (see the clause(30) priority national from the the Instructions To Bidders clause (30) from Bid informations sheet.

5.the interested bidders could purchase the complete set of Bidding Documents in English or Arabic Language upon submission of a written application to the address below and after payment of a non-refundable fee with lump sum as follows:

a- (1.000.000)one million Iraqi Dinar of the tender that less than (1.000.000) Dollars.

b- (2.000.000) two million Iraqi Dinar for the tender that more than (1.000.000) Dinar.
 Otherwise the offer will be neglected.

The way of payment, this duty will be cash & the Bidding Document will be sent as state in ITB (Instruction To Bidders) &the bidder who is previously participated in the re-announced bid to submit the previous purchasing receipt with the tender documents

6. Announcement date of this tender will be on 9/2/2020 and The date of conference convening will be on 4/3/2020 for responding the inquire of the participants against the tender.

Bids must be delivered at or before the end of formal work on 9/3 / 2020]. The late bids will be rejected. Bids will be opened in the presence of the bidders' representatives who choose to attend in person at the address below.



The date of opening the tender will be the day after closing date in Kimadia and in publicly form.

. All bids must be accompanied by a Bid Security at ratio 1% from the estimated cost on condition issued from Iraqi dependable bank according to report issued from the Iraqi central bank for the bank financial performance & it depend on

a- Bid Bond shall only be accepted if presented as a bank guarantee or legalize check or svtjh& the swift of a guarantee letter or direct bond are not accepted.

b-Bid Bond should submit by the bidder or any of the share holders of the company or companies participate under contract for the benefit of contracting party as mentioned in attached sample in Bidding Forms/part 4th.

c-Public companies exempt from submitting the bid bond & letter of guarantee good execution stipulated by instruction of implementation the contracts (no.2) year 2014.

d-the bond issued from company which contracted with it or with its legal authorized for issuing the bond under formal & certified authorization.

e-the submitting of bond should attachedwith litter of legalized issuing (private&secret)send toMinistry of Health / Environment / The State Company For Marketing Drug Medical Appliances (kimadia) by the bank who issued the bond. f-the bond should not conditional & for the favor of The Ministry of Health / Environment / The State Company For Marketing Drug Medical Appliances (kimadia)

g-the bond must issued by two languages (Arabic & English).

h-the primary insurance will be confiscated for who to be the successful upon his abstain for signing the contract after the notification with awarding matter & all other legal procedures will be taken against him that indicated in these instructions & confiscate the bid bonds for those who referred to him the tender when withdraw its bid during the period of validity after the closing of tender orrefused correction on his calculations mistakes in tender & its reflection or awarding decision & take legal actions set forth in the instructions of implementation the Government contracts against him.

i-Final bid bond expiration date be valid until after the end of validity tender specified in the documents of tender. 7. The address(es) referred to above is Baghdad/bab-AlmadhmMinistry of Health / Environment / The State Company For

Marketing Drug Medical Appliances (kimadia)/6th floor/Financial Dept. to submit the bid bond or Receipt &Opening the offers to submit the tenders

Tel.4157667, Mobil: 707705419074, switchboard: 8, 7, 5, 4158401 (switchboard with 4 line)

Contracting Entity The Ministry of Health / Environment / The State Company For Marketing Drug Medical Appliances (kimadia) Contracting Authority:PH.MUDHAFAR ALI ABBAS Title:Director General of The State Company For Marketing Drug Medical Appliances (kimadia) Signature: { singned }





	<u>MED/3/2020</u> لتوفير احتياج عام 2021
All human products must be of	f human recombinant origin wherever these are avialable in the markets.
For oral solution	on it is preferable: Syrup then Suspension and then Elixir
v i	ducts contain metabisulphite as following (Caution: this product contain ty cause broncho spasm in atopic & Asthmatic subjects)
It doesn't matter of all tablets the	nat approved in the national list as scored tab to be plain tab (Not scored).
The measuring unit of medica-1 mil	k powder weight is 400gm up to 1000gm (as upper limit)
.N.M.T. 10%	🗷 لا تزيد نسبة الكحول الموجودة في الشرابات (بشكل عام) عن
ئىلة N.M.T 5%،	🗷 فيما يخص شرابات الأطفال يفضل بدون كحول أو بنسبة ضئا
(Oily pre	p) يجب استخدام soft gelatin Capهمستحضرات soft gelatin Cap
فل CFC.	🗵 بحل الغاز الدافع CFC – free بحل الغاز الدافع
۱۰۰۰غم کحد اعلی	وحدة قياس الحليب الطبي (بودرة) باعتماد الوزن هي ٤٠٠ غم لغاية
note:Trade name is mentioned as an I	Example only and not limited to the trade name mentioned beside the item.
-	ملاحظة: ان الكلفة التخمينية هي للتعبئة اما الاحتياج الكلي فهو للو. ost is per packing size while the total need is for unit dose



	national_c	item	total2021	PACK SIZE	Mean Brand price \$	70% mean price	45% mean price	25% mean price
1	02-H00-014	Lipas 2000 - 10000IU Protease 200-600 IU Amylase 2000-10000 IU/gm لسهولة استخدامة للاطفال sachet ويفضل ان يكون بشكل	32200	20gm sachet	41.58	29.11	18.71	10.4
2	03-A00-044	Salbutamol as a base100mcg/metered Inhalation Aerosol Using of propellant 134a CFC -free is approved in these preparations - Salbutamol aerosol - Beclomethasone aerosol بما يعادل mcg100 (as sulphate or as base) Valita من اعتماد المادة الفعالة بشكل يعادل مusulphate or base Salbutamol Maniza من اعتماد المادة الفعالة بشكلها الصيدلانية وحسب المقر mcg ١٠٠ ليعادل بالميدورياً وباشكالها الصيدلانية وحسب المقر mcg ١٠٠ من يعادل بالمادة الفعالة بشكل الميدلانية وحسب المقر mcg ١٠٠ من يعادل بالميدورياً وباشكالها الميدولانية وحسب المقر من SPACER عن SPACER عن SPACER عن SPACER (بنسبه ١٢٠ (ويكون استيراد ال SPACER (بنسبه ١٢٠ (من كمية الاحتياج الكلي للبخاخات من كمية الاحتياج الكلي للبخاخات	1042038	200 dose	2.50	2.45	1.5	
3	03-B00-015	Beclomethasone dipropionate aerosol 250mcg/ each actuation (For adults only)	306483	200 dose		4.8	4	
4	03-D00-047	Icatibant as acetate injection 10mg\ml - 3ml pfs	1	3-ml PFS	1743.75	1220.63	784.69	435.94



	06-C00-033	Recombinant human protein TSH (thyrotropine alfa) injection 0.9 mg vial يحصر استخدامها في هذة المراكز اعلاه فقط لمرضى سرطان الغدد الكرخ / مستشفى / دائره صحه بغداد 1 الدرقيه الرصافه / مركز الغدد الصم والسكري /دائره صحة بغداد -2 دائره صحه مدينه الطب / قسم الطب النووي -3 دائره صحه نينوى / مستشفى الاورام والطب النووي -4 وزاره الصحه / مجلس السرطان / مستشفى الامل / قسم الطب - تحيث يتم اخذها بواقع (افيال) لكل النووي مريض ولمده يومين متتالين وبعد ذلك يتم اعطاءه ماده اليود المشع خاصه للمرضى كبار السن والامراض القلبيه والمزمنه والذين لايقدرون على ايقاف علاج الثايروكستن لمده شهر مما يؤدي الى مضاعفات صحيه للمريض	2548	2 vial kkit	850.00	595	382.5	212.5
5	06-E00-014	Fludrocortisone acetate 0.1mg Tablet	57000	100 tab	6.313	4.42	2.84	1.58
7	06-J00-010	mecasermin (recombinant human insulin - like growth factor - 1 rhl GF-1)Increlex inj mecasermin 10mg/ml (4 ml vial)	400	4ml vial	756.25	529.38	340.31	189.06
8	08-H00-016	Fibrinogen concentrate(Human):- Lyophilized powder for reconstitution 900 mg to 1300 mg for reconstitution with 50 ml of sterile water for injection-	220	1gm vial	425	297.5	191.25	106.25
9	09-AD0-023	calcitriol (1, 25 Dihydrocholecalciferol)(D3) 250 nanogram capsule	14000	100 cap	22.55	15.79	10.15	5.64
10	09-AD0-024	calcitriol (1, 25 Dihydrocholecalciferol)(D3) 1 mcg / ml injection (1 ml ampoule)	20	1ml ampoule	4.348	3.04	1.96	1.09



11	09-CD0-001	Anhydrus Sodium acid phosphate Anhydrous 1.936g+Sod.bicarbonate 350mg+Pot.bicarbonate 315mg equivalent to Phosphorous 500mg+Sod.468.8mg(20.4mmol Na+)+Pot.123mg(3.1mmol K+) Effervecent Tablet	15400	20 tab	4.1125	2.88	1.85	1.03
12	09-Ebi-001	milk formula for maple syrup urine disease (MSUD) patients for age (0_1) year Leucine,Isolucine and Valine free.	942	400 gm	54.633766	38.2436362	24.585195	13.658442
13	09-Ebi-002	milk formula for maple syrup urine disease (MSUD) patients for age (above1 year) Leucine,Isolucine and Valine free	3136	30*29gm sachet	291.8124	204.26868	131.31558	72.9531
14	09-Ebj-001	milk formula for tyrosinemia for age (from birth- 1year) phenylalanine,tyrosine free	300	400 gm	54.633766	38.24	24.59	13.66
15	09-Ebj-002	milk formula for tyrosinemia patients for age (above 1 year) phenylalanine,tyrosine free	192	500 gm	45	31.5	20.25	11.25
16	09-Ebk-001	milk formula for Homocystineuria patients for age (from birth-1year) Methionine free	160	400 gm	101.33	70.93	45.6	25.33
17	09-Ebk-002	milk formula for Homocystineuria patients for age (above 1year) Methionine free	450	500 gm	137.93294	96.55	62.07	34.48
18	09-Ebl-001	milk formula for glutaric acid uria patients for age (from birth_1 year) lysine and tryptophan free	200	400 gm	54.633766	38.24	24.59	13.66



		1		i			1	1
19	09-Ebl-002	milk formula for glutaric acid uria patients for age (above 1 year) lysine and tryptophan free	380	500 gm	45	31.5	20.25	11.25
20	09-Ebn-001	 milk formula for Isovaleric acidemia patients suitable (from birth – 1year) Leucine free 	60	400 gm	83.33	58.33	37.5	20.83
21	09-Ebn-002	 milk formula for Isovaleric acidemia patients suitable (above 1year) Leucine free 	180	500 gm	137.93294	96.55	62.07	34.48
22	09-Ebo-001	milk formula for methylmalonic academia / propionic acidemia patients suitable from birth. Methionine,Threonine, and Valine free	1000	400 gm	54.633766	38.24	24.59	13.66
23	09-H00-001	Mercaptamine (Cysteamine) as Bitartrate 50mg capsule	115040	100 cap	87.5	61.25	39.38	21.88
24	09-H00-002	Mercaptamine (Cysteamine) as Bitartrate 150mg capsule	179640	100 cap	237.5	166.25	106.88	59.38
25	09-H00-004	Laronidase 100 Untit / ml (5ml vial)	5384	5ml vial	792	554.4	356.4	198
26	09-H00-006	Zinc acetate 25 mg capsule	149380	250 cap	315	220.5	141.75	78.75
27	09-H00-008	Nitisinone (NTBC) 2 mg capsule or tab	7000	60 cap	705	493.5	317.25	176.25
28	09-H00-011	alglucosidase alfa 50 mg vial I.V. infusion	1476	1 vial	630	441	283.5	157.5
29	09-H00-013	Mercaptamine (Cysteamine) 0.55 % eye drop	6976	5ml eye drops solution of 0.55%	1000	700	450	250
30	09-H00-017	L . carnitine : oral pediatric solution 300 mg /ml (30 %) (20 ml)	4510	20 ml	26.25	18.38	11.81	6.56
31	09-H00-018	L . carnitine 200 mg / ml (5ml ampoule)I.V , I.M	370	5ml amp	14.875	10.41	6.69	3.72



32	09-H00-019	Miglustat 100 mg capsule	3120	84 cap	4917.7	3442.39	2212.97	1229.43
33	09-H00-020	imiglucerase. I.V infusion 400 unit/ vial () ب 2/ ب ج/ه ا ب 2/ ا ب 2/ () / / / / / /) ا ب 2/ ا ب 2/ ا ب 2/ ا ب 2/) / / / / / / / / / / / / / / / / / / /	11030	1 vial	1776	1243.2	799.2	444
34	09-H00-023	Betaine (anhydrous) powder (180 OR 300 gm)	272	180 gm	685.42	479.79	308.44	171.36
35	09-H00-024	galsulfase concentrate for I.V injaction 1 mg\ml (5ml-vial)	12965	5ml vial	1227.5	859.25	552.38	306.88
36	09-H00-025	Velaglucerase alpha 400 unit / vial ج/٦ ٤ ١. ج/٥ ٤ ٢ ج/٥ ٤ ٢ مفصلة تقرر اقرار النادرة واستعراض الحقائق العلمية بصورة مفصلة تقرر اقرار النادرة واستعراض الحقائق العلمية بصورة (imiglucerase & Velaglucerase) العقاريين بقائمة الامراض النادرة للجنة العلمية للامراض النادرة تحديد ونخول لعدد المرضى والحالات المسجلة "كمية الاحتياج من كل مادة وفقا للحقائق العلمية مع الزام الشركات المجهزة بتوفير "الجديدة والقديمة وفقا الفحوصات اللازمة لاثبات التشخيص والمتابعة لاستجابة المرضى و عدم بموجب كتاب "التلكؤ في ارسال النتائج وحسب ما جاء بمحضر اللجنة انفا ٢٠١٨/٩/٤ في ١٢٩٦ ٢. كيماديا المرقم ١٢٩٦ في ٢٠١٨/٩/٤	1264	1 VIAL	1,833.26\$			
37	09-H00-029	Carglumic acid 200 mg tab	1990	5 tab	388.7	272.09	174.92	97.18
38	09-H00-031	Agalsidase beta 35mg/ vial	876	1 vial	2855.56	1998.89	1285	713.89
39	09-H00-032	Idursulfase 2mg/ml vial	1653	1 vial	2,580.5\$			
40	09-h00-033	elosulfase alfa 5 mg / 5 ml solution for infusion vial	6498	1 vial	975\$			
41	10-AC0-005	Penicillamine 250mg capsule	30840	50 cap	15.7	11		



42	10-AC0-006	Penicillamine 250mg Scored Tablet		100 tab	22.225	15.557	10	5.556
43	15-AA0-028	Temozolomide 100mg capsule	58238	5 сар	295.00	150	132.75	73.75
44	15-AB0-011	Methotrexate inj as sodium salt 2.5 mg/ml, 2ml Ampoul OR vial ,subcutaneus,intrathecal للجادية والكلية	33070	1 vial	3.11	2.16	1.14	0.78
45	15-AB0-019	Fludarabine phosphate 50mg vial, powder for reconstitution, for I.V. inj. or infusion.	6161	1 vial	100.34	72	45.15	25
46	15-AB0-020	Cladribine (2-CDA) 10mg / Vial, 5ml Or 10ml يحصر استخدامه لعلاج اللوكيميا الشعيرية Leukemia)	1912	1 vial	211.43	148.00	84	52.86
47	15-AB0-022	cytarabine (for S.C, I.V.)100mg/ml, 10 ml vial. في حالة Intrathecal يجب ان يكون التركيز هو Intrathecal الاعطاء بطريقة الزرق	46065	1 vial	27.00	25	20	15
48	15-AB0-031	Decitabine I.V injection 50mg vial ج /٨٤٨ يستخدم فقط في مراكز امراض الدم والعيادات التخصصية لامراض الدم 1042 : يحصر استخدامه لعلاج 1042 لعلاج اعتلال نخاع العظم MDS لتوفر دراسات علمية تؤكد فعاليته في هذا المجال	12498	1 vial	1,116.6	781.6	502.5	279.2
49	15-AB0-033	Methotrexate vial 1g base i.v infusion على ان لايتجاوز التركيز I00mg/ml	15635	1 vial	32.30	22.63	14.54	12



50	15-AB0-034	mg vial، • • • : Pemetrexed (as Pemetrexed di - sodium) in Folate analogue تستورد بكميات قليلة (حصة مريض) ويصرف بموافقة لجنة استشارية حصرا ولمرضى ولمرضى (On need) بمعنى كميات محدودة تودع لدى مخازن الشركة ولاتصرف الا عند الحاجة ومن قبل لجنة استشارية حصراً ولمرضى Mesothelioma ان دواعي الاستخدام في سرطان الرئة هي الاتي:- Non Squamous, Non Small Cell Lung :subtypes Cancer(NSCLC)which include the following Adenocarcinoma Large cell (NSCLC NOS(nonspecific subtype It is indicated as neoadjuvant, adjuvant, and maintenance advanced and metastatic non squamous in locally second and third •NSCLC as a treatment option in first line treatment in patients with performance status 0-2	12275	1 vial	1,165.00	815.5	390	291.25
51	15-AC0-014	Mitoxantrone as Hcl , concentrate for I.V. infusion, 2mg/ml, 10 ml vial	1414	10-ml vial	140.00	57		
52	15-AC0-018	Doxorubicin Hcl (pegylated liposomal)conc.for i.v infusion 2mg/ml(10ml vial)i.e inj pegylated Doxorubicin Hcl 2mg /ml incapsulated in liposomes	13278	10-ml vial	388.39	271.87	174.78	97.10
53	15-AD0-004	Etoposide concentrate for I.V. infusion 20mg/ml, 5 ml vial OR Ampoul	56414	5-ml vial	11.57	8.1	5.2	2.89
54	15-AD0-006	Vinblastine sulphate 1 mg/ml, 10 ml vial or ampoul.	9266	1 amp or 1 vial	25.00	20	15	10
55	15-AE0-003	Recombinant asparginase (E-coli type) 10.000 unit vial powder for concentrate for solution for infusion	7993	1 vial		161.3		
56	15-AF0-010	ايضا يستخدم كعلاج في Hydroxyurea 500mg Capsule مراكز امراض الدم الورائية وخاصة مرض فقر الدم المنجلي sickle cell anemia)	1105913	100 cap	40.00	28	18	15



57	15-AF0-011	Octreotide 0.05mg/ml Injection استخدام المادة لحالة (Acute Variceal Hemorrhage)	24217	5 amp of 1ml	21.53	15.07	9.69	5.38
58	15-AF0-061	Arsenic trioxide(Concentrate for intravenous infusion) 1mg/ml 10 ml amp. to be use in :- يحصر استخدامة في مراكز امراض الدم وحسب الاستطبابات المقرة في الجلسة 1018 a/ relapsed acute promyelocytic leukemia b/ first line in acute promyelocytic leukemia in low risk group only (platelet less than 40,000, WBC less than 10,000)	13305	1 amp	370.84	259.58	166.87	92.71
59	15-AG0-008	Letrozole 2.5mg Tablet الاسعار مع وعلى قاعدة اقل (15-AG-14).	1837905	30 tab	25.700	18	17	38.421
60	15-AG0-014	Anastrozole tablet 1mg To be dispence by medical committee for these thromboembolic indications في حالة وجود تاريخ مرضي تختري في حالة عدم تحمل المريض لعلاج في حالة عدم تحمل المريض لعلاج Not to be used as an Alternative in case that Tamoxifen - available tab are not لايستعمل كبديل في حالة عدم توفر حبوب (AG0-008-1° N.C) وعلى قاعدة الل	1837905	28 tab	35.00	8.4		
61	15-B00-023	Mycophenolate mofetil 500mg Tablet اعتماد مادة (mycophenolic acid) بشكل منفصل واعتماد البروتوكول العلاجي مرفق بالجلسة ١٠٣٣	6231073	50 tab	24.00	16.8	10.8	6
62	15-B00-024	يحدد صرفها ضمن مراكز زرع Tacrolimus 1mg Capsule الكلى	2908097	100 cap	121.42	85.8	54.6	30.35



63	15-B00-067	Sunitinib (as maleate) 50 mg capsule كونها تعتبر جرع (Sunitinb 25+12.5 mg) توفير كبضاعة مجانية (Sunitinb 50 mg) من كل تركيز من الاحتياج الكلي لتركيز %وينسبة ٨ تكميلية : تستخدم المادة أنفأ للحالات الأتيةحصرا المادة (mg) : مطاورة الفائذ المحالات الأتيةحصرا المادة (Material or metastatic Stromal Tumor (GIST) after failure of imatinib renal cell carcinoma على ان (certificate) ضرورة تزويد الشركات المجهزة للعراق بشهادة - تكون اصلية و على ان (certificate) ضرورة تزويد الشركات المجهزة للعراق بشهادة الداخلة في جيلاتين الكيسول من مسببات جنون البقر و مصدقة تضمن خلو المادة عدم الداخلة في جيلاتين الكيسول من مسببات جنون الموار و مصدقة تضمن خلو المادة عدم الداخلة في جيلاتين الكيسول من مسببات جنون البقر و مصدقة تضمن خلو المادة عدم الداخلة في جيلاتين الكيمول من مسبات جنون البقر و مصدقة تضمن خلو المادة عدم الداخلة في جيلاتين الخيم مع استراحه الميوعين المداخلة الموعين (الخنزير) مع ماستراحه الموعين (الخنزير) مع المدر المائة حيوان (الخنزير) مع ماستراحه الموعين (الخنزير) مع ماستراحه الموعين (الاسعار مع مالة (389)	106529	30 cap	3,999.90	2799.93	1799.95	999.98
64	15-B00-071	تستعمل المادة وفق Thalidomide 50 mg cap or tab الضوابط المتعارف عليها وبصورة مشددة للرجل والمرأه في سن الانجاب منعا لحدوث تشوهات خلقية اذا حدث الحمل وتستعمل (ج (١٠١٢) موانع الحمل بصورة فعاله واكيدة للجنسين	24621	28 cap	373.10	300	200	125
65	15-B00-078	Lenalidomide 25mg tablet or cap a- as consolideition post bone marrow transplant for 2 cycles b- in relapsed - refractory myeloma after bortozomibe containg regimen c- relapse after autologuse bone marrow transplant in both (b) &(c) to be used for 4 cycles then to go for transplant or to continue for 1 year if not eligible	32398	21 cap	5,950.48	4165.33	630	
66	15-B00-094	pazopanib Hcl 200mg film coated tab (989) ج ^{٥٨٥} (15-B00-067)قاعدة اقل الاسعار مع	564981	30 tab	711.80	498.26	320.31	177.95



67	15-B00-095	Interferon gamma -1B100 mcg / 0.5 ml vial	438	1 vial(200MCG/ML)	97.5	68.25	43.88	24.38
68	15-C00-003	mcg(30MU) /1ml S.C/I.V infusion inj ۳۰۰ Filgrastim or mcg(30MU) /0.5 ml pfs۳۰۰ Filgrastim (solution) Vial or it's approved biosimilar بالنسبة للرمز الوطنی (٥٥-٥٥٥-٥٥) يتم اختيار احدی المادتين اما ال (biosimilar) او (reference) وحسب التنافس السعري مع الرمز (٥٠- اور ۲۵-٥٥٩) وحسب قاعدة اقل الاسعار ج/١٠٣٢	130012	1 PFS	40.00	23		
69	15-C00-009	Lenograstim powder for reconstitution , 33.6 million IU (263 μg) vial (with 1 ml prefilled syringe water for injections) code 15-C00-003 تخضيع لقاعدة اقل الإسعار مع	122809	5vial + 5 pfs D.W.	400.00	280	180	100
70	16-B00-002	Anti D immunoglobulin (500 IU)sol. for Injection (تكون (By nanofilteration & SDF method) (IM / IV) خاضعة لكافة المتطلبات والمواصفات العالمية المتعلقة بالنقاوة وخلوها من الفاير وسات	26941	Inj	43.00	30	19.35	10.75
71	16-B00-004	Anti D immunoglobulin (1500 IU) sol. for injection يتم استير اده بعد استيفائه لشرط تقديم شهادات * (IV IM الذي تم تصنيعه التحليل والسلامة الأصلية الخاصة بمصدر بلازما الدم الذي تم تصنيعه مع الاشارة الى أرقام الوجبات) بالأضافة الى تلك التي يتم أجرائها)منها مع الاشارة الى أرقام الوجبات) بالأضافة الى تلك التي يتم أجرائها)منها مع الاشارة الى أرقام الوجبات) بالأضافة الى تلك التي يتم أجرائها)منها مع الاشارة الى أرقام الوجبات) بالأضافة الى تلك التي يتم أجرائها)منها مع الاشارة الى أرقام الوجبات) بالأضافة الى تلك التي يتم أجرائها)منها مع الاشارة الى أرقام الوجبات) بالأضافة الى تلك التي يتم أجرائها)منها مع الاشارة الم الوجبات العالمية (على المنتوج النهائير وسات المتعلقة بالنقاوة وخلوها من الفاير وسات	65466	1 PFS	42.69	29.8	19.21	10.67
72	16-B00-033	Human normal immunoglobulin 5% protein (200 ml) OR 10% protein (100 ml) (10 gm / container). مراعاة الشركة المصنعة بتوفير الشروط * انظر الشروط اسفل القائمة	18515	200-ml vial	560.00	392	252	140
73	09-H00-028	Sapropterin dihydrochloride 100 mg tab	30100	30 soluble tab	746.525	522.57	335.94	186.63



74	09-Ebh-001	milk formula for phenyketoneuria (PKU) patients for age (from birth-1year) Phenylalanine free.	5666	400 gm	49.652322	34.76	22.34	12.41
		milk formula for phenyketoneuria (PKU) patients for age(above1 - 3years) Phenylalanine free.		500 gm	36.166	25.32	16.27	9.04
75	09-Ebh-002		10128					
		milk formula for phenyketoneuria (PKU) patients for age (above3 - 8)year Phenylalanine free.	44004	500 gm	149.480165	104.64	67.27	37.37
76	09-Ebh-003	milk formula for phenyketoneuria (PKU) patients for age (8years and above) Phenylalanine free	11984	500 gm	126.201494	88.3410458	56.790672	31.5503735
77	09-Ebh-004		2256					



78	04-H00-010	Pethidine Hcl 50mg/ml inj. , (2ml) Ampoule(see 4H)	138498	AMP of 2ml	1.28	0.90	0.58	0.32
79	15-B00-088	Antithymocyte globulin equine 250 mg in 5 ml ampoule يستخدم لعلاج فشل نخاع العظم المكتسب على ان تراجع اللجنة (Acquired aplastic anemia) الاستشارية لامراض الدم الكمية المطلوبة من الدوائر بالتنسيق مع قسم تقدير الحاجة لتحديد اعداد المرضى الفعلي وفق قاعدة البيانات الرسمية المتوفرة لدى الدوائر اعلاه وحسب ما جاء بتوصيات اللجنة الاستشارية لامراض الدم السريرية ج٩٨٧	5391	5 AMP of 5ml	1,706.16	1,194.31	767.77	426.54
80	08-C00-004	Recombinant human erythropoietin (alfa rh Epo) 4000 IU per PFS or vial sol. For inj (Solution without human serum albumine,HAS Free). Or its approved biosimilar (alfa or Zeta) خمن القائمة الإساسية بالمستوى (Epoetin zeta) تقر مادة (erythropoietin alfa) الأول باحتياج ضمني ج٩٦٠٤, ٢٠١٩, ٢٠١٢, ٢٩٠٤, ٢٩٠٤, ٢٩٠٤	1055457	6 PFS	56.50	45.00		
81	08-C00-001	Recombinant human erythropoietin (alfa rh Epo) 2000 I.U per vial or PFS sol. for inj without human serum albumin, HAS Free) Or its approved biosimilar (alfa or Zeta) فمن القائمة الاساسية بالمستوى (Epoetin zeta) تقر مادة (erythropoietin alfa) بلاول باحتياج ضمني مع ج٢١٠١ ،ج٩١٠١, ج٩٤٠١ ج ١٠٤٧ ج	154466	1 PFS	12.50	7.30	5.63	3.13

B00-034 *11-B00-033 *13 ×10-804مراعاة توفر الشروط المذكورة ادناه في المستحضرات لجميع الشركات المتقدمة للتجهيز وكالاتي :- *1 ٦

() The lot should be prepared from a pool of at 1000 donors .

(*At least 3 validated methods of virus inactivation has been used in the preparation.

(*Each manufactuers will list the indication that have been demonstrated in clinical trials using their own preparation and this should cover the FDA – Approved uses for IVIG, ITP primary immunodeficiency 20 secondary immunodeficiency due to CLL prevention of



GVHD and in infection in adult BMT and Kowaski syndrome. (*The lot should contain at least %٩٠ intact IgG. (*IgG sub classes should be in a distribution similar to natural plasma (WHO reference plasma : IgG1 ؛ %٦٠ IgG2 ؛% ٢٩.٤ IgG3 ؛ %٦.॰ IgG4.%٤.) (*IgA and IgM should be as little as possible IgA °٠ > mg /ml (but in the Ig used in IgA deficent patient should be ".٧> mg /ml) and IgM ۱۰ > mg/ml. (*The fragments should be lass than 50 % and the prekallikrein activator ≤ 35 Ul/ml.((*The Ig should be modified biochemically as little as possible. (*The Ig should retain opsonizing and complement fixing activities and other natural biologic characteristics. (*Anti HBs Ag-Ab ≥ 0.05 Ul/ml.

وبالتالي فأن هذه الشروط يجب ان تكون المعيار لتقييم العروض المقدمة من الناحية الفنية.



CONTENTS PART 1 – BIDDING PROCEDURES

Section I. Instructions to Bidders Section II. Bid Data Sheet Section III. Evaluation and Qualification Criteria Section IV.

Bidding Forms

PART 2 – PROCUREMENT REQUIREMENTS Section V Schedule of Requirements

PART 3 – CONDITIONS OF CONTRACT AND CONTRACT FORMS Section VI. General Conditions of Contract Section VII. Special Conditions of Contract Section VIII. Contract Forms





PART 1 BIDDING PROCEDURES



SECTION I. INSTRUCTIONS TO BIDDERS TABLE OF CLAUSES

A. Introduction..... 4 1. Scope of Bid.....4 2. Fraud and Corruption..... 4 B. The Bidding Documents...... 5 3. Content of Bidding Documents..... 5 4. Clarification of Bidding Documents..... 5 5. Amendment of Bidding Documents..... 6 C. Preparation of Bids..... 6 6. Eligibility..... 6 Establishing Eligibility of Goods and Services and Conformity 7.7 8. Qualifications of the Bidder..... 8 9. One Bid per Bidder..... 9 10. Cost of Bidding...... 9 Language of Bid 11.9 12. 13. Bid Form..... 10 14. Bid Prices and Discounts...... 10 15. Currencies of Bid..... 12 Period of Validity of Bids...... 12 16. 17. Bid Security..... 12 18. Format and Signing of Bid..... 14 D. Submission of Bids..... 14 19. Sealing and Marking of Bids..... 14 20. Deadline for Submission of Bids..... 15 21. Late Bids..... 15 Modification and Withdrawal of Bids..... 22. 15 E. Opening and Evaluation of Bids..... 16 23. Bid Opening16 24. Clarification of Bids..... 18 25. Confidentiality...... 18 Examination of Bids and Determination of Responsiveness...... 18 26. 27. Correction of Errors..... 19 28. Conversion to Single Currency..... 19 29. Evaluation and Comparison of Bids......20 30. Margin of Preference20 Contracting Entity's Right to Accept Any Bid and to Reject Any or All Bids.....21 31. 32. F. Award of Contract 33. Award Criteria..... 21 34. 35. Notification of Award..... 21 36. Complaints and Appeals..... 22 Signing of Contract..... 37. 22 38.





PART 1

BIDDING PROCEDURES Section I. Instructions to Bidders Instructions to Bidders A. INTRODUCTION

1. Scope of Bid	1.1 The Contracting Entity, as specified in the Bid Data Sheet (BDS) and in the Special Conditions of Contract (SCC) , invites bids for the supply of Goods (pharmaceuticals, vaccines, contraceptives, or medical equipment) as specified in the Bid Data Sheet and Schedule of Requirements .
	1.2 Throughout these bidding documents, the terms "writing" means any typewritten or printed communication, including letters delivered by hand, telex, and facsimile transmission, and "day" means
2. Fraud and Corruption	 calendar day. Singular also means plural. 2.1 The Contracting Entity requires that bidders, suppliers, and contractors, their subcontractors and their staff shall observe the highest standard of ethics during the procurement and execution of contracts. In pursuance of this policy, the Contracting Entity: (a) defines Fraud and Corruption as per the relevant applicable Iraqi laws. For the purpose of this provision, the Contracting Entity will be guided further by the definition of the terms as set forth here below: (i) "corrupt practice" is the offering, giving, receiving or soliciting, directly or indirectly, of anything of value to influence improperly the actions of another party; (ii) "fraudulent practice" is any act or omission, including a misrepresentation, that knowingly or recklessly misleads, or attempts to mislead, a party to obtain a financial or other benefit or to avoid an obligation;
	 (iii) "collusive practice" is an arrangement between two or more parties designed to achieve an improper purpose, including to influence improperly the actions of another party; (iv) "coercive practice" is impairing or harming, or threatening to impair or harm, directly or indirectly, any party or the property of the party to influence improperly the actions of a party; (v) "obstructive practice" is (aa)deliberately destroying, falsifying, altering or concealing of evidence material to the investigation or making false statements to investigators in order to materially impede a Contracting Entity's investigation into allegations of a

الله اک

corrupt, fraudulent, coercive or collusive practice in accordance with the applicable Iragi laws; and/or threatening, harassing or intimidating any party to prevent it from disclosing its knowledge of matters relevant to the investigation or from pursuing the investigation; or (bb)acts intended to materially impede the exercise of inspection and audit rights provided for under Sub-Clause 2.1 (d) below in accordance with the applicable Iragi laws. (b) will reject the Bid if it determines in accordance with the applicable Iragi laws that the bidder recommended for award has, directly or through an agent, engaged in corrupt, fraudulent, collusive, coercive or obstructive practices in competing for the contract in question; (c) will sanction a firm or individual in accordance with the applicable Iraqi laws, including declaring ineligible, either indefinitely or for a stated period of time, to be awarded contract if it at any time it is determined by the competent Iragi authorities that the firm has, directly or through an agent, engaged in corrupt, fraudulent, collusive, coercive or obstructive practices in competing for, or in executing, a Contracting Entity financed contract: and (d) will have the right to inspect the accounts and records and other documents relating to the bid submission and contract performance of bidders, suppliers, and contractors and their sub-contractors and to have them audited by the competent authorities in accordance to the applicable Iraq Laws.

B. THE BIDDING DOCUMENTS

3. Content of	3.1 The Bidding Documents are those stated below and		
Bidding	should be read in conjunction with any addendum issued		
Documents	in accordance with ITB Clause 5:		
	Section I.Instructions to Bidders (ITB)		
	Section II. Bid Data Sheet (BDS)		
	Section III. Evaluation and Qualification Criteria		
	Section IV. Bidding Forms		
	Section V Eligible Countries		
	Section VI. Schedule of Requirements		
	Section VII General Conditions of Contract (GCC)		
	Section VIII. Special Conditions of Contract (SCC)		
	Section IX Contract Forms		
	3.2 The "Invitation for Bids" does not form part of the		
	Bidding Documents.		
4. Clarification of	4.1 A prospective Bidder requiring any clarification of the		

Bidding

Documents

5. Amendment of Bidding Documents Bidding Documents shall contact the **Contracting Entity** in writing or by cable (the term "cable" is deemed to include electronic mail, telex, or facsimile) at the **Contracting Entity**'saddress indicated in the Bid Data **Sheet.** The **Contracting Entity** will respond in writing to any request for clarification received no later than fourteen (14) calendar days prior to the deadline of submission of bids. Copies of the Contracting Entity's response shall be sent to all prospective Bidders who have purchased the Bidding Documents, including a description of the inquiry but without identifying its source.

- 4.2 In order to maintain the confidentiality of the procedures during the Bid advertisement period, information about the names and addresses of Bidders and their agents shall not be disclosed to any unconcerned party.
- 5.1 At any time prior to the deadline for submission of bids, the **Contracting Entity** may amend the Bidding Documents by issuing Addenda.
- 5.2 Any addendum thus issued shall be part of the Bidding Documents pursuant to ITB Sub-Clause 3.1 and shall be communicated in writing to all purchasers of the Bidding Documents and will be binding on them. Bidders are required to immediately acknowledge receipt of any such amendment, and it will be assumed that the information contained in the amendment will have been taken into account by the Bidder in its bid.
- 5.3 To give prospective Bidders reasonable time in which to take the amendment into account in preparing their bids, the **Contracting Entity shall extend**, at its discretion, the deadline for submission of bids, in which case, the Contracting Entity will notify all Bidders by cable confirmed in writing of the extended deadline. The Contracting Entity shall advertise any extension of the deadline for bid submission in same media as was done for the Short Procurement Notice of this tender.

C. PREPARATION OF BIDS				
6. Eligibility	6.1	This bidding process is open to qualified firms from any Eligible country as specified in Section - V. The Firms may be excluded from bidding if:		
	(a)	 the firms have a conflict of interest. All Bidders found to have a conflict of interest shall be disqualified. A Bidder may be considered to have a conflict of interest with one or more parties in this bidding process, if : (1) they have a controlling partner in common; or (2) they receive or have received any direct or indirect subsidy from any of them; or (3) they have the same legal representative for purposes of this bid; or 		

الله اک

- (4) they have a relationship with each other, directly or through common third parties, that puts them in a position to have access to information about or influence on the bid of another Bidder, or influence the decisions of the Contracting Entity regarding this bidding process; or
- (5) a Bidder submits more than one bid in this bidding process, either individually or as a partner in a joint venture. This will result in the disqualification of all such bids. However, this does not limit the participation of a Bidder as a subcontractor in another bid or of a firm as a subcontractor in more than one bid. or
- (6) a firm has been engaged by the Contracting Entity or a Purchasing Agent that has been duly authorized to act on behalf of the Contracting Entity - to provide consulting services for the preparation of the design, specifications, and other documents to be used for the procurement of the Goods described in these Bidding Documents. or
- 6.2 Staff of the Government and Public Sector cannot participate directly or indirectly in Public Tenders
- 6.3 A firm declared Black listed or Suspended by the competent authorities shall be ineligible to bid during the period of time determined. A list in this regard is available on the website **specified in BDS**.
- 7.1 Pursuant to ITB Clause 12, the Bidder shall furnish, as part of its bid, documents establishing, to the Contracting Entity's satisfaction, the eligibility of the Health Sector Goods and Medical Equipment and services to be supplied under the Contract.
- 7.2 The documentary evidence of the eligibility of the Goods and Services shall consist of a statement in the Price Schedule of the country of origin of the Goods and Services offered that shall be confirmed by a certificate of origin to be issued at the time of shipment and approved by the competent Iraqi authorities in the country of origin; such an approval is waived for items of certified Arab origin.
- 7.3 The documentary evidence of conformity of the Goods and Services as **specified in Section VI Schedule of Requirements** may be in the form of literature, drawings, and data and shall consist of:
- (a) a detailed description of the essential technical and performance characteristics of the Goods;
- (b) an item-by-item commentary on the Contracting Entity's Technical Specifications demonstrating substantial responsiveness of the Goods and Services to those specifications, or a statement of deviations and exceptions to the provisions of the Technical

7. Documents Establishing Eligibility of Goods and Services and Conformity to Bidding Documents

Specifications;

- (c) any other procurement-specific documentation requirement as stated in the **Bid Data Sheet**.
- 7.4 Unless the **Bid Data Sheet** stipulates otherwise, the Goods to be supplied under the Contract shall be registered with the competent authority in Iraq. A Bidder who has already registered its Goods by the time of bidding should submit a copy of the Registration Certificate with its bid. Otherwise, the successful Bidder, by the time of Contract signing, shall submit to the Contracting Entity either:
- (a) a copy of the Registration Certificate of the Goods for use in the Iraq.
- OR, if such Registration Certificate has not yet been obtained,
- (b) evidence establishing to the Contracting Entity's satisfaction that the Bidder has complied with all the documentary requirements for registration as specified in the Bid Data Sheet.
- (c) it is permitted to take excepting by the health minister.
- 7.4.1 The Contracting Entity shall at all times cooperate with the successful Bidder to facilitate the registration process within Iraq. The agency and contact person able to provide additional information about registration are identified in the **Bid Data Sheet.**
- 7.4.2 (a): If the Goods of the successful Bidder have not been registered in Iraq at the time of Contract signing, then the Contract shall become effective upon such date as the Certificate of Registration is obtained.
- (b) : minister of health has the right to take exception for the winner bidder from submitting registration certificate at the time of signing contract.
- 7.5 For purposes of the commentary to be furnished pursuant to ITB Sub-Clause 7.3 (b) above, the Bidder shall note that standards as well as references to brand names designated by the Contracting Entity in its Technical Specifications are intended to be descriptive only and not restrictive. The Bidder may substitute alternative standards, brand names, and/or catalog numbers in its bid, provided that it demonstrates to the Contracting Entity's satisfaction that the substitutions ensure substantial equivalence to those designated in the Technical Specifications.
- 8.1 The Bidder shall provide documentary evidence to establish to the Contracting Entity's satisfaction that
- (a) the Bidder has the financial, technical, and production capability necessary to perform the Contract, meets the Qualification Criteria specified in Section III Evaluation and Qualification Criteria.
- (b) in the case of a Bidder offering to supply Goods,
- 8. Qualifications of the Bidder

		identified in the Bid Data Sheet, that the Bidder did not manufacture or otherwise produce, the Bidder has been duly authorized by the manufacturer or producer
		of such Goods to supply the Goods in Iraq as per format of Manufacturer's Authorization Form in Section IV;
	(c)	in the case of a Bidder who is not doing business within Iraq (or for other reasons will not itself carry out
		service/maintenance obligations), the Bidder is or will
		be (if awarded the Contract) represented by a local service/maintenance provider in Iraq equipped and
		able to carry out the Bidder's warranty obligations prescribed in the Conditions of Contract and/or
	(d)	Technical Specifications; and the Bidder meets the qualification criteria listed in the
		specified in Section III Evaluation and Qualification Criteria(see additional clauses of Section III for
	_ Th	pharmaceuticals, vaccines and medical equipment). e companies should be submitted a letter of no
	- 11	objection issued by the general authority for taxes
		when participating in the tenders announced.
9. One Bid per	9.1	A firm shall submit only one bid as an individual Bidder
Bidder		and in accordance with ITB 6.1.a.
10.Cost of Bidding	10.1	The Bidder shall bear all costs associated with the
		preparation and submission of its bid, and the
		Contracting Entity will in no case be responsible or
		liable for those costs, regardless of the conduct or
11		outcome of the bidding process.
11.Language of Bid	11.1	The bid, as well as all correspondence and documents relating to the bid exchanged by the Bidder
ыа		and the ContractingEntity , shall be written in the
		language specified in the Bid Data Sheet . Supporting
		documents and printed literature furnished by the
		Bidder may be in another language provided they are
		accompanied by an accurate translation of the relevant
		passages in the language specified, in which case,
		for purposes of interpretation of the Bid, the translation
12.Documents	121	shall govern . The bid submitted by the Bidder shall comprise the
Constituting the	12.1	following:
Bid	(a)	duly filled-in Bid Form and Price Schedule, in
	(b)	accordance with the forms indicated in Section IV; original form of bid security in accordance with the
	(0)	provisions of ITB Clause 17 (Bid Security);
	(c)	written power of attorney authorizing the signatory of
	(-)	the hid to commit the Bidder:

(d) documentary evidence establishing to the Contracting Entity's satisfaction, and in accordance with Documents required as per ITB Clause 7 and that they conform to the Bidding Documents;



- (e) documentary evidence establishing to the Contracting Entity's satisfaction, and in accordance with Qualification of the Bidder as per ITB Clause 8 that the Bidder is qualified to perform the Contract if its bid is accepted.
- (f) Bidder's voucher of purchasing the Bidding Document.
- (g) if applicable as per ITB Sub-clause 8.1(b), Manufacturer's Authorization Form as per format in Section IV
- (h) Bidder's voucher of purchasing the Tender Document. Any other required document shall be specified in the Bid Data Sheet
- 13.1 The Bidder shall complete the Bid Form and the appropriate Price Schedule provided under Section –
 IV indicating the Goods to be supplied, a brief description of the Goods, their country of origin, quantity, and prices.
- 14.1 The Bidder shall quote their prices as per format of Price Schedule provided under **Section IV** all the specified components of prices shown therein. All the columns shown in the Price Schedule should be filled up as required. If any column does not apply to a Bidder, same should be clarified as "NA" (means Not Applicable) by the Bidder.
- 14.2 The quoted prices for goods offered for domestic goods or goods of foreign origin located in Iraq shall be quoted in the Price Schedule given under Section IV (2). The quoted prices for goods to be imported from abroad, shall be quoted in the Price Schedule given under Section IV (3).
- 14.3 While filling up the columns of the Price Schedule, the following aspects should be noted for compliance:
- 14.3.1For domestic goods or goods of foreign origin located in Iraq, the prices under column 5 in the corresponding Price Schedule in at **Section IV** (2) shall be entered separately in the following manner:

Column 5(a): The price of goods, quoted ex-factory/ ex-showroom/ ex-warehouse/ off-the-shelf, as applicable, including all taxes and duties like Sales Tax, Custom Duty, Excise Duty etc. already paid or payable on the components and raw material used in the manufacture or assembly of the goods quoted exfactory etc. or on the previously imported goods of foreign origin quoted ex-showroom etc. This will also include charges towards Packing & Forwarding,

Column 5(b): Any sales and other taxes and duties like Excise Duty, Sales Tax etc., which will be payable on the goods in Iraq if the Contract is awarded;

Column 5(c): Inland Transportation, Insurance, Loading/ Unloading and other incidental costs till to

13. Bid Form

14. Bid Prices and Discounts ىللە ئەك

delivery of the goods to their final destination as specified in the Schedule of Requirements.

Column 5(d): The Price of Incidental Services including installation, demonstration and onsite training at End-users' site, if applicable, as mentioned in Schedule of Requirements.

14.3.2 For goods offered from abroad, the prices under Column 5 in the corresponding Price Schedule as per format in Section IV (3) shall be entered separately in the following manner:

Column 5(a): The price of goods quoted CIP at port/airport of destination;

Column 5(b): The price of goods quoted DDP (Delivery Duty Paid) at End-user site in Iraq as specified in the Schedule of Requirements.

Column 5(c): The price of Incidental Services including installation, demonstration and onsite training at Endusers' site, if applicable, as mentioned in Schedule of Requirements;

- 14.3.3 For Medical Equipment, Annual Maintenance Contract (AMC) at End-users' site for the stipulated years after warranty period in the Price Schedule as per format in Section IV (4), if applicable as specified in Schedule of Requirements. The cost of AMC may be quoted along with taxes applicable on the date of Bid Opening. The taxes to be paid extra, to be specifically stated. In the absence of any such stipulation the price will be taken inclusive of such taxes and no claim for the same will be entertained later. During AMC contract period the Supplier shall keep sufficient stock of spares required during and will to attend to the break down calls promptly. An UPTIME warranty of 'x'% per year during Annual Maintenance Contract, if applicable, as specified in Section VI Schedule of Requirements should be provided. In such cases if the Down Time exceeds (100-x) % per year during AMC period, it will extend the AMC period by double the down time period.
- 14.4 The terms EXW, FCA, FOB, CIF, CIP, DDP, etc., shall be governed by the international rules for interpreting trading terms as prescribed in the current edition of INCOTERMS® published by the International Chamber of Commerce, Paris.
- 14.5 The Bidder's separation of price components in accordance with ITB Sub clause 14.3 above will be solely for the purpose of facilitating the comparison of bids by the Contracting Entity and will not in any way limit the Contracting Entity's right to contract on any of the terms offered.

- 14.6 Price quoted by Bidder shall be fixed during the currency of the Contract and not subject to any variation on any account.
- 14.7 If more than one schedule (or lot) has been **specified inSection VI** Schedule of Requirements, these Bidding Documents allow Bidders to quote separate prices for one or more schedules (or lots). The Bidder may quote for one or more schedules (or lots) but are required to quote for all items and its full quantity of the goods of that schedule. The Schedules (or lots) must be listed and priced separately in the Price Schedules. Bids shall be evaluated for each schedule (or lot) separately.
- 15.1 Prices shall be quoted in the following currencies:
- (a) The Bidder shall express its prices for such goods to be supplied from Iraq in the Iraqi Dinar.
- (b) The Bidder may express the bid price of the Goods to be supplied from abroad as indicated in the **Bid Data Sheet.**
- 16.1 Bids shall remain valid for the period stipulated in the **Bid Data Sheet** after the date of bid submission specified in ITB Clause 20. A bid valid for a shorter period shall be rejected by the Contracting Entity as nonresponsive.
- 16.2 In exceptional circumstances, prior to expiry of the original bid validity period, the Contracting Entity may request that the Bidders extend the period of validity for a specified additional period. The request and the responses thereto shall be made in writing. A Bidder may refuse the request without forfeiting its bid security. The Bidder agreeing to the request will not be required or permitted to modify its bid, but will be required to extend the validity of its bid security for the period of the extension.
- 17.1 The Bidder shall furnish as part of its bid a bid security in the form of an unconditional guarantee and payable upon first demand and in any of the following modes:
- (a) a bank guarantee as per format in Section IV; or
- (b) a cashier's or certified check; or
- (c) or any mode depended by the contracting entity in data sheet.
- The amount of the Bid Security shall be as stipulated in the Bid Data Sheet and in the Schedule of Requirements in Section VI.
- 17.2 The bid security shall be addressed to the Contracting Entity stating the number and title of the IFB and shall remain valid for a period of 28 days beyond the validity

- 15. Currencies of Bid
- 16.Period of

Validity of Bids

- 17. Bid Security

period for the bid, and beyond any extension subsequently requested under Sub-Clause 16.2.

- 17.3 The bid security shall, at the Bidder's option, be in the form of either or a Bank Guarantee from an accredited bank in Iraq and in accordance with the instructions of Central Bank of Iraq or certified check in the format provided in the Bidding Documents any mode depended by the contracting entity in data sheet. In the case of Bank Guarantee furnished from the banks outside Iraq, it should be endorsed and countersigned by accredited bank in Iraq by way of back-to-back counter guarantee.
- 17.4 Any bid not accompanied by an acceptable bid security shall be rejected by the Contracting Entity as nonresponsive excepting that of the producing drugs company or medical equipment manufacturing companies which are cover by the valid exeption of the minister of health.
- 17.5 Upon the approval of the Contracting Authority, the Contracting Entity has the right to release the Bid Securities of the unsuccessful Bidders that are unlikely to be awarded the Contract before the end of the Bid Validity and after the referral recommendation has been made. In such a case, the Bid Securities of the first three (3) candidates Bidders shall be retained in view of ITB Sub-Clause 38.2
- 17.6 The bid security of the successful Bidder will be returned when the Bidder has signed the Contract and furnished the required performance security.
- 17.7 The bid security may be forfeited
- (a) if the Bidder withdraws its bid, except as provided in ITB Sub-Clauses 16.2 and 22.3; or
- (b) in the case of a successful bidder, if the Bidder fails within the specified time limit to:
 - (i) sign the contract, or
 - (ii) furnish the required performance security.
- (c) In the case of Complaint and Appeal as per Clause 36 by an unsuccessful Bidder and when this complaint or appeal is found by the competent authorities to be for false or unjustified reasons. The amount of damage resulting from delaying the contract signature will be recovered from the Bid Security of the here above unsuccessful Bidder. However, such amount which forfeited from Bid Security which equale to the penalties value limited in accordance with the applicable Iraqi laws and procedures.
- 17.8 If the bid security is not provided by some Bidders, due to exemption provided by the Iraqi applicable laws, as in the case of Public Companies or others as

specified in Bid Data Sheet Sub-Clause 17.1, and

- a) if such a Bidder withdraws its bid during the period of bid validity specified by the Bidder on the Bid Submission Form, except as provided in ITB Sub-Clause 16.2, or
- b) if such a Bidder is nominated as a successful Bidder and fails to: sign the Contract in accordance with ITB Clause 37; or furnish a performance security in accordance with ITB Clause 38;
- the Contracting Entity may, if provided for in the **Bid Data Sheet**, declare the Bidder disqualified to be awarded a contract by the Contracting Entity and proceed with the administrative actions as stated in the **Bid Data Sheet**.
- 18.1 The Bidder shall prepare an original and it is permitted to be as (compact disk) with the technical bid, while the financial bid should be submitted in one written original copy.
 - 18.2 The original and all copies of the bid, each consisting of the documents listed in ITB Sub-Clause 12.1, shall be typed or written in indelible ink and shall be signed by the Bidder or a person or persons duly authorized to bind the Bidder to the Contract. The authorization shall be indicated as specified in the **Bid Data Sheet** by those legally authorized to signed, which pursuant to ITB Sub-Clause 12.1 (c) shall accompany the bid. The Bidder has to ensure the signature of the Bid Submission Form and of every page of the Price Schedules and the attached documents to the Bid by the person signing the Bid. Noting that all pages of the bid where entries or corrections on entries have been made by the Bidder shall be signed or initialled by the person signing the bid. Prices shall be incorporated by the Bidder in words and figures as required in the Price Schedules. Any other requirement is specified in theBid Data Sheet.
 - 18.3 The Bid shall contain no interlineations, erasures, or modifications to the Bidding Documents, except to correct errors made by the Bidder in preparing the Bid Forms and where accordingly such corrections should be signed and initialled by the authorised person or persons signing the bid.

D. SUBMISSION OF BIDS

 19. Sealing and Marking of Bids
 19.1 Bidders may always submit their bids by express mail, express courier or by hand. The Bidder shall enclose the original and each copy of the bid in separate sealed envelopes, duly marking the envelopes as "ORIGINAL" or "COPY." The envelopes containing the

18. Format and Signing of Bid

		original and copies shall then be enclosed in stamped outer envelope.
		The inner and outer envelopes shall:
	(a)	bear the name and address of the Bidder and Bidder stamp on four corners;
	(b)	be addressed to the Contracting Entity at the address given in the Bid Data Sheet ;
	(c)	bear the Tender, Tender number. and IFB number indicated in the Bid Data Sheet ; and
	(d)	bear a statement "DO NOT OPEN BEFORE [9 -3 - 2020]" to be completed with the time and date specified in the
	19.3	Bid Data Sheet relating to ITB Sub-Clause 20.1. If the outer envelope is not sealed, stamped and marked
		as required by ITB Sub-Clause 19.2 and in accordance with the applicable Iraqi laws, the Contracting Entity will assume no responsibility for the misplacement or
20. Deadline for Submission of	20.1	premature opening of the bid. Bids must be received by the Contracting Entity at the address specified in ITB Sub-Clause 19.2 (b) no later
Bids	20.2	than the time and date specified in the Bid Data Sheet. A receipt will be provided by the Contracting Entity against each Bid submitted. One copy of the receipt will be for the Bidder, and the second copy will be kept by the Contracting Entity for a further reference The Contracting Entity may, at its discretion and before the deadline, extend the deadline for the submission of bids by amending the Bidding Documents in accordance with ITB Sub-Clause 5.3, in which case all rights and obligations of the Contracting Entity and Bidders previously subject to the deadline will thereafter be subject to the deadline as extended.
21.Late Bids	21.1	Any bid received by the Contracting Entity after the deadline for submission of bids prescribed in ITB Clause 20 will be rejected and returned unopened to
22.Modification and Withdrawal of Bids	22.1	the Bidder. The Bidder may modify or withdraw its bid after submission, provided that written notice of the modification, or withdrawal of the bids duly signed by an authorized representative with a valid proof of the authorization, is received by the Contracting Entity
	22.2	prior to the deadline prescribed for submission of bids. The Bidder's modification or substitution shall be prepared, sealed, marked, and dispatched prior to the
		deadline for submission of bids and as follows:
	(a)	The Bidder shall provide an original and the number of copies specified in ITB Sub-Clause 191 of any

copies specified in ITB Sub-Clause **19.1** of any modifications to its bid, clearly identified as such, in two inner envelopes duly marked "BID MODIFICATION-ORIGINAL" or "BID SUBSTITUTION-ORIGINAL" and "BID MODIFICATION-COPIES" or "BID SUBSTITUTION-COPIES."

	(a) (b) (c) 22.4	The inner envelopes shall be sealed in an outer envelope, which shall be duly marked "BID MODIFICATION" or "BID SUBSTITUTION." Other provisions concerning the marking and dispatch of bid modifications shall be in accordance with ITB Sub-Clauses 19.2 and 19.3. A Bidder wishing to withdraw its bid shall notify the Contracting Entity in writing prior to the deadline prescribed for bid submission. A withdrawal notice shall be received prior to the deadline for submission of bids and shall: be addressed to the Contracting Entity at the address named in ITB Sub-Clause 19.2 (b) bear the Invitation for Bids (IFB) title and number indicated in named in ITB Sub-Clause 19.2 (c) and the words "BID WITHDRAWAL NOTICE" and be accompanied by a valid written power of attorney authorizing the signatory of the withdrawal notice to withdraw the bid. Bids requested to be withdrawn in accordance with ITB Sub-Clause 22.3, shall be returned unopened to the Bidders. No bid may be withdrawn, substituted, or modified in the interval between the bid submission deadline and the expiration of the bid validity period specified in ITB Clause 16. Withdrawal of a bid during this interval may result in the forfeiture of the Bidder's bid security, pursuant to ITB Sub-Clause 17.7.
	E. Opi	ENING AND EVALUATION OF BIDS
23. Bid Opening		The Contracting Entity (Bid Opening Committee) will open all bids, including withdrawal notices and modifications, in public, in the presence of Bidders' representatives who choose to attend, at the time, on the date, and at the place specified in the Bid Data Sheet. Bidders' representatives shall sign a register as proof of their attendance. Envelopes marked "WITHDRAWAL" shall be read out and the envelope with the corresponding bid shall not be opened but returned to the Bidder. No bid withdrawal notice shall be permitted unless the corresponding withdrawal notice with a valid authorization is read out at bid opening. Next, envelopes marked "SUBSTITUTION" shall be opened and read out and exchanged with the corresponding bid being substituted, and the substituted bid shall not be opened, but returned to the Bidder. No bid substitution shall be permitted unless the corresponding bid being substituted, and the substituted bid shall not be opened, but returned to the Bidder. No bid substitution shall be permitted unless the corresponding bid being substituted in the Bidder. No bid substitution shall be permitted unless the corresponding bid

request the substitution and is read out at bid opening. Envelopes marked "MODIFICATION" with a valid authorization shall be read out and opened with the corresponding bid.

- 23.3 All other Bids shall be opened one at a time, reading out: the name of the Bidder and the Bid Price of each item or schedule (or lot) including any discounts, and indicating whether there is: the presence or absence of a bid security, if required; the presence or absence of requisite powers of attorney; and any other such details as the Contracting Entity may consider appropriate. No bid shall be rejected at bid opening except for late bids pursuant to Sub-Clause 21.1.
- All pages of the original of each Bid shall be stamped with the bid opening committee stamp and the bid opening committee members shall sign on all pages of the price schedules of the original of each Bid.
- 23.4 Bids (and modifications sent pursuant to ITB Sub-Clause 22.2) that are not opened and read out at bid opening shall not be considered further for evaluation, irrespective of the circumstances.
- 23.5 The Contracting Entity will prepare minutes of the bid opening at the end of the opening session, with the here above mentioned information of ITB Sub-Clauses 23.1, 23.2. 23.3, and 23.6 and including in minimum the following information about: --sealing and stamping of the envelopes;
 - -bid prices (unit price for each lot if itisavailable) in addition to any conditional pricing or discounts based on other Bids;
 - marking (with the signature of the Chairman of Bids Opening Committee and the members) of any alteration, erasure, correction made by the Bidder on the prices schedules (while slashing un-priced items with horizontal lines);
 - Bidder's signature of the Bid Submission Form and other attached Bid Forms and of every page of the price schedules;

-number of pages of each Bid;

- -any other relevant remarks and reservations made by the Bidder on the Bid;
- any other remarks and general description and highlights to be made by the Committee on any attachments to the Bid. All Bid's content and attachments will be initialled by the Bids Opening Committee.
- 23.6 The Bidder's representatives who are present shall be requested to sign the minutes with the right to add any comment on the performance of the Committee. The omission of a Bidder's signature on the minutes shall

		not invalidate the content and effect of the minutes. The minutes should be distributed to all Bidders who wish to retain its copy.
	23.7	
	23.8	The Bids will be referred by an official report to the Bids Evaluation Committee according to the agreement of The Contracting Entity chairman.
24. Clarification of	24 1	During evaluation of the bids, only the Contracting
Bids	27.1	Entity (evaluation & analysis committee) may, at its
2100		discretion, ask the Bidder for a clarification of its bid.
		The request for clarification and the response shall be
		in writing, and no change in the prices or substance of
		the bid shall be sought, offered, or permitted, except to
		correct arithmetic errors identified by the Contracting
		Entity in the evaluation of the bids, in accordance with
		ITB Sub-Clause 27.1.
	lt a	Bidder does not provide clarifications of its bid by the
		date and time set in the Contracting Entity's request for
25. Confidentiality	25.1	clarification, its bid may be rejected.
25. Confidentiality	23.1	Information relating to the examination, clarification, evaluation, and comparison of bids, and
		recommendations for the award of a Contract shall not
		be disclosed to bidders or any other persons not
		officially concerned with such process until the
		notification of Contract award is made to all Bidders.
	25.2	Any effort by the bidder to influence the Contracting
		Entity (evaluation & analysis committee) in the
		Contracting Entity's bid evaluation, bid comparison, or
		contract award decisions may result in the rejection of
	05.0	the Bidder's bid.
	25.3	From the time of bid opening to the time of Contract
		award, if any Bidder wishes to contact the Contracting Entity on any matter related to its bid, it should do so in
		writing.
26.Examination of	26 1	The Contracting Entity (evaluation & analysis
Bids and	_0.1	committee) will examine the bids to determine whether
Determination		they are complete, whether any computational errors
of		have been made, whether required Bid Securities have
Responsiveness		been furnished, whether the documents have been
-		properly signed, and whether the bids are generally in order

order. 26.2 The Contracting Entity (evaluation & analysis committee) may waive any minor informality, nonconformity, or irregularity in a bid that does not constitute a material deviation, provided such waiver does not prejudice or affect the relative ranking of any Bidder. الله اک

- 19
- 26.3 Prior to the detailed evaluation, pursuant to ITB Clause 29, the Contracting Entity (evaluation & analysis committee) will determine whether each bid is of acceptable quality, is complete, and is substantially responsive to the Bidding Documents. For purposes of this determination, a substantially responsive bid is one that conforms to all the terms, conditions, and specifications of the Bidding Documents without material deviations, exceptions, objections. conditionality, or reservations. A material deviation, exception, objection, conditionality, or reservation is one: (i) that limits in any substantial way the scope, quality, or performance of the Goods and related Services; (ii) that limits, in any substantial way that is inconsistent with the Bidding Documents, the Contracting Entity's rights or the successful Bidder's obligations under the Contract; and (iii) that the acceptance of which would unfairly affect the competitive position of other Bidders who have submitted substantially responsive bids.
- 26.4 If a bid is not substantially responsive, it will be rejected by the Contracting Entity (evaluation & analysis committee) and may not subsequently be made responsive by the Bidder by correction of the nonconformity. The Contracting Entity's determination of a bid's responsiveness is to be based on the contents of the bid itself.
- 27.1 Arithmetical errors will be rectified as follows. If there is a discrepancy between the unit price and the total price that is obtained by multiplying the unit price and quantity, the unit or subtotal price shall prevail. If there is a discrepancy between subtotals and the total price, the total price shall be corrected. If there is a discrepancy between words and figures, the amount in words will prevail. If a Bidder does not accept the correction of errors, its bid will be rejected. If the Bidder that submitted the lowest evaluated bid does not accept the correction of errors, its bid security shall be forfeited.
- 28.1 To facilitate evaluation and comparison, the Contracting Entity will convert all bid prices expressed in the various currencies in which they are payable to Iraqi Dinar at the selling exchange rate established for similar transactions by the Central Bank or a commercial bank in Iraq.
- 28.2 The currency selected for converting bid prices to a common base for the purpose of evaluation to common currency in Iraqi Dinar as on the date of Bid submission.

27. Correction of Errors

28. Conversion to Single Currency



- 29. Evaluation and Comparison of Bids
 - 29.1 The Contracting Entity (evaluation & analysis committee) will evaluate and compare the bids that have been determined to be substantially responsive, pursuant to ITB Clause 26.
 - 29.2 For comparison for ranking purpose for evaluation, the comparison of the responsive Bids shall be carried out on Delivery Duty Paid (DDP) End-users' site basis / Free Delivery at End-users' Site basis. The quoted AMC (Annual Maintenance Contract), if applicable as per Schedule of Requirements as per ITB Sub-Clause 14.3.3 for subsequent stipulated years after warranty period will also be added for comparison/ranking purpose for evaluation.
 - 29.3 For domestic goods or goods of foreign origin located within Iraq, the various prices as brought out in ITB Sub-Clause 14.3.1 and stipulated in Price Schedule in format in Section IV(2), and for goods offered from abroad, the various prices brought out in ITB Sub-Clause 14.3.2 and stipulated in Price Schedule in format in **Section IV**(3) will be loaded for comparison/ranking purpose for evaluation. In addition, price. Annual Maintenance Contract (AMC) if applicable as per Schedule of Requirements as per ITB Sub-Clause 14.3.3 for stipulated years after Warranty period in Price Schedule in format in Section IV(4) will be loaded for comparison/ranking purpose for evaluation.
 - 29.4 The rate of quoted Annual Maintenance Contract (AMC), if applicable, as per **Section VI Schedule of Requirements**, will be loaded for comparison/ranking purpose at Net Present Value (NPV) considering discount rate as brought out in **Bid Data Sheet**.
 - 29.5 If more than one schedule (or lot) has been specified in Section VI Schedule of Requirements, the Bidders are required to quote as stipulated in ITB Sub-Clause 14.7. Bids shall be evaluated for each schedules (or lots) separately.
 - 29.6 The Contracts may be awarded Schedule wise to the lowest responsive Bidder who meets the laid down Qualification Criteria as per ITB Clause 8 subject to Margin of Preference, as per Clause- 30.
 - 30.1 As not contrary to what specified in **Bid Data Sheet.** Margin of domestic prefernce will be depende for the domestic bidders.
- 30. Margin of Domistic Preference



_

31.Contracting Entity's Right to Accept Any Bid and to Reject Any or All Bids	31.1 The Contracting Entity reserves the right to accept or reject any bid, or to annul the bidding process and reject all bids at any time prior to contract award, without thereby incurring any liability to the affected Bidder or Bidders.In case of annulment, all bids submitted and specifically, bid securities, shall be promptly returned to the Bidders together with the fees of purchasing the Bidding Documents as paid by the Bidders.
32. Eligibility and Qualification of bidder	32.1 The Contracting Entity will determine to its satisfaction whether the Bidder that is selected as being eligible and having submitted the lowest evaluated responsive bid is qualified to perform the Contract satisfactorily, in accordance with the criteria listed in ITB Sub-clause 8.1.32.2 The determination will evaluate the Bidder's financial,
	technical, and production capabilities. It will be based on an examination of the documentary evidence of the Bidder's qualifications submitted by the Bidder, pursuant to ITB Sub-Clause 8.1, as well as other information the
	Contracting Entity deems necessary and appropriate. 32.3 An affirmative Qualification of bidder determination will be a prerequisite for award of the contract to the eligible and lowest evaluated Bidder schedule wise. A negative determination will result in rejection of the Bidder's bid, in which event the Contracting Entity will proceed to the next-lowest evaluated Bidder to make a similar determination of that Bidder's capabilities to perform satisfactorily. F. AWARD OF CONTRACT
33. Award Criteria	33.1 Pursuant to ITB Clauses 29, 30 and 32, the Contracting Entity will award the Contract to the eligible Bidder whose bid has been determined to be substantially responsive and has been determined to be the lowest evaluated bid, provided further that the Bidder is determined to be qualified to perform the Contract satisfactorily.
	33.2 Before the award, the Contracting Entity has to verify from the competent authorities the validation of the substantial forms provided in the Bids including the Bid Security
34. Contracting Entity's Right to Vary Quantities at Time of Award	34.1 The Contracting Entity reserves the right at the time of Contract award to increase or decrease, by the percentage of 20% the quantity of goods and services beyond that originally specified in the Schedule of Requirements without any change in unit price or other terms and conditions.
35. Notification of Award	35.1 Prior to the expiration of the period of bid validity, the Contracting Entity will notify the successful Bidder in writing or by cable, to be subsequently confirmed in writing by registered letter, that its bid has been

Republic of Iraq

الله اک

accepted. At the same time, the Contracting Entity shall also notify all other Bidders of the results of the bidding, and shall publish the results as per the applicable Iraqi Laws identifying the bid and lot numbers and the following information: (i) name of each Bidder who submitted a Bid; (ii) bid prices as read out at Bid Opening; (iii) name and evaluated prices of each Bid that was evaluated; (iv) name of bidders whose bids were rejected and the reasons for their rejection; and (v) name of the successful Bidder, and the Price and currency it offered, as well as the duration and summary scope of the contract awarded.

- 35.2 The notification of award will constitute the formation of the Contract subject to settlement of Appeal by unsuccessful bidder as per ITB Clause 36.
- 35.3 Upon the successful Bidder's furnishing of the signed Contract Form and performance security pursuant to ITB Clause 38, the Contracting Entity will promptly discharge the bid securities of the unsuccessful Bidders, pursuant to ITB Clause 17.
- 35.4 If, after notification of award, an unsuccessful Bidder wishes to ascertain the grounds on which its bid was not selected, which are not in pursuant to ITB Clause 36, it should address its request to the Contracting Entity. The Contracting Entity will promptly respond in writing to the unsuccessful Bidder.
- Validation general governmetal implementation contrats procedures reresent the dependable criteria in vewing the comlaints bidders.
 - 37.1 Promptly after the Contracting Entity notifies the successful Bidder that its bid has been accepted and after lapse of the standstill period and settlement of Appeals as per ITB Clause 36 (as the case may be), the Contracting Entity will send the Bidder the Contract Form provided in **Section IX** of the Bidding Documents, incorporating all agreements between the parties and as indicated **in Bid Data Sheet**. The Contract has to be endorsed as indicated in **Bid Data Sheet**.
 - 37.2 the successful Bidder shall sign, date, and return the Contract Agreement to the Contracting Entity.within the permitted period . In case of an unsuccessful Bidder's appeal as per ITB 36.2, the Contracting Entity has still the right to proceed with the Contract with the Successful Bidder upon finding that the contract is fully compliant and it is in the public interest not to delay the commencement of the Contract and where the cancellation of the Contract will impose great damages on the public interest. Nevertheless, the Contracting Entity has to notify the relevant Administrative Court of

36. Complaints and Appeals

37. Signing of Contract



Contracting Entity has the authority to implement the Contract after providing to the approval of the relevant Administrative Court a signed commitment for compensating the future damages resulting from implementing the Contract in case the ruling of the relevant Administrative Court was unfavourable to its decision. 38. Performance 38.1 Within fourteen (14) days of the receipt of notification Security of award from the Contracting Entity, or twenty nine (29 days) in case of complaints as per ITB 36.1, the successful Bidder shall furnish the performance security in accordance with the Conditions of Contract, using the Performance Security Form provided under Contract Forms in **Section IX** of. If rules and regulation of Republic of Iraq grants exemption to Public Companies of the state and public sectors, they are accordingly exempted of submitting Performance Security. 38.2 Upon the failure of the successful Bidder to submit the above-mentioned Performance Security or sign the Contract within the period specified under ITB 37.2, the Contracting Entity will send an official notice for the successful Bidder to sign the Contract within fifteen (15) days from receiving this notice, after which the Contracting Entity has sufficient grounds to proceed with the annulment of the award and forfeiture of the bid security of the here above declined Bidder. In that event the Contracting Entity may award the Contract to the next lowest evaluated Bidder whose offer is substantially responsive and is determined by the Contracting Entity to be qualified to perform the Contract satisfactorily. In that case the declined Bidder will be responsible for paying the difference in the bids prices in addition to forfeiture of the bid security. These actions will be taken against the declined bidders provided they decline during their Bid validity.

such a decision with all above justifications. The



SECTION II. BID DATA SHEET

Bid Data Sheet (BDS)

The following specific data for the Goods to be procured shall complement, supplement, or amend the provisions in the Instructions to Bidders (ITB). Whenever there is a conflict, the provisions in the Bid Data Sheet (BDS) shall prevail over those in the ITB.

A. GENERAL

ITB 1.1	Name of Contracting Entity: [Ministry of Healh / Environment / The State Company for Marketing Drug and Medical Appliances].
	Name of authorized Purchasing Agent: authorized by contracting entity : "none" Type of goods:Medicine as mentioned in tender lists
	<u>Tender:</u> Purchasing medicine <u>Tender Number:</u> Med/ 3 /2020 as listed in the Iraqi Federal Budget] IFB Number 3
	The number and identification of schedules (lots)comprising this IFB is detailed in Schedule of Requirementsare:[Schedule (1)-(4)] the year of the Federal
	Budget that certified by the competent authorities is 2018 to purchase the medicines for The Ministry of Health/ Environment / The State Company for Marketing Drug and Medical Appliances (Kimadia)
	The source of funding for the contract(s) is::[Ministry of Finance]

\B. THE BIDDING DOCUMENTS

ITB 4.1 Contracting Entity's Ministry of Health / Environment / The State Company For Marketing Drug and Medical Appliances (kimadia)/Drug Media Department & the Public Relations- 5th floor ,position of MOH(Ministry of Health),E-mail (dg@kimadia.iq) phone no.(07705419074) Requests for Clarification are to be hand delivered or sent by mail or by express courier and accepted by E-mail Adoption the bidder address which install in the tender & address for correspondence &communications, the bidder should notice the contracting party with any change to this address within seven days of receiving.

-additional to ITB :
Specifying the date of conference specialized to answer all the participants in the bid inquiries will be on (4/3/2020).

C. PREPARATION OF BIDS



List of disqualified bidders is available on the following website address: HTTP://WWW.mop.gov.iq
In addition to what is stated in the instructions to bidders, the following are added:
-Dilatory or violating the previous contractual obligations according to legal
documents with the same contracting party or in other contracting parties.
- companies are blacklisted in the following cases:
A- when dealing with foreign balcklisted companies.
B-When it is proved that one of the government staff takes bribery.
C-When it is proved that there is a forgery in the offer or any tender
documents.
D-When it is proved that they submit incorrect information or matters concerning
the work assigned to them for the purpose of harming the public interest.
E-When there is a violation in the conditions of the tender or technical
specifications contracted on, for the purpose of harming the public interest
F-When it is proved that there is a non-compliance with the profession principles
by using unfair methods of competition.
G- When refrains signing after being informed about the decision of awarding
H-The withdrawal of work due to the delay in the execution of the tender or the
breach of its contractual obligations.
The authentication of the certificate should be according to the instructions of implementing the governmental contracts No. (2) in 2014 concerning theitems imported from the Arab country.



Documentation requirements for eligibility of Goods. In addition to the documents 7.3 C stated in Sub-Clauses7.2 and 7.3 (a) and (b), the following documents should be included with the Bid: 1- The certificate of origin, of the imported materials in favor of the contracting party issued by the country of manufacture or product or country in which the final assembly takes place or country of shipment (country of export), should be submitted with reference to the origin of imported materials which must be accurate in terms of technical specifications for materials or equipment to be exported to Iraq on condition that there is a duly authenticated undertaking from the company of shipment which provide the imported materials bearing all the financial and legal responsibilities concerning the validity of the information mentioned in the original certificates of origin sent by the manufacturers or producers to the supplier in the last shipping country 2-To submit certificates of (U.S. FDA, GMP., EMA, JAP., MHLW, Canadian AUS - TAG, UK.MHRA, SWISS -MEDIC U.s) 3- To submit a certificate of company establishment for the manufacturer and supplier companies provided that the certificate should be original, authenticated and new. 4-Presenting the original and authenticated final balance sheet of the Manufacturer Company for the last five years which shows that there is a profit achieved during the last five years & stating the average rates provided . The final balance should be presented in English and Arabic languages only. In addition, the indicator of the final balance of the last five years should be positive. 5-The companies that participated in the tender shall submit their prices that are stated in their contracts with other countries and neighboring countries of Iraq provided that such prices should be attached to the tender supported by a confirmation, stamp and signature of the bidder. The following should be submitted for products manufactured from blood origin-: 1A- Certificates for plasma pool data and safety certificates during the



	manufacturing process.
	B- Methods used to get rid of the viruses of HBV, HCV, HIV and others the
	manufacturing process.
	C-Method of analysis and the safety certificate of the final product that the final
	product is free from viruses.
	2-To submit documents stating that the gelatin which is used in
	manufacturing capsules is from botanic or animal (halal) origin to Islamic
	law
	3- Companies supplying cancer drugs are obliged to re-issue the expired
	quantities of these medicines and not asking our companies consume them
	4- The companies that supply the chemotherapeutic products should available all
	the diagnosis requirements and clinical follow up in accordance with the Iraqi
	guidance of CMI treatment.
	-Special condition for medical milk:
	1-Adopting the weight of 400grn as a unit of measurement. The maximum limit is1000gm for Kimadia when contracting,2- The milk should be mentioned in (BNF) OR (Martin)-last edition as the
	specifications can be varied according to the updates that may appear in
	the future.
	3-The Milk should to be identical to recently updated British specifications. 4-The milk should be packed in the country of origin to avoid contamination during packaging.
7.4	Registration of goods is required in Iraq . {Note: Bid security or performance security will not be confiscated if the bidder fails to register the goods .
7.4 B	By the time of Contract signing, the successful Bidder shall have complied with the following documentary requirements in order to register the Goods to be supplied under the Contract:
	The conditions for registration which are approved by the Ministry of Health / Department of technical Affairs / registration section / Eighth floor {Note : Bidders should inquire about the conditions and procedures for registering the goods as soon as possible in order to avoid any delay that may result during the registration process by the various competent governmental bodies .}



	 -In addition to what has been mentioned, the following shall be considered: 1- The company should register its products before paying their shipped goods dues. 2- When the award is made for unregistered material ,the specifications, analysis method and standard material should be submitted upon the confirmation of the award at a maximum one- month period. 3- In case the item is not registered, no payment will be made for this contract unless the company proves submitting the documents of the material for the registration department or re- registered it.
7.4. 1	For the purpose of obtaining additional information about the requirements for registration, Bidders may contact { Ministry of Health/ Environment/Department of technical things /Registration section [Eighth floor].
11.1	The language of the bid is: Arabic or English In case the tender documents and contract are received in both languages : Arabic and English, and there is a difference in the interpretation, the Arabic language shall be adopted as it is the official language of the State



In addition to the documents stated in Paragraphs 12.1 (a) through (f), the following 12.1 documents must be included with the Bid. 1-The bidder who previously participated in the tender, should submit the prior purchase receipt together with the re-announced tender documents . In case there is an amendment in the prices of the tender documents, the bidder will bear the difference in the price when there is an increasing in the price and should attach the first and the second receipt with his tender. 2-When contracting, the beneficiary from the documentary credit should be the same contracted party and the banking details should bear the name of that company. It should exclusively contain (name and address of the bank, name of owner of account (the company contracted with) (swift code and sort code and Iban..... etc). The account should not bear a person name. Any change in the beneficiary name and address, , bank name and address, account no. and any other bank information after the agreement is considered a violence after informing the supplier about the information stated in the tender, a fine will be imposed on the supplier. 3-Submitting a the factory license renewal regarding the national factories. 4- Factories and their materials must be registered in the registration section of the Iraqi Ministry of Health, as the ministry will not market any unregistered product. 5-The displayed Items or materials should bear its commercial or brand name. In case items are displayed in scientific names, the pharmacopoeia should be stated 6- The companies should submit a letter permission issued by the general commission for taxes when participating in the announced tenders.

Republic of Iraq

14	14.6 -In addition to what mentioned in instructions devoted to the bidders, the
	following will be done:
	-Neglecting the offer which is based on reduction a percentage or taking out a
	certain sum from any of the other presented offers in the tender. Any
	reservation and reduction of the price presented after the closing date of tender
	will be not accepted. We confirm the condition of not making any change after
	the notification of awarding. All letters regarding decreasing the offered items
	prices after the closing date of the tender without a request from KIMADIA will
	be neglected.
15.1	b) Foreign currencies: In US dollar or by ink or by printed Form in numbers and
10.1	written forms and should be clear without erasing or scratching
	written forms and should be clear without erasing of scratching
16.1	The bid validity period shall be (365) days so , each bid must be valid until (9/3 /2021)
	Bid security must be valid twenty-eight (28) days after the end of the bid validity period. Accordingly, a bid with a bid security that expires before(6/4/2021) shall be rejected as nonresponsive.



17.1	 Public Companies of the state and public sector are exempted from submitting tender securities in accordance with the valid instructions of implementing the government contracts . The amount of the tender securities shall be 1% from estimated cost of ender in Iraqi Dinar or its equivalent in a convertible currency from the list of currencies from which the Central Bank of Iraq issues the price of exchange o the Iraqi Dinar In addition to what mentioned in 17.1 be (c) or saftaja. Taking into account the following:
	1- Bidder should submit Preliminary Insurance (Bid Bond) or any of the share
	holders of the company or share according to share contract for the benefit
	of contracting party which should refer to the tender name and number.
	2-The Guarantee Bond should be issued according to the order of the company with
	Which we contracted with or with its legal authorized figure who gained the
	authority to issue the guarantee in accordance with formal authenticated
	authorization.
	3-The guarantee Bond should be attached with a letter of authenticity of issuance.
	(Private & confidential) send to kimadia by the bank who issued the guarantee.
	-The guarantee should be issued in the Arabic and English languages.
	4-In addition to what has been mentioned in 17.7, the following should be taken into account
	(or refuse to correct his statistical errors in the tender which have an effect on the decision of awarding, All the legal actions written in the instructions of the governmental contract implementation will be applied against him.



17.4	Concerning the approved companies & according to the approved companies
	conditions.
17.8	If the Bidder defaults under the actions prescribed in subparagraphs (i) or (ii) of this provision, the Contracting Entity will declare the Bidder in violation and will inform the Ministry of Planning and Economic Development to take the required actions against the violating Bidder (including Suspension or Black Listing) as per the applicable Iraqi laws. In addition to what have been mentioned in the instructions to bidders, the
	following should be added:-
	If the participants in the tender reject making the contract after notification by awarding, the following procedures will be taken against bidder
	-Executing the contract on his expense without a need to warn him or take any other legal procedure
	-In case of breach the two nominees(the first &second) the contracting party has
	the right to award the tender to a third bidder & each of the two breach will bear
	the difference of price according to the difference amounts for their nomination
	confiscating preliminary securities of the two.
	-In case of the third nominee breaches the tender, his preliminary securities will
	be confiscated & re-announcing the bid while the three breach bidders will bear
	the difference of price according to the submitted price of each one of them
	confiscating the securities of the three breach bidders.
	-The above procedures should be applied upon the three bidders when
	breached during the period of tender validity.
18.1	Required number of copies of the bid in additino to the original bid is: [3 copies]. What is mentioned in item 18.1 of the instruction to bidders has been modified to
	be as following:
	-The offers have to be delivered in the same format as requested for tender in CD
	& hardcopy (printed out from CD or Disk) . All the papers should be signed and
	stamped and the information should be compatible. When there are substantial
	inconsistencies between the hard copy offer and CD, our company (Kimadia) has



	the right to neglect the offer on CD and depend upon the hard copy offer in case
	of the availability of simple differences provided that these differences will be
	specified whether they are simple or not by the committee of analysis and
	studying offers
18.2	The written confirmation of authorization to sign on behalf of the Bidder shall
10.2	consist of: a Power of Attorney issued by the Bidder dated no more than 3 month or Company
	Registration Form (Certificate of establishment showing the authorized signatory).
	The Offers should be submitted directly by the manufacturing company through
	the following:
	-Director General or his representative.
	-Assistant of Director General or his representative
	-Sales manager (marketing)
	-Commercial manager.
	-Authorized scientific bureau which has a legal authorization.
	-We can accept the authorization of any representative of the company staff whose title is not stated above provided that his authorization should fulfill the legal form and the required authentications.
	-Special instructions concerning the authorization letters (A.L)
	First—The authorization letter should be authenticated officially by-:
	A-Chamber of commerce in the country of origin
	B-Ministry of foreign affairs or notary public in the country of origin.
	C -Iraqi embassy its representative in the country of origin.
	D- Iraqi ministry of foreign affairs in Baghdad should fixed its stamp and



signature to authenticate the stamp of the Iraqi embassy in the country of origin.

E-If the Iraqi embassy cannot stamp all the above mentioned documents either because there is no Iraqi embassy or there is no information about the identity of the persons who represented the company, the embassy of the country of origin in Iraq has to authenticate the official authorization letters in order to be legal and Agreed upon.

F- If there is no (diplomatic representation)) between the country of origin the authentication should be made in a third country from the embassy of the country of origin and the Iraqi embassy in the third country then the ministry of foreign affairs has to authenticate the signature and the stamp of the Iraqi embassy.

Second-The company should mention in the authorization letter whether it's a manufacturer or supplier (marketing company)

A- In case of being a supplier company, the followings should be clear -: -names &specialties of the manufacturing companies.

-It should have an authenticated authorization letter from the manufacturing companies as mentioned above item (first)

-your manufacturing company should mention that you are a sole and exclusive (supplier) for all its products in Iraq

B- In case of being a manufacturer company, your specialties (having special knowledge a particular system) should be mentioned and written down and you should mention that you are a sole &exclusive representative to deal with concerning all your products ,also the company should refer to the names of its factories and branches by submitting original authenticated certificates of establishment that proved the company factories & its branches.

C -the A.L should be authenticated as mentioned in item (First).

D —Catalogues with (CD) stating the company's products should be submitted by the manufacturing companies to **Drug Media Department& the Public Relations**. The manufacturing companies should write down their emails on the letters of authorization. Any authorization letter with no emails will be neglected.



Third — (A) The company should specify the name of Iraqi scientific bureau & the name of pharmacist who is licensed from Iraqi syndicate of pharmacists for following up and completing the technical data upon request by the committee of study and analysis in case of submitting the tenders through the scientific bureau, or providing an authorization for signing the contract the list of the submitted tender and its documents as an agent. The scientific bureau should be the exclusive representative of all company products or dealing directly with the company through formal authorized figure as it is shown in item no. (6). B- The scientific bureau will stay responsible till after the expiration of the authorization from foreign companies which authorized him unless the following Authorization has fixed the obligations of the previous foreign companies and its effects. **Fourth**—The authorization letter must be entitled to kimadia, the state company for marketing drugs and medical appliances, General Drug Media Department& the Public Relations fifth floor —before the closing date. Fifth- The name of scientific bureau should be added in the contract **Sixth**-The authorization issued by the manufacturer to supplying company, (in case of necessity to make contract with supplying company), the capacities of the supplying company concerning the following should be clarified. A-Signing the contract & executing all its obligations, provided that it should be signed by the manufacturer company exclusively B-The negotiation about technical affairs and prices.

C- Specifying clearly and in details the beneficiary applicant from documents L/C& beneficiary from the bank account with the whole banking details noting that the one who signs the contract without company should be the beneficiary party itself.

	اله اکبر Republic of Iraq 36
	 D- Specifying the correspondences & the authorities concerning the tenders as for submitting, stamping, signing, opening & submitting the prices without being satisfied by issuing a general authorization which authorizes all these powers. E-Confirming to go on executing all the contracting obligation. The marketing company will bear a legal responsibility for the period of execution the contract even when the period of authorization is expired. Noting that all the procedures including registration the company ,its products . Full address and details of the manufacturing & supplying companies should be fulfilled. In addition, to accomplishing the stamps& legalizations as applicable now.
	 F-The contracted companies should submit the legal &required assurances according to the conditions of invitation within stipulated period in these instructions. Seventh: Names of the authorized persons of signing &stamping the contracts & offers and their administrative description and samples of their signatures should be mentioned(written down)
	7-Your offers should include a copy of all original authorization letters issued and legalized producing companies to the marketing ones addition to the original authenticated copies as it is mentioned in item (4) from article (six) to be handed to (3RD bearing all above mentioned authentications.
18.3	In addition to what are mentioned in Instructions to the bidders, the followings are added. The participant has no right to object on any condition of the tender conditions



19.2B	For bid submission purposes, the Contracting Entity's address is :
	Attention:Baghdad – Bab Al-Moadham – Ministry of Health /Environment
	Ministry of Health / Environment (Kimadia) – sixth floor – receiving and opening
	tenders committee
	CityBaghdad
	Country: IRAQ]
40.00	The Tender Tender Ne, and ICD Ne are
19.2C	The Tender, Tender No. and IFB No are: Tender: Med/ 3 /2020
	Tender No. : 3
	Contracts of supplying medicine be arranged according to the current balance
	Reference letter invitation to tender :
	In addition to what is mentioned in this article concerning the bids that are
	submitted through the fast mail, all authorization letters and documents(original
	and authenticated) should be included in a separated envelope in order to be
	checked and it should be reached to Kimadia before the closing date, otherwise
	the offer will be neglected provided that the address of the company inside and
	outside Irag and the additional attachments attached with the offer and the
	number of pages for each offer should be written on the envelope
20.1	Deadline for bid submission is: the date of closing the bid is the end of the
-	official work on 9/3 /2020
	If the closing day happens to be on an official holiday the new closing date
	shall be in the first working day following the holiday.

E. BID OPENING AND EVALUATION

23.1	The bid opening shall take place at:
	Street Address: Baghdad-Bab AI moaadham -Ministry of
	Health
	Floor/Room number: Ministry of Health /Environment /The state company for
	drug and medical appliances (Kimadia)-sixth floor -receiving and opening of
	tenders commitee.
	City: Baghdad
	Country : Iraq
	Date: [10 -3 -2020]
	Time: [



27	In addition to what are mentioned in the instruction to bidders:
	- If an item or items are mentioned in the tender without their price , the cost of the item or items with all their specified quantities will be included within the total price of the tender
29.4	It is not applicable to medicines supplement
30.1	In case the bid which has been evaluated to be the lowest cost and which meets the demanded Qualification Criteria includes foreign goods according to article 29 of the Instructions to bidders, A preference remark will be given to the responsive bid offered by National Private Sector Factories of the Republic of Iraq provided that the national product price does not exceed that of the foreign product by 10%." -the second party undertakes to prioritize the raw materials manufactured
	inside Iraq for supplying the contract materials or for implementing the projects through the companies of the Ministry of Industry and Minerals according to the
32	letter of Ministry of Planning no. 16135 dated 3/8/2017. 32.2 In addition to what is mentioned in this item of instructions for
52	bidders, the following conditions should be taken into account.
	Exclusion the bid which is less or greater than 20% or more of the estimated cost allocated for the awarding and in case there is an appropriate price of a bid that meets the required qualifications but there is a rate of diverse in the price analysis of some items (unbalanced) by more than 20% increase or decrease for each item separately and which constitute atotal of not more than 10% of the total items , it is possible to accept the awarding and otherwise the bid will be excluded taking into account the exception provided by the office of Prime Minister no. 15773 on 10/11/2015 regarding the acceptance of bid which is less than 20% of the estimated cost .
34	34.1 amending this paragraph of ITB to be :
	The contracting party may increase the quantity of non-consulting goods or materials or services or modify its technical specifications contracted to no more than the percentage of reserve amount stipulated in the annual budget implementation instructions provided that the financial allocation is available and that the prices of the paragraphs covered are increased in accordance with the quoted paragraphs (20%) of the quantity of the paragraph and the above is subject to the prevailing market prices taking into account the reflection of these variables on the contractual obligations as well as the financial guarantees with a contract attachment and under the same conditions contracted for projects listed in the

Republic of Iraq الله الكبر

39

	balance sheet Exclusive
	The contracting party may increase the quantity of non-consulting goods or materials or services, or amend their technical specifications contracted by not more than (20%) of the amount of the contract provided that the financial allocation is available and that the prices of the paragraphs included in the increase are approved in accordance with the paragraphs quoted by the contractor (20%) of the amount of the paragraph and the above is subject to prevailing market prices taking into account the reflection of these variables on contractual obligations as well as financial guarantees with a contract attachment for the projects included in the operating budget and special budgets issued by the approvals of the competent authorities For approval by the Ministry of Finance(
	The contracting party may deduct the non-advisory goods, materials or services, and not more than (15%) fifteen per cent of the contract amount
	The contracting entity may partition the awarding of supplying the goods , materials or services required to be supplied .
37.1	The Contract to be signed with the successful Bidder shall be written in the language in which the Bid was submitted, and which will be the language that shall govern the contractual relations between the Contracting Entity and the successful Bidder. A Bidder shall not sign a translated version of its Contract. In addition to that should be written an original contract copy in Arabic language The contract must be ratified in accordance with the procedures adopted in this
37.2B	regard in Iraq. In case that the judgment of the specialized court was on the contrary to
57.20	
	the contracting party decision which has continued in the procedures of
	contracting, the bidder who appeal the judgment has to contact the
	specialized courts to ask for compensation if the appeal was based on true
	causes.
	In case the procedures of contracting were stopped by specialized court order & judgment issued by the same court committing the contracting party to fulfill all the contracting procedures with the objecting bidder, contracting party could filled up a suitcase that claim to obligate the objecting bidder to compensate any damage that will appear in the future as a result of the contract execution.

In addition to what mentioned in ITB the following will be added : The participant has no right to object any condition of the tender conditions .



Bid Data Sheet (BDS) <u>VACCINES</u> (Additional Clauses)

 1. The Goods to be supplied under the Contract must be licensed both in the country of manufacture and in Iraq by the time of Contract signing by a recognized NCA. An NCA is an organization that performs all six critical functions for control of biological products as defined by the World Health Organization, namely: licensing based on published set of requirements; surveillance of vaccine field performance; system of lot release for vaccines; use of laboratory when needed; regular inspections for good manufacturing practice and evaluation of clinical performance. The license from country of manufacture the Goods by the NCA in the manufacturing country. Documentary evidence in the form of a certified copy of the license and a copy of the vaccine license/registration that the offered vaccine has been licensed by the NCAs of the manufacturer's country shall accompany the bid and a copy of the license issued by an NCA in Iraq must be submitted by Contract signing. If there is no NCA with specific biologics expertise in Iraq, the Bidder shall furnish evidence that the Goods meet the qualification criteria in the Technical Specifications. 2. If the Goods offered do not meet the specified pharmacopoeia standards as stated in the Technical Specification, the Bidder will provide testing protocols and alternative reference standards. 		
	ITB 7.3 (c)	 licensed both in the country of manufacture and in Iraq by the time of Contract signing by a recognized NCA. An NCA is an organization that performs all six critical functions for control of biological products as defined by the World Health Organization, namely: licensing based on published set of requirements; surveillance of vaccine field performance; system of lot release for vaccines; use of laboratory when needed; regular inspections for good manufacturing practice and evaluation of clinical performance. The license from country of manufacture must state that the Bidder is licensed to manufacture the Goods by the NCA in the manufacturing country. Documentary evidence in the form of a certified copy of the license and a copy of the vaccine license/registration that the offered vaccine has been licensed by the NCAs of the manufacturer's country shall accompany the bid and a copy of the license issued by an NCA in Iraq must be submitted by Contract signing. If there is no NCA with specific biologics expertise in Iraq, the Bidder shall furnish evidence that the Goods meet the qualification criteria in the Technical Specifications. 2. If the Goods offered do not meet the specified pharmacopoeia standards as stated in the Technical Specification, the Bidder will provide testing protocols



SECTION III. EVALUATION AND QUALIFICATION CRITERIA

1. Evaluation Criteria

The Evaluation Criteria has been specified in Instructions to Bidders(ITB) in Section I and Bid Data Sheet(BDS) in Section II. The specific data Bid Data Sheet(BDS) for the Goods to be procured shall complement, supplement, or amend the provisions in the Instructions to Bidders (ITB). Whenever there is a conflict, the provisions in the Bid Data Sheet (BDS) shall prevail over those in the ITB.



2. Qualification Criteria

Qualification requirements for Bidders Goods are:

{Note: Contracting Entity may insert appropriatequantifiable qualification criteria for experience and / or financial viability etc depending upon type of good}

A) {For Health Sector Goodsinsert}

The following documents must be included with the bid:

Documentary evidence of the Bidder's qualifications to perform the Contract if its bid is accepted:

- (i) that, in the case of a Bidder offering to supply Goods under the Contract that the Bidder manufactures or otherwise produces (using ingredients supplied by primary manufacturers) that the Bidder:
 - (a) is incorporated in the country of manufacture of the Goods;
 - (b) has been licensed by the regulatory authority in the country of manufacture to supply the Goods;
 - (c) has manufactured and marketed the specific goods covered by this Bidding Document, for at least [insert two (2) years or as per market availability], and for similar Goods for at least five (5) years;
 - (d) has received a satisfactory GMP inspection certificate in line with the WHO certification scheme on pharmaceuticals moving in International Commerce from the regulatory authority (RA) in the country of manufacture of the goods or has been certified by the competent authority of a member country of the Pharmaceuticals Inspection Convention (PIC), and has demonstrated compliance with the quality standards during the past two years prior to bid submission;

(ii) that, in the case of a Bidder offering to supply Goods under the Contract that the Bidder does not manufacture or otherwise produce,

(a) that the Bidder has been duly authorized by a manufacturer of the Goods that meets the criteria under (i) above to supply the Goods in Iraq; and

(iii)The Bidder shall also submit the following additional information:

- (a) a statement of installed manufacturing capacity;
- (b) copies of its audited financial statements for the past three fiscal years;
- details of on-site quality control laboratory facilities and services and range of tests conducted;
- (d) list of major supply contracts conducted within the last five years and relevant certifications endorsed by respective Clients. }
- A1 {For Pharmaceuticals insert the following additional clauses}

Documentary evidence of the Bidder's qualifications to perform the Contract if its bid is accepted:

- (i) (e) has a Good Distribution Practice (GDP) Certificate where appropriate.
- (iii) The Bidder will submit the following additional information:
 - (e) list of pharmaceuticals being manufactured by the Bidder with product registration/license number and date.
 - (f) a Certificate of Pharmaceutical Product as recommended by the WHO for each item offered.]
- A2 {For Vaccines insert the following additional clauses}



Documentary evidence of the Bidder's qualifications to perform the Contract if its bid is accepted:

- (i) (e)is certified by a competent authority in the country of manufacture according to resolution WHA 28 65 (2) of the World Health Organization's Certificate Scheme on the Quality of Pharmaceutical Products Moving in International Commerce.
- (iii) The Bidder will submit the following additional information:

(e) list of vaccines being manufactured by the Bidder with product registration/license number and date.]

B) In addition to what are mentioned above the Qualification criteria are:

1-Accurate technicality specifications which specify the technical features of Goods and the related services that requested by contracting Entity. They are technical features and quality standards of the Goods ghat requested by contracting Entity and the rate of meeting the specifications and which make the evaluation the bid process easier. They have clear indicators that show the purpose of using Goods and contain work environment details (warmth, wetness, storage condition,.etc) and packing requirements

ratification drug and its degree of meeting the technique specifications stated by the national committee of selecting medicines

- 2- Financial efficiency and ability
 - a- the final balance for the last (2) years and (5) years concerning the

dependable company authenticated by the auditor and gain profit in

the balance

b-annual income: of years from(1-10). c--liquid pecuniary :

- Liquid pecuniary (large contracts) in proportion of assessment cost to contract.
- Liquid pecuniary (medium contracts) range between (70%) to (100%) of assessment cost.
- Liquid pecuniary (small contracts) range between (30%) to (50%) of assessment cost.



3- specialization experience (the Identical works)

-Number of required work in the document of tender range between (1-3)

-Number of years required for similar works range between (5-10) years noting that requested similar works is "potential" in small works.

- 4- The kind of commercial sale and the method of supplying(transport, insurance & delivery and delivery place of the items.
- 5- domestic preference.
- 6- The availability of contracts and similar executed works within the specialization and the rate and level of execution and commitment of the company when implementing them.
- 7- certificate of trading in the country of origin.
- 8- manufacturing goods meets the requirement of good manufacturing Practices (GMP) other certifications (FDA) that are mentioned in bid documents and mechanisms of quality control.
- 9- Responding to the legal conditions ,technical specifications, standards of required rehabilitation, table prices meet samples of standard-documents as being the lowest price and balanced with the estimated cost.
 - 10- duration of executing the contract.
 - 11-company status from registration.



12- Status of the product from registration knowing that instructions that bidder shall begin to register in the specialized authorities and the contract will become effective from the date of receiving the registration certificate in case the product is not registered. If the product is registered or under the exception of the Minister of Health from submitting the registration certificate, the contract shall be effective from the date of its signature.



SECTION IV. BIDDING FORMS

NOTES ON THE BIDDING FORMS

The Bidding Forms provided in this SSBD provide standard formats for a number of the key documents that the Contracting Entity and Bidders will exchange in the process of bidding.

{The Contracting Entity shall fill in the Forms with the needed information relevant to each procurement before launching the Bidding Process. The required place for writing this information is under the paragraphs written in Italic style and shaded in grey. Any notes provided to the Contracting Entity which is underlined and shaded in yellow is for information only and shall be deleted before releasing the Bidding Documents.}

The Bidder will fill in his part of the form where it is designated between brackets or_____.

The Bidders must complete the Forms as indicated on the form, and submit them to the Contracting Entity.

Price Schedules: The price breakdown given in the sample Price Schedules generally follows the usual breakdown requested for procurement of Goods in order for the domestic preference procedure to be applied. It is essential that Bidders submit their prices in the manner prescribed by the Price Schedules. Failure to do so may result in loss of the preference, if applicable.

Manufacturer's Authorization Form: In accordance with ITB Sub-Clause 8.1 (b), Bidders must submit, as part of their bids, Manufacturer's Authorization Form(s) in the format provided in the SSBD for all items specified in the Bid Data Sheet.

Bid Security Form: Regarding ITB Clause 17, the Contracting Entity should include the Bid Security form provided in the SSBD in the Bidding Documents. The Contracting Entity must ensure that the submitted form substantially complies with the features of the form included here in respect to its degree of protection and clarity of conditions under which it can be made effective in accordance with the applicable Iraqi Laws.



1. Bid Submission Form

Date: [insert: date of bid] {ContractingEntity to insert: Tender Number: [MED/ 3 /2020]"} IFB Number: [3 "}

To: {Contracting Entity to insert: [Name and address of Contracting Entity]}

Dear Sir or Madam:

Having examined the Bidding Documents, including Addenda Nos. [insert **numbers**], the receipt of which is hereby acknowledged, we, the undersigned, offer to supply and deliver the Goods under the above-named Contract in full conformity with the said Bidding Documents for the sum of:

[insert:	amount of "Iraqi Dinar" in words]	([insert: amount of "Iraqi Dinar" in figures])
plus	insert: amount of "US Dollar" in words]	([insert: amount of "US Dollar" in figures])
plus	[insert: amount of "Euro" in words]	([insert: amount of "Euro" in figures])

(hereinafter called "the Total Bid Price") or such other sums as may be determined in accordance with the terms and conditions of the Contract. The above amounts are in accordance with the Price Schedules attached herewith and are made part of this bid.

- We undertake, if our bid is accepted, to deliver the Goods in accordance with the delivery schedule specified in the [insert "Schedule of Requirements in Section-VI"or"as quoted in Price Schedule in Section-IV"] (the Bidder may select as appropriate clause).
- 3. We agree to all General Conditions of Contract in Section-VII read in conjunction with the Special Conditions of Contract in Section-VIII.
- 4. If our bid is accepted, we undertake to provide an advance payment security and a performance security in the form, in the amounts, and within the times specified in the Bidding Documents.
- 5. We agree to abide by this bid, for the Bid Validity Period specified in Sub-Clause 16.1 of the Bid Data Sheet in Section II and it shall remain binding upon us and may be accepted by you at any time before the expiration of that period.
- 6. Until the formal final Contract is prepared and executed between us, this bid, together with your written acceptance of the bid and your notification of award, shall constitute a binding Contract between us.
- 7. We understand that you are not bound to accept the lowest evaluated bid or any other bid that you may receive.
- 8. We agree to the following Eligibility Criteria:
 - (a) We have nationality from Eligible countries as per ITB Sub-Clause-6.1 of Section-I.
 - (b) We do not have conflict of interest in accordance with ITB Sub-Clause-6.1(a) of Section-I.
 - (c) We are not a Government-owned Entity in Republic of Iraq./ We are a Government-owned Entity in the Republic of Iraq and meet the requirement as per Sub-Clause 6.1(b) of Section I.



- (d) We including any of our subcontractors or manufacturers for any part of the contract, have not been declared ineligible by the Contracting Entity, under the Contracting Entity's country laws or official regulations or by an act of compliance with a decision of the United Nations Security Council.
- (e) We have not been Black listed or Suspended by Republic of Iraq and declared ineligible to bid during the period of time determined as per ITB Clause 6.3 of Section-I.

9.	We	cont	firm	that or	ur wel	osite	add	ress is	s <mark>inser</mark>	t web	<mark>o side</mark>	 		,
and	our	mail	add	ress i	s:									,
and	that	t Mr.	/Ms	·									of Job	Title:
						_ and	de-n	nail ad	ddress					will be
· ···								~						

following up all matters relevant to any Clarifications.

Dated this [insert: number] day of [insert: month], [insert: year]. Signed:

Date

In the capacity of [insert: title or position]

Duly authorized to sign this bid for and on behalf of [insert: name of Bidder]





2. A. Price Schedule for Domestic Goods or Goods of Foreign Origin Located In Iraq

								Bri	ef Desc	1 ription	of Goods									
No. of bid tpreciept committee	Code of manufactur company	Offers submission	National code	Generic name	Generic name related to company that submit the bid	Trade name	Active item	Pharmaceutical from	volume	weight	Registration item no.	Registration item date	Quality certificate	Sample submission	sodium meta bisulfate) existance in this compand ornot)	Raw material	Registration product no.	Registration product date	Perunite of package	Per uniteof sheet

Delivery Period: ______ [Bidder may insert quoted delivery period] as per INCOTERMS[®] current edition ______ [Insert Incoterms].

Signature	of Bidder		
Name			&
Designation	on		
Seal	of	the	Bidder
Date:			



2 4 5 3 **Quantity offered Country of origin** Price per physical unit Iraq **Price & the transport way Total Price** currency (NO., Write) Total Price on DDP/Free **Delivery** at Ex-factory/ex-End-users' warehouse/ex-Inland show room/off-Sales and transportation (Iraqi Dinar) the shelf insurance Incidental other taxes including and duties loading/unloading services as Price on and incidental defincal in DDP/free packing and pavable if Quantity of The name of The origin of forwarding contract is costs till end-users schedule of delivery at bid producting producting Per unit Currency charges awarded site requirement end-users quantityX 5 submitted e=(a+b+c+d) company (a) **(b)** (c) (**d**) Free goods company Package price price type

2. B. Price Schedule for Domestic Goods or Goods of Foreign Origin Located In Iraq

Grand Total of Bid price in Iraqi Dinar: (I	In figures)	(In words)
---	-------------	------------

[Bidder may insert quoted delivery period] as per INCOTERMS[®] current edition ______ [Insert Incoterms]. Delivery Period:

Signature of Bidder
Name & Designation
Seal of the Bidder
Date:

6

site.

(e)



3.A. Price Schedule for Goods to be imported from Abroad

Seria	l no.			1				2					Γ	Descripti	ion item o	3 of manufa	ctur coi	mpany					Cou	4 ntry origin.	
NaOf item	no.of tander receipt committe e	Nation Man ufact uring com p. Code (K- code)	nal code National itemcode	National Generic name	description Pharmasufic alfirm	Unit per blist er	Unit per pack	Qty. Offer Quantity	Desicri ption itemof manuf actur co.	Generic name of compan yikm	Active ingredi ent	(sodiu m meta bisulfa te) existan ce in this compa nd or not	Trade Name	volume	wight	Anival way	Entr y poin tto cou ntry	Shel filie of item	Supplyin gperiod	liem Registrati on Date &No.	Submissio nof Samples	origin of Raw material	Goods	Country origin	Ra a Ni Sul i co
			02- H00- 014	Lipas 2000 - 1000 0IU Prot ease 200- 600 IU Amyl ase 2000 - 1000 0 IU/g m 																					



		200	 	 	 	
	ل ان يكون بشكل sach et اسهولة استخدا مة للاطفا					
03- A00- 044	Salbu tamol as a base 100m cg/m etere d Inhal ation Aeros ol Using of prope Ilant 134a CFC -free is appro ved in these prepa ration s - Salbu tamol aeros ol - F Beclo meth					



	200					
ason						
е						
aeros						
بما ol						
يعادل						
mcg1						
00						
(as						
sulph						
ate or						
as						
base) لمستح						
لمستد						
ضرات						
sulph						
ate or						
base						
لامانع						
من						
من اعتماد						
المادة						
الفعالة						
بشكل						
وبأشكال						
له						
الصيدلاد						
ية						
وحسب						
المقر						
وحسب المقر دستورياً Salbu						
Salbu						
tamol						
mca						
بما						
بما يعادل						
١						
(as						
sulph						
ate or						
as						
base)						
base) أن						
-يكون						
ضمن						
المستلز						
ضمن المستلز Sمات						
<u> </u>	1 1	I I	1 1	 	I I I	I



		· · · · · · · · · · · · · · · · · · ·	·	 	·	 	 	 	_
	PAC ER								ļ
	ویکون NEB ULIZ								
	ER عن SPA CER يفصل -ال								
	(بنسبه ۱/۲۰) SPA CER								ļ
	CER ویکون استیر اد ال								
	Aeros ol من كمية الاحتياج الكلي للبخاخا								
	الكلي الكلي للبخاخا Becl						 		
	beci omet haso ne								
	dipro pion ate								
03- B00- 015	aero sol 250 mcg/								
	mcg/ each actu ation								
	(For adult s only)								ļ



		200	 	 		 		
	Icati							
	bant							
	as							
	acet							
03-	ate							
D00-	injec							
047	tion							
	10m							
	g∖ml							
	- 3ml							
	pfs							
	Reco							
	mbin							
	ant							
	hum							
	an							
	prot							
	ein							
	TSH							
	(thyr							
	otro							
	pine							
06-	, alfa)							
C00-	injec							
033	tion							
033	0.9							
	mg							
	vial							
	يحصر							
	أستخدا							
	مها في							
	هذة							
	المراك							
	j							
	اعلاه							
	فقط							
	لمرضد							



 	1 1		 	1	-	 	 			 		1		
		ی سرطا												
		سر ط۱												
		ن الغدد												
		الغدد												
		الدرقيه												
		1												
		т												
		دائرہ												
		صحه												
		/ بغداد												
		ألكرخ												
		/												
		مستشد												
		فى												
		اليرمو												
		اليرمو ك												
		التعليم ي / قسم الطب												
		(سعبيد												
		ي /												
		قسم												
		الطرب												
		•11												
		النوو ي												
		ي												
		2-												
		Z												
		دائرہ صحة												
		صحة												
		/بغداد الرصا												
		1 11												
		الرصا												
		فه /												
		فه / مركز الغدد												1
		الخدر												
		1												
		الصبم												
		الصىم و السك												
		(6.)												
		ري 3-												
		3-												
		دائرہ												
		صحه												
														1
		مدينه												1
		مدينه الطب												
		/ قسم												
		V /	1		1							I	1	<u> </u>



	200	 	1 1	 	 I I I I I I I I I I I I I I I I I I I	
الطب						
النوو						
35-1						
ي						
ي 4-						
دائرہ						
صحه						
نينوى						
/						
مستشد						
في الاور ا						
الاورا						
_ م						
م و الطب						
و الطب						
النوو						
النوو ي 5- وزاره						
5-						
J-						
وراره						
الصد						
, internet						
ہ / مجلس السرط ان / فی الامل						
السرط						
ان /						
قي						
الامل						
/ قسم						
الُطبُ						
الصب						
النوو						
ې						
النوو ي حيث يتم						
يبم						
اخذها						
بو اقع						
(Terl)						
بواقع (٢فيال) لكل						
مريا						
`مري ض ولمدہ						
a) al a						
وتمده						
يومين						



التقاري التقاري
الجائر الجائر الجائر
الجائر الجائر الجائر
الجائر الجائر الجائر
مداد مداد الشغ الشغ الشغ الله الشغ الله الله الله
مداده مداده الشنج الشنج الحالية الشنج التحالية التحالية التحالية
السان السان السان
الس الس الس ا
السان عبار عبار السن والأمر القليه اللقليه القليه القليه القليه القليه القليه القليه القليه العام
السان عبار عبار السن والأمر القليه اللقليه القليه القليه القليه القليه القليه القليه القليه العام
السان عبار عبار السن والأمر القليه اللقليه القليه القليه القليه القليه القليه القليه القليه العام
عبل عبل عبل السن والاحر السن والاحر الشابه القابه الشابه القابة الشابة القابة المابة المابة المابة الما
والامر التليبة والمزام والمزام والمزام والمزام لايتشر ولتون ون لايتشر ولتون ون لايتشر ولتون ون لايتشر ولتون ون لايتشر ولتون ون لايتشر ولتون ون لايتشر ولتون ون لايتشر ولتون ون لايتشر ون لايتشر ولتون ون لايتشر ولتون ون لايتشر ولتون ولت ولتون ولتون ولت ولتون ولتون ولت ولت ولت ولتون ولتون ولتون ولتون ولت ولتون ولتون ولت ولتون ولت ولت ولت ول ولت ولت ول ولت ولت
والامر التليبة والمزام والمزام والمزام والمزام لايتشر ولتون ون لايتشر ولتون ون لايتشر ولتون ون لايتشر ولتون ون لايتشر ولتون ون لايتشر ولتون ون لايتشر ولتون ون لايتشر ولتون ون لايتشر ون لايتشر ولتون ون لايتشر ولتون ون لايتشر ولتون ولت ولتون ولتون ولت ولتون ولتون ولت ولت ولت ولتون ولتون ولتون ولتون ولت ولتون ولتون ولت ولتون ولت ولت ولت ول ولت ولت ول ولت ولت
والامر التليبة والمزام والمزام والمزام والمزام لايتشر ولتون ون لايتشر ولتون ون لايتشر ولتون ون لايتشر ولتون ون لايتشر ولتون ون لايتشر ولتون ون لايتشر ولتون ون لايتشر ولتون ون لايتشر ون لايتشر ولتون ون لايتشر ولتون ون لايتشر ولتون ولت ولتون ولتون ولت ولتون ولتون ولت ولت ولت ولتون ولتون ولتون ولتون ولت ولتون ولتون ولت ولتون ولت ولت ولت ول ولت ولت ول ولت ولت
يؤدي الى مضاع فات سحيه
يؤدي الى مضاع مضاع محيه للمري
يؤدي الى مضاع فات سحيه
يؤدي الى مضاع مناع للمري
مضاع مضاع فات مضاع ساع مضاع ساع مضاع ساع مضاع ساع مضاع ساع مضاع ساع مضاع مضاع مضاع
مضاع مضاع فات مضاع ساع مضاع ساع مضاع ساع مضاع ساع مضاع ساع مضاع ساع مضاع مضاع مضاع
مضاع مضاع فات مضاع ساع مضاع ساع مضاع ساع مضاع ساع مضاع ساع مضاع ساع مضاع مضاع مضاع
المريا



		200	 			-		 		
	Fludr	T I	T	T I] [Ē.	
	ocor									
	tison									
00	e									
06-	acet									
E00-	ate									
014	0.1m									
	g									
	Tabl									
	et									
	mec									
	aser									
	min									
	(reco									
	mbin									
	ant									
	hum									
	an									
	insuli									
	n -									
	like									
	grow									
06-	th									
J00-	facto									
010	r - 1									
	rhl									
	GF-									
	1)Inc									
	relex									
	inj									
	mec									
	aser									
	min									
	10m									
	g/ml									
	(4									
1			1 1		I		I			1



			20	0									
		ml											
		vial)											
		Fibri											
		noge											
		n											
		conc											
		entr											
		ate(
		Hum											
		an):-											
		Lyop											
		hilize											
		d											
		pow											
		der											
		for											
		reco											
		nstit											
	08-	ution											
	H00-	900											
	016	mg											
		to											
		1300											
		mg											
		for											
		reco											
		nstit											
		ution											
		with											
		50											
		ml of											
		steril											
		e											
		wate											
		r for											
		injec											
			I										I



 · · · · · ·					200						———————————	 					,					
		tion-				L				ļ		 	ļ				l				۱ <u> </u>	
		calcit			ļ				ļ				!		1				1		۱	
		riol (ļ								!		1		ļ l		1		۱ I	
		1, 25			ļ								ļ į		1		۱ I		1			
		Dihy			ļ								ļ į		1		۱ I		1			
		droc			ļ				ļ į				۱ I		1	l	۱		1			
	09-	hole			ļ								ļ į		1		۱ I		1			
	AD0-	calcif			ļ								۱ I		1	l			1			
	023	eror			ļ								۱ I		1	l		ļ į	1			
)(D3)			ļ								۱ I		1	l			1			
		250			ļ								۱ I		1	l		ļ į	1			
		nano			ļ								۱ I		1	l	۱				۱ I	
		gram			ļ								۱ I		1	l		ļ į	1			
		caps ule			ļ										1	l		ļ į	1		۱ I	
 $\left \right $				$\left - \right $	ļ	<u> </u>	┼───┧		\vdash			 ·	└ <u></u>	┝──┤	└──┼	——	ļi	\vdash		μ	└───┤	
		calcit riol (ļ								۱ I		1	l		ļ į	1			
		1, 25			ļ										1	l		ļ į	1		۱ I	
		Dihy			ļ								۱ I		1	l		ļ į	1			
		droc			ļ					۱ I			۱ I			l	۱ ۱		1			
		hole			ļ								۱ I		1	l		ļ į	1			
		calcif			ļ					۱ I			۱ I			l	۱ ۱		1			
		erol			ļ								۱ I		1	l		ļ į	1			
	09-	1(02)			ļ								۱ I		1	l		ļ į	1			
	AD0-	1			ļ					۱ I			۱ I			l	۱		1			
	024	mcg			ļ								۱ I		1	l		ļ į	1			
		/ ml			ļ										1	l		ļ į	1		۱ I	
		injec			ļ								۱ I		1	l		ļ į	1			
		tion (ļ								۱ I		1	l		ļ į	1			
		1 ml			ļ								۱ I		1	l		ļļ	1			
		amp			ļ								۱ I		1	l		ļ į	1			
		oule			ļ										1	l		ļ į	1		۱ I	
ļļ)	ļ		ļ	<u> </u>	<u> </u>	i	ļļ			 		\square	1						l	
	09-	Anhy			ļ								۱ I		1	l		ļ į	1			
	CD0-	drus			ļ								۱ I		1	l		ļ į	1			
	001	Sodi	<u> </u>									 	!		1		۱				1	



 	-		200	1		 -			 				
		um											
		acid											
		phos											
		phat											
		е											
		Anhy											
		drou											
		S											
		1.93											
		6g+S											
		od.bi											
		carb											
		onat											
		е											
		350											
		mg+											
		Pot.											
		bicar											
		bona											
		te											
		315											
		mg											
		equi											
		vale											
		nt to											
		Phos											
		phor											
		ous											
		500											
		mg+											
		Sod.											
		468.											
		8mg(
		20.4											
		mmo											
		1											



				200			 	 	 	 			
			Na+)										
			+Pot.										
			123										
			mg(3										
			.1m										
			mol										
			K+)										
			Effer										
			vece										
			nt										
			Tabl										
			et										
			milk										
			form										
			ula										
			for										
			mapl										
			e										
			syru										
			р										
			urine										
			disea										
		00	se										
		09-	(MS										
		Ebi-	UD)										
		001	patie										
			nts										
			for										
			age										
			(0_										
			1)										
			year										
			Leuci										
			ne,ls										
			oluci										
			ne										
·	· · · · · · · · · · · · · · · · · · ·		•	•								 •	



 			200		-							
		and										
		Valin										
		e										
		free.										
		milk										
		form										
		ula										
		for										
		mapl										
		e										
		syru										
		p										
		urine										
		disea										
		se										
		(MS										
		UD)										
	09-	patie										
	Ebi-	nts										
	002	for										
		age (abo										
		ve1										
		year) Leuci										
		ne,ls										
		oluci										
		ne										
		and										
		Valin										
		e										
		free	 									
	09-	milk										
	Ebj-	form										
	001	ula										
		for										



 			200		-		 				
		tyros									
		inem									
		ia for									
		age									
		(fro									
		m									
		birth									
		-									
		1yea									
		r)									
		phen									
		ylala									
		nine,									
		tyros									
		ine									
		free									
		milk									
		form									
		ula									
		for									
		tyros									
		inem									
		ia									
		patie									
	09-	nts									
		for									
	Ebj- 002	age									
	002	(abo									
		ve 1									
		year									
)									
		phen									
		ylala									
		nine,									
		tyros									
		ine									
		· ·	•								•



Image: bit in the state in				200				 					
Image: Second			free										
ula u			milk										
ula u			form										
or for ocyst ineur ia patie patie ineur iai patie patie ineur iai patie iai patie patie ineur iai patie iai </td <th></th> <td></td>													
Hom Hom A Operation A													
ocyst ineur is pate pate for 001 ocyst ineur is pate for 001 is pate for 1yea r va va v													
ia jaie													
i i			ineur										
09- nsic 09- nsic 001 age (1/2a -													
09- ns 001 age (from bit - 1yea r/ Met hoin ne r/ Met hoin ne r/ Met hoin ne r/ Met hoin ne r/ met													
Ebk- 001 for age (from birth - 1yea r) Met hioni ne free for age (for free Image (from birth - ree Image (for free Image (for for for for for for Image (for for for for for Image (for for for for for for Image (for for for for Image (for for for for Image (for for for for Image (for for for Image (for for for Image (for for Image (for for Image (for for Image (for Imag		09-											
001 age (from i													
from birth - 1yea r) - Net hioni ne free - met ree -													
birth - <th></th> <td>001</td> <td>from</td> <td></td>		001	from										
- -													
1 1yea r) Met hioni ne free 1yea r) Met hioni ne free 1													
n n													
Met M			Iyea										
initial initia initial initial													
Image: second													
Image: state in the state													
09- Ebk- 002 milk form ula for Hom ocyst ineur ia patie nts for age (abo n													
9- 60m 000 00	 				 								 \square
09- Ebk- 002 00- ia 00- ia<													
for Hom OP- For 09- OCyst OCyst Incur incur incur Incur Incur ia Patie Incur Incur nts for Incur Incur Incur age Incur Incur Incur Incur Incur													
Hom Image: 1 minimized in the second sec			ula										
09- 0cyst ineur ineur ineur ineur ineur ia ia <t< td=""><th></th><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></t<>													
100-1 ineur ineur ia 1002 ia ia 101 patie 101 ints 102 ia 102 ia 103-1 ia 103-2													
Ebk- 002 ia patie nts ia for age (abo) ia		09-											
002 1a 1a <		Ebk-											
nts for age (abo													
for age (abo			patie										
age (abo													
(abo													
			age										
ve v													
			ve										



	1		1	1								r 1	 				
		1yea															
		r)															
		Met															
		hioni															
		ne															
		free															
		milk															
		form															
		ula															
		for															
		gluta															
		ric															
		acid															
		uria															
		patie															
		nts															
	00	for															
	09-	age															
	Ebl-	(fro															
	001	m															
		birth															
		_ 1															
		year)															
		lysin															
		e															
		and															
		trypt															
		opha															
		n															
		free															
		milk															
		form															
	09-	ula															
	Ebl-	for															
	002	gluta															
		ric															
L	I	I				I	1 1		L	1 I	1	ı l		I	i	·	



		200	 	 	 	 			
	acid								
	uria								
	patie								
	nts								
	for								
	age								
	(abo								
	ve 1								
	year)								
	lysin								
	e								
	and								
	trypt								
	opha								
	n								
	free								
	•								
	milk								
	form								
	ula								
	for								
	Isova								
	leric								
	acide								
	mia								
09-	patie								
Ebn-	nts								
001	suita								
	ble								
	(fro								
	m								
	birth								
	_								
	1yea								
	r)								
	Leuci								
	LEULI								



				206										
		ne												
		free			-				 					
	09- Ebn- 002	 milk form ula for Isova leric acide mia patie nts suita ble (abo ve 1yea r) Leuci ne free 												
	09- Ebo- 001	milk form ula for met hylm aloni c acad emia / prop ionic acide												



		 			200								-		
Γ				mia		T									T
				patie											
				nts											
				suita											
				ble											
				from											
				birth											
				Met											
				hioni											
				ne,T											
				hreo											
				nine,											
				and											
				Valin											
				e											
				free											
				Merc											
				apta											
				mine											
				(Cyst											
				eami											
			09-	ne)											
			H00-	as											
			001	Bitar											
				trate											
				50m											
				g											
				caps											
				ule											
				Merc											
			09-	apta											
			09- H00-	mine											
			HUU- 002	(Cyst											
			002	eami											
				ne)											
L	1														



	1	1				200	r		 		·,				<u> </u>	·		 r	·
			as								۱ I		۱ I		۱		۱ 		
			Bitar								۱		۱		۱		۱		
			trate								۱		۱		۱		۱		
			150								۱ I		۱		۱		۱ I		
			mg								۱ I	1	۱				۱ ا		
			caps								۱ I	1	۱		۱		۱ ا		
			ule								۱۱		ا ا		۱		۱		
			Laro								1								
			nidas								۱ I		۱		۱		۱ I		
		09-	e								۱ I		۱		۱		۱ I		
		09- H00-	100									1	۱ I						
		H00- 004	Untit									1	۱ I			ļ			
		004	/ ml									1	۱ I			ļ			
			(5ml									1	۱ I						
			vial)								۱ <u> </u>	۱ <u> </u>	ا		۱ <u> </u>				
			Zinc								!	1]					
			acet									1	۱ I						
		09-	ate									1	۱ <u>۱</u>						
		H00-	25									1	۱ I						
		006	mg								۱ I	1	۱ <u>۱</u>		۱ I		۱		
			caps									1	۱ I						
			ule								l	·	!		I				
1 T			Nitisi		T						!]]	<u>ا</u> ا		ΙŢ		_		
			none									1	۱ I						
			(NTB									1	۱ I						
		09-	C) 2									1	۱						
		H00-	mg									1	۱ I						
		008	caps									1	۱ I						
			ule									1	۱ I						
			or									1	۱ I						
			tab								۱	l	l						
I T			alglu	T	Ī			_			!]	1]	ا		ΙŤ		_		1
		09-	cosid									1	۱ I						
		H00-	ase									1	۱ I						
		011	alfa									1	۱ I						
			50								۱ <u> </u>	۱ <u> </u>	!		۱ <u> </u>		۱ I		
	•																		



 	 						 	 					_
		mg											
		vial											
		I.V.											
		infus											
	 	ion	 	ļ									\square
		Merc											
		apta											
		mine											
	09-	(Cyst											
	H00-	eami											
	013	ne)											
	015	0.55											
		%											
		eye											
		drop											
		L.											
		carni											
		tine :											
		oral											
		pedi											
		atric											
	09-	solut											
	H00-	ion											
	017	300											
		mg											
		/ml											
		(30											
		%)											
		(20											
		ml)	<u> </u>	<u> </u>									\square
		L.											
	09-	carni											
	H00-	tine											
	018	200											
	510	mg /											
		ml											



			200										
		(5ml											ŢĮ
		amp											
		oule)											
		I.V ,											
		I.M											
		Migl	\Box]
	09-	ustat											
	H00-	100											
	019	mg											
	019	caps											
		ule											
		imigl											
		ucer											
		ase. I.V											
		infusi											
		on											
		400											
		unit/											
		vial											
		<i>اج</i> ۱۰٤٦											
		17											
		ج/ ۱۰٤٥											
	09-	"لاحقا											
	H00-	لقرار الجلسة											
	020	الجلسة ١٠٢٩											
		وبعد											
		استضبا											
		فة											
		اللجنة											
		العلمية											
		للامرا											
		ض النادر ة											
		واستعر											
		اض											
		الحقائق											
		العلمية											
		بصورة											



	200	· · · · · ·	 	 			
مفصلة تقرر تقرر القرار بقرار بالعاري العائمة ض النادرة (imigl ucer ase & Vela gluc eras e Vela gluc eras e)) النادرة النادرة عد عد النادرة من النادرة عد عد عد النادرة النادرة من النادرة النادرة النادرة من النادرة من النادرة من النادرة من النادرة من النادرة من النادرة من النادرة النادرة النادرة النادرة النادرة النادرة من النادرة النادة النادة النادة النادة النادة النادة النادة النادة النادة النادة النادة الناد النادة الام الام الام الام الام الام الام الا							
gluc eras e							
ونخول اللجنة العلمية للامرا ض							
تحديد تحديد كمية الاحتيا ج من							
مادة "وفقا لعدد المرضد ى							
ى والحالا ت المسجل الجديدة							
الجديدة والقديم "ة وفقا للحقائق							





			200	 	 		 	 					
	023	anhy											
		drou											
		s)											
		pow											
		der (
		180											
		OR											
		300											
		gm)											
		galsu											
		lfase											
		conc											
		entr											
		ate											
	09-	for											
	H00-	1.V											
	024	injac											
		tion											
		1											
		mg∖											
		ml											
		(5ml-											
		vial) Vela											+
		gluc											
		eras											
		е											
		alph											
		a 400											
	09-	unit /											
	H00-	vial											
	025	vial /ह १२६२											
		1.27											
		ج/ ١٠٤٥											
		الاحقا"											
		لقر ار											
		لقرار الجلسة											
L	 i			- 1						ι	L	 ۱ <u> </u>	



	200	 	
1.79			
وبعد استضا			
استضبا			
فة			
اللجنة			
العلمية			
للامرا			
ض النادرة			
النادرة			
واستعر			
اض الحقائق العلمية			
الحقائق			
العلمية			
بصورة مفصلة			
مفصلة			
يفرز			
تقرر اقرار العقاري			
العفاريـ			
ي <i>ن</i> بقائمة			
بقائمة			
וצמנין היי.			
ض النادرة)			
imigl			
ucer			
ase			
& Vela			
gluc			
eras			
e			
و نخو ل			
(ونخول اللجنة			
العلمية			
للامرا			
ض			
ض النادرة			
تحديد			
كميَّة			
تحديد كمية الاحتيا			
ج منّ			
			1 I I



 	 			200		 			 				 -
		کل											
		مادة "وفقا لعدد المرضد											
		"وفقا											
		I											
		,,											
		المرضد											
		ى والحالا											
		والحالا											
		ت											
		t ti											
		المسجد											
		ت المسجل ة											
		5 June 11											
		,											
		والقديم											
		"ة وفقا											
		:::: II											
		للحقانق											
		ة الجديدة والقديم "ة وفقا للحقائق العلمية											
		• •											
		مع الزام الشركا											
		الزام											
		الشير كا											
		ت											
		المجهز											
		50. 10											
		٥											
		بتوفير الفحو صات اللازمة لاثبات التشخي											
		الفحم											
		العجو											
		صات											
		اللاز مة											
		لانبات											
		التشخد											
		ص											
		ً والمتابع											
		ö											
		1											
		لاستجا بة المرضد											
		ىة											
		· . 11											
		المرصد											
		16											
		.)											
		وعدم											
		التلكؤ							1				
		ف											
		_ي							1				
		ارسال											
		النتائج											
		وحسب											
		و عدم التلكؤ في ارسال وحسب ما جاء											
		بمحضد							1				
									1				
		ر							1				
		-							 1			·	



 					200								1		
			اللجنة "انفا												
			بموجب												
			کتاب کیمادیا												
			المرقم ۱۲۹٦												
			1797												
			في ۹/٤/												
			1.14												
			Cargl												+
		20	umic												
			acid												
		129	200												
			mg tab												
			Agals												
		09-	idase												
			beta												
	C	031	35m g/												
			vial												
			Idurs												
		J9-	ulfas e												
		HUU-	e 2mg												
	0	032	/ml												
			vial											<u> </u>	
			elos												
			ulfas												
	6	09-	e alfa												
		h00-	5 mg												
		033	/5												
			ml												
			solut												
			ion												



				200											
		for													
		infus													
		ion													
		vial													
		Peni													
		cilla													
	10-	mine													
	ACO-	250													
	005	mg													
		caps													
		ule													
		Peni													\square
		cilla													
		mine													
	10-	250													
	ACO-	mg													
	006	Scor													
		ed													
		Tabl													
		et													
		Tem													\square
		ozol													
	1 -	omid													
	15-	e													
	AA0-	100													
	028	mg													
		caps													
		ule													
		Met													
		hotr													
	15-	exat													
	15- AB0-	e inj													
	АВО- 011	as													
	011	sodi													
		um													
		salt													
					•		1	1		•			•	•	



			200									
		2.5										
		mg/										
		ml,										
		2ml										
		Amp										
		oul										
		OR										
		vial										
		,subc										
		utan										
		eus,i										
		ntrat										
		hecal										
		للجلدية والكلية										
		والكلية										
		Flud										
		arabi										
		ne										
		phos										
		phat										
		e										
		50m										
		g										
		vial,										
	15-	pow										
	ABO-	der										
	019	for										
		reco										
		nstit										
		ution										
		, for										
		I.V.										
		inj.										
		or										
		infus ion.										



15- AB0- 020	Cladr ibine (2- CDA) 10m g / Vial, 5ml Or 10ml بحصر استخدا اللوكيم						
15- AB0- 022) cytar abin e (for S.C, I.V.)100 mg/ ml, 10 ml vial. 20m						



		200							
	g/ml								
	يجب								
	يجب ان								
	يكون التركي ز هو								
	الْتَر كَب								
	ز هو								
	Intra								
	thec								
	thec								
	al في حالة								
	حاله								
	الاعطا								
	ç								
	بطريق ة								
	ö								
	الزرق								
	Decit								
	abin								
	e I.V								
	injec								
	tion								
	50m								
	g								
	vial								
	ب								
	ς Λ έ λ/								
15-	يستخد								
AB0-	د فقط								
031	, à l								
	م فقط في مراكز								
	ا مر احر								
	امر ا								
	ض								
	الدم والعياد التخ								
	والعياد								
	ات								
	التخ								
	صصد								
	ية								
	لامرا								
	-	1 1	I	I	1 1	1 1	<u> </u>	<u> </u>	



· · · · · · · · · · · · · · · · · · ·		 	 	 	 	
	ض الدم الدم یحصر یحصر استخدا مه اعلاج اعتلال اعتلال العظم العظم در اسا توفر توکد فعالیته					
15- ABO- 033	في مَذا المجال Met hotr exat e vial 1g base i.v infus ion 100 mg/ ml لايتجا الايتجا					



		200	 	 	 	 	 	 	
	وز التركير								
15- AB0- 034	<u>j</u> Peme trexe d (as Peme trexe d di - sodiu :m) in م mg vial Folat e analo gue دیمیات تستورب بکمیات زیر مریض روی ا								



الحكمة الحك			 	 	 	·
الإكسر الإلى		مخازن				
الحالي على الحالي الحالي<		السركة				
المركزة <		ف الا				
النائي النا		عند				
المحمد المحم المحمد المحمح المحمح المحمح الممحم الممحمم المحمم المحمم المحممم المحمممممممممممممممممممممممم		الحاجة				
المحمد المحم المحمد المحمح المحمح المحمح الممحم الممحمم المحمم المحمم المحممم المحمممممممممممممممممممممممم		ومن				
المحمد المحم المحمد المحمح المحمح المحمح الممحم الممحمم المحمم المحمم المحممم المحمممممممممممممممممممممممم		<u>مبل</u> ۱ ـــ : :				
المحمد المحم المحمد المحمح المحمح المحمح الممحم الممحمم المحمم المحمم المحممم المحمممممممممممممممممممممممم	1	استشار				
المحمد المحم المحمد المحمح المحمح المحمح الممحم الممحمم المحمم المحمم المحممم المحمممممممممممممممممممممممم		ية				
الموال الموال Meso الموال thelio ma الموال الموال الموال		حصرأ				
Meso thelio ma i		ولمرضد				
helio ma u u u u u u u u u u u u u	1	ى Meso				
ma iiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiii		thelio				
الإيتقدا المراج المراحم المراح المراح المراح المراح المراح المراح المراح الم		ma				
الدينة الدية الدية		ان				
الدينة الدية الدية		دواعي ۱۷۰۰ خدا				
squa mous , Non Small Cell Lung Canc er(NS CLC) which includ e the follow ing subty :pes Aden ocarc inom a	1	م في				
squa mous , Non Small Cell Lung Canc er(NS CLC) which includ e the follow ing subty :pes Aden ocarc inom a		سرطان				
squa mous , Non Small Cell Lung Canc er(NS CLC) which includ e the follow ing subty :pes Aden ocarc inom a		الرئة				
squa mous , Non Small Cell Lung Canc er(NS CLC) which includ e the follow ing subty :pes Aden ocarc inom a		هي				
squa mous , Non Small Cell Lung Canc er(NS CLC) which includ e the follow ing subty :pes Aden ocarc inom a		الاني:- Non				
mous , Non Small Cell Lung Canc er(NS CLC) which includ e the follow ing subty : pes Aden ocarc inom a		Squa				
Non Small Cell Lung Canc er(NS) CLC) which includ ether official ether follow ing subty :pess Aden ocarc inom a		mous				
Cell Lung Canc er(NS CLC) which includ e the follow ing subty :pes Aden ocarc inom a		, Non				
Lung Canc er(NS C(C) which includ e the follow ing subty :pes Aden ocarc inom		Small				
which includ e the follow ing subty :pes Aden ocarc inom a						
which includ e the follow ing subty :pes Aden ocarc inom a		Canc				
which includ e the follow ing subty :pes Aden ocarc inom a	1	er(NS				
includ e the follow ing subty :pes Aden ocarc inom a		CLC)				
e the follow ing subty :pes Aden ocarc inom a	1	includ				
follow ing subty :pes Aden ocarc inom a	1	e the				
ing subty :pes Aden ocarc inom a	1	follow				
ipes Aden ocarc inom a Image: Construction of the second o	1	ing				
Aden ocarc inom a	1	subty				
ocarc inom a	1	Aden				
a inom a la l	1	ocarc				
a a a a a a a a a a a a a a a a a a a	1	inom	1			
	1	a				
		Large	<u>ı </u>			



	200					
cell						
NSC						
LC						
NOS(
nons						
pecifi c						
С						
subty (pe It is						
(pe						
lt is						
indica						
ted						
leu						
as						
neoa						
djuva						
nt,						
adjuv						
ant,						
and						
moint						
maint						
enan						
ce in						
locall						
у						
adva						
nced						
and						
meta						
static						
non						
squa						
mous						
NSC						
LC as						
a						
troot						
treat						
ment						
optio						
n in						
۰first						
seco						
nd						
and						
third						
umu Kas						
line						
treat						
ment						



		in patie nts with perfor manc e statu s 0-2										
	15- ACO- 014	Mito xantr one as Hcl, conc entr ate for I.V. infus ion, 2mg /ml, 10 ml vial										
	15- AC0- 018	Doxo rubic in Hcl (peg ylate d lipos omal)con c.for i.v										



	infus la
	ion
	2mg 2mg
	/ml(/
	10ml
	vial vial vial vial vial vial vial vial
)i.e
	inj
	pegy
	lated
	Doxo
	rubic
	in land land land land land land land lan
	Hcl
	2mg
	inca
	psula
	ted
	lipos
	ome
	S S
	Etop
	osid
	entr
15-	ate
AD0-	
004	
	infus
	ion
	20m
	g/ml,



		200	 	 	 	 	 -			
	vial									
	OR									
	Amp									
	oul									
	Vinbl									\square
	astin									
	e									
	sulp									
	hate									
15	1									
15- AD0-	mg/									
006	ml,									
006	10									
	ml									
	vial									
	or									
	amp									
	oul.									
	Reco									
	mbin									
	ant									
	aspa									
	rgina									
	se									
	(E-									
15-	coli									
AEO-	type									
003)									
	10.0									
	00									
	unit									
	vial									
	pow									
	der									
	for									
	conc									



			entr												
			ate												
			for												
			solut												
			ion												
			for												
			infus												
			ion												
			Hydr												\square
			oxyu												
			rea												
			500												
			mg												
			Caps												
			ule												
			ايضا												
			ايضىا يستخد												
			م												
			م كعلاج في مراكز امرا												
			في												
		4 5	مراكز												
		15-	امرا												
		AF0-	ض												
		010	ض الدم الور ا ثية وخا صة												
			الورا شة												
			ىپ- اخا												
			وحت												
			مرض												
			حر <u>ص</u> فقر												
			الدم												
			مرض فقر الدم المنجل												
			ې												
			ي sickl												
			e cell												
			ane												
			mia)												
L			- 1								l	i	I	1	4



 			200			 	 		 		 	 '
		Octr	Ţ	T			-T 1		T	Γ '	T I	- ۲
		eotid										1
		e										1
		0.05										1
		mg/										1
		ml										1
		Injec								!		1
		tion										1
	15-											1
	AF0-	استخدا										1
	011	م المادة										1
		المادة لحالة										1
		(Acu										1
		te										1
		Varic								!		1
		eal										1
		Hem								!		1
		orrh										1
		age)								'		1
·		Arsen			/	, <u> </u>			1	++	++	1
.		ic				.	'			!		1
		trioxi de(C				.	'	1		!		1
		once										1
		ntrate										1
		for intrav								!		1
		enou										1
	15-	S								!		1
	AF0-	infusi on)										1
	061	on) 1mg/ ml 10										1
		ml 10										1
		ml amp.										1
		to be								!		1
		use										1
		in :-										1
		یحصر استخدام										1
		ة في					 I		 	<u> </u>		<u>`</u> ــــــــــــــــــــــــــــــــــــ



Image: Section of the section of th			200	 	 	 	
	راض الدم بيبت المقرة بيابات المقرة المقمة المقرة المقرة الممماممممامعمام المممة الممة المممة المممم الممممامعمامماممماممامممامم	بمر امرا الرا الرا الالا الالا الا الج الا الج الج الا الج الج					
	15- Letr	tro					



		008	2.5m											
			g											
			Tabl											
			et											
			وعلى											
			قاعدة اقل											
			الاسعا											
			ر مع											
			(15-											
			AG-											
			14).											
			Anast											
			rozol e											
			tablet											
			1mg To be											
			dispe											
			nce											
			by medi											
			cal											
			com mitte											
			e for											
		15-	these											
		AG0-	indica tions											
		014	throm											
			boem											
			bolic في حالة											
			ي وجود تاريخ											
			تاريخ											
			مرضي تخثري											
			-											
			Drug) intole											
			rabilit											
			y) /Tam											
			oxife											
L	1 I	I	0/010	1	L		1	1	 1	I I	1	1	I	1



 		1	 200			 	 	 	 			 -
	ي بة	n في حال										
	م	عد تحمل										
	ر ب	المر										
	L	المر ضر لعلاج Not -										
	ة N	Not -										
	te	o be										
	u a	used as an										
	A	Altern										
	a ii	ative n										
	C	case										
	T T	hat Famo										
	х	kifen										
		ab are										
	r	not										
	a b	availa ble										
	Г	Tamo										
	X م	kifen لايستع										
	Ċ	ifen لايستع ل كبديل في حال										
	له ه	في حال عد										
	5	ً عد توفر										
	<u>ب</u>	حبوب و علم قاعد										
	ة. ا	قاعد										
		اقل الاسعار										
	č											
	۲ -	м.С) N.C)										
	A	AG0- 008										
		008 Vyc			 		 					\parallel
		ophe										
	J-	nolat										
	00- 22 e	2										
	r	nofe										
	t	il										



				200									
			500										
			mg										
			Tabl										
			et										
			cı										
			1										
			(myc										
			ophe										
			nolic										
			acid)										
			اعتماد										
			مادة										
			بشكل										
			منفصد										
			J										
			واعتما										
			د										
			البرو توكول										
			توكول										
			العلاج										
			(S										
			مر فق										
			ي مرفق بالجل سة										
			 سة										
			1										
			Tacr					-					┝┤
			olim										
			us										
			1mg										
		4 5	Caps										
		15-	ule										
		B00-	يحدد										
		024	صرفه										
			1										
			ضمن										
			مر اکز										
			زرع الکلی										
			الكلى										
L			•		1. I.						L		



				<u> </u>	200	T		 	·		<u> </u>	<u> </u>							<u> </u>	
	1	1	'	Suniti					1 1		!				1 1	1	'			
		۱	' 1	nib			1	.	1 1		1				1	1	'			
		۱	' 1	(as			1	.	1 1		1				1	1	'			
		۱	' 1	molo			1	.	1 1		1				1	1	'			
			' 1	male				.	1 1	1	۱ I			.	l 1	1	'			
	1	I	' 1	ate)				.	1 1	1	۱ I			,	l i	I	'			
1			' 1	50				.	1 1	1	۱ I			.	l 1	1	'			
		I	' i	mg				.	1 1	1	۱ I			.	1 1	I	'			
			' 1	cans				.	1 1	1	۱ I			.	l 1	1	'			
1		I	' i	caps ule				.	1 1	1	۱ I			.	1 1	I	'			
		I	' i					.	1 1	1	۱ I			.	1 1	I	'			
1 1	1	I	' 1	توفير كبضاعة				.	1 1	1	۱ I			,	l i	I	'			
	1	I	' ì	كبضاعه				.	1 1	1	۱ I		- 1	.	1 1	1	'			
		I	' i	مجانية				.	1 1	1	۱ I			.	1 1	I	'			
	1	I	' 1	(.	1 1	1	۱ I			,	l i	I	'			
	1	I	' 1	Suniti				.	1 1	1	۱ I			,	l i	I	'			
		I	' i	nh				.	1 1	1	۱ I			.	1 1	I	'			
		I	' i					.	1 1	1	۱ I			.	1 1	I	'			
		I	' i	25+				.	1 1	1	۱ I			.	1 1	I	'			
	1	۱ I	' 1	nb 25+ 12.5			1	.	1 1	1	۱ I		- 1	.	1 1	1	'			
		I	' i	mg) کونها تعتبر				.	1 1	1	۱ I			.	1 1	I	'			
	1	۱ I	' 1	کونها			1	.	1 1	1	۱ I		- 1	.	1 1	1	'			
		I	' i					.	1 1	1	۱ I			.	1 1	I	'			
		I	' i					.	1 1	1	۱ I			.	1 1	I	'			
1		I	' i	جرع				.	1 1	1	۱ I			.	1 1	I	'			
1 1	1	I	' <u>-</u> '	تكميلية	,				1 1	1	۱ I			,	l 1	I	'			
	1	۱ I	15-	جرع تکمیلیة وینسبة ۸% من کل ترکیز الاحتیاج التکی (Sunit inb 50			1	.	1 1	1	۱ I		- 1	.	1 1	1	'			
	1	۱ I	B00-	۸%			1	.	1 1	1	۱ I		- 1	.	1 1	1	'			
		I	0.00-	(K in				.	1 1	1	۱ I			.	1 1	I	'			
	1	۱	067	س س بر م				.	1 1	1	۱ I		- 1	.	1 1	1	'			
		I	' i	ىرحير				.	1 1	1	۱ I			.	1 1	I	'			
	1	۱ I	' 1	من	,				1 1	1	۱ I		1	,	l i	1	'			
		I	' i	الاحتياج				.	1 1	1	۱ I			.	1 1	I	'			
1		I	' i	الكلي				.	1 1	1	۱ I			.	1 1	I	'			
		I	' i	لتركيز				.	1 1	1	۱ I			.	1 1	I	'			
	1	I	' 1	(Supit	,				1 1	1	۱ I			,	l 1	I	'			
		I	' i	(Suriit				.	1 1	1	۱ I			.	1 1	I	'			
	1	۱ I	' 1	anı			1	.	1 1	1	۱ I		- 1	.	1 1	1	'			
1		I	' i	50				.	1 1	1	۱ I			.	1 1	I	'			
	1	۱ I	' 1	mg) المادة			1	.	1 1	1	۱ I		- 1	.	1 1	1	'			
1 1	1		' 1	ألمادة	,				1 1	1	۱ I			,	l 1	I	'			
		I	' i	تستخده				.	1 1	1	۱ I			.	1 1	I	'			
		I	' i	تستخدم المادة أنفاً				.	1 1	1	۱ I			.	1 1	I	'			
		I	' i	الماده				.	1 1	1	۱ I			.	1 1	I	'			
		I	' i	انفا				.	1 1	1	۱ I			.	1 1	I	'			
	1	۱ I	' 1	للحالات الأتية			1	.	1 1	1	۱ I		- 1	.	1 1	1	'			
		I	' i	الأتيةد				.	1 1	1	۱ I			.	1 1	I	'			
		I	' i	: صرا				.	1 1	1	۱ I			.	1 1	I	'			
1	1		' 1	· · - ·	,				1 1	1	۱ I			,	l 1	I	'			
1	1	۱ I	' 1	A -1-			1	.	1 1	1	۱ I		- 1	.	1 1	1	'			
		I	' i	_Adv				.	1 1	1	۱ I			.	1 1	I	'			
1	1	۱ I	' 1	ance			1	.	1 1	1	۱ I		- 1	.	1 1	1	'			
	1	۱ I	' 1	d			1	.	1 1	1	۱ I		- 1	.	1 1	1	'			
	1	۱ I	' 1	Unre			1	.	1 1	1	۱ I		- 1	.	1 1	1	'			
		I	' i	socto				.	1 1	1	۱ I			.	1 1	I	'			
	1		'ı	secta				 	Li		<u> </u>				Li		' <u>l</u>			



	200				
ble or					
meta					
static					
_mali					
gnant					
Geetr					
Gastr					
0					
Intest					
inal					
Indi					
or					
meta					
static					
Stro					
Silo					
mal					
Tumo					
r					
(GIS					
T)					
after					
failur					
Tallul					
e of					
imati					
nib					
ropol					
renal					
cell					
carci					
noma					
noma					
-					
ضرورة					
تزويد					
ضرورة تزويد الشركا					
,,					
ت ا					
المجهزة					
للعراق					
المجهزة للعراق بشهادة					
(a antif					
(certif					
icate) على ان تكون اصلية و					
علي ان					
بدون					
اصليه و					
مصدقة					
تضمن					
1:					
خلو المادة					
المادة					
الداخلة					
في جيلاتين					
سي ا					
جيلانين					



الكبسول من مىريبات جنون البقر و عدم الخنزير		
) الجيلاتي الجيلاتي الجيلاتي منشأه ناتي حيوان م م الجرعه الجرعه م الجرعه م استراحه م استراحه م استراحه م استراحه م م استراحه م م استراحه م م م استراحه م م م استراحه م م م م استراحه م م م استراحه م م م م م م م م م م استراحه م م م م م م م م م م م م م		
15- Thali B00- domi		



50 50 mg cap or cap itab active active active joint active <				200	1		 т т	 		
50 50 mg cap or cap or cap itab cap ucit cap		071	de							
mg mg mg cap or tab or axini or tib or tab or <th></th> <th></th> <th>50</th> <th></th> <th></th> <th></th> <th></th> <th></th> <th></th> <th></th>			50							
cap cap cap or or tab cana tab cana <th></th>										
or العاد tab العند العند العند العند<			сар							
tab بهنتي نابي نابي <			or							
المالة المالة المالة										
الالتجاء السالة التوارا التوارا التوارا التوارار التوارا التوارا التوارا التوارا			เล่ม							
اوقا البط										
اوقا البط			المادة							
المالية المالية التفا التفا										
المالية المالية التفا التفا			الضوا							
الفيها إيفيها الفيها إيفيها المية إلية إلية			بط							
الفيها إيفيها الفيها إيفيها المية إلية إلية			المتعا							
وبصو وبالر مشدد مشدد مشدد والر الإبجار منها الإبجار الجار الإبجار الإبجار </th <th></th> <th></th> <th>رف</th> <th></th> <th></th> <th></th> <th></th> <th></th> <th></th> <th></th>			رف							
وبصو وبالر مشدد مشدد مشدد والر الإبجار منها الإبجار الجار الإبجار الإبجار </th <th></th> <th></th> <th>عليها</th> <th></th> <th></th> <th></th> <th></th> <th></th> <th></th> <th></th>			عليها							
قار م دان م			و تصبو							
اللحيان اللحيان والمرأ اللحيان والمرأ اللحيان اللحيان اللحيان ا			رة (زة							
اللحيان اللحيان والمرأ اللحيان والمرأ اللحيان اللحيان اللحيان ا			مشددة							
ب ب منعا منعا لحدق ث تشوها ت تفاقة ت تابعالی ت تابعالی تابعالی			للر جل							
ب ب منعا منعا لحدق ث تشوها ت تفاقة ت تابعان ت <			والمرأ							
ب ب منعا منعا لحن ب مناب ب ماب ماب ب			ہ فی							
ب ب منعا منعا لحن ب مناب ب ماب ماب ب			سن							
ب ب منعا منعا لحن ب مناب ب ماب ماب ب			الانجا							
الحدو الحدو الحدو التعليم التي التي التي التي التي التي التي			ب							
الحدو الحدو الحدو التعليم التي التي التي التي التي التي التي			منعا							
حدث حدث الحمل وتستع مل الحمل الحمل			لحدو							
حدث حدث الحمل وتستع مل الحمل الحمل			ڎ							
حدث حدث الحمل وتستع مل الحمل الحمل			تشوها							
حدث حدث الحمل وتستع مل الحمل الحمل			ت							
حدث حدث الحمل وتستع مل الحمل الحمل			خلقية							
حدث حدث الحمل وتستع مل الحمل الحمل			اذا							
وتستع مل موانع الحمل			حدث							
مل موانع الحمل			الحمل							
مل موانع الحمل			وتستع							
			مل							
الحمل الحمل الحمل			موانع							
			الحمل							
			بصور							



		ة فعاله							T			['
		واكيدة										
		للجنسر										
		ج ين										
		1.17										
		N										
) Lenal										
		idomi										
		de										
		25mg										
		tablet										
		or										
		cap a-										
		a-										
		as cons										
		olideit										
		ion										
		post										
		bone										
		marro										
		W										
		trans plant										
	15-	for 2										
	B00-	cvcle										
	078	cycle s										
	070	b- in										
		relap sed -										
		sed -										
		refrac										
		tory myel										
		oma										
		after										
		borto										
		zomi										
		be										
		conta										
		ing regim										
		en										
		C-										
		relap										
		se										



		200		 	
	after autol ogus e bone marro w trans plant in both (b) &(c) to be used for 4 cycle s then to go for trans plant or to conti nue for 1 year if not eligibl				
15- BOC 094)- coat				



 				200																		/
		15-		· · ·	ſ'	· _ '	'	<u> </u>	<u>ا</u> ا			'				I	I	['				T
		B00-	'	'	1 '	'	1 '	1 1	1	1	'	1 '	1 1	1 1	1	1	1 '	'	1			/
		067)		'	1 '	'	1 '	1	1	1	1 '	1 '	1 '	1		1	1 '	1 '	1			1
		ج٥٨٥		'	1 '	'	1 '	1	1	1	1 '	1 '	1 '	1		1	1 '	1 '	1			1
		('	1 '	'	1 '	1 '	1	1	1 '	1	1 '			1	1 '	'	1			/
		989)	'	'	1'	'	1'	1'	1'	I	$ _'$	'	1'	1_	<u>ا ا</u>	ı'	ı'	'	l	'		
		Inter		,	('	ļ			1	1						,,	,,					
		fero		'	1 '	'	1 '	1 '	1	1	1 '	'	1 '			1	1 '	'	1			/
		n		'	1 '	'	1 '	1 '	1	1	1 '	1	1 '			1	1 '	'	1			/
		gam		'	1 '	'	1	1	1	1	1 '	'	1 '			1	1 '	'	1			7
		ma -		'	1 '	'	1 '	1 '	1	1	1 '	1	1 '			1	1 '	'	1			/
		1B10		'	1 '	'	1 '	1 '	1	1	1 '	1	1 '			1	1 '	'	1			/
		0		'	1 '	'	1 '	1 '	1	1	1 '	1	1 '			1	1 '	'	1			/
		mcg		'	1 '	'	1 '	1 '	1	1	1 '	1	1 '			1	1 '	'	1			/
		/ 0.5		'	1 '	'	1 '	1 '	1	1	1 '	1	1 '			1	1 '	'	1			/
1		ml		'	1 '	'	1 '	1 '	1	1	1 '	'	1 1			1	1 '	'	1			/
		vial		'	1	'	1 '	1 '	1	1	1 '	'	1 '			1	1 '	'	1			/
·		Filgra		· ['	()	├ ── '		+	[]	·+	!	!	+	$ \longrightarrow$	[]	ı ————————————————————————————————————	('	├ ───′	 	+'	<u> </u>	+7
		stim		'	1 '	'	1 '	1 '	1	1	1 '	1	1 '			1	1 '	'	1			/
		۳		'	1 '	'	1 '	1	1	1	1 '	'	1 '			1	1 '	'	1			!
1		mcg(30M U) /1ml		'	1 '	'	1 '	1 '	1	1	1 '	'	1 1			1	1 '	'	1			!
		U)		'	1 '	'	1 '	1 '	1	1	1 '	1	1 '			1	1 '	'	1			!
		/1ml		'	1 '	'	1 '	1	1	1	1 '	'	1 '			1	1 '	'	1			!
		S.C/I. V		'	1 '	'	1 '	1 '	1	1	1 '	1	1 '			1	1 '	'	1			!
		infusi		'	1 '	'	1 '	1	1	1	1 '	'	1 '			1	1 '	'	1			/
		on inj		'	1 '	'	1 '	1 '	1	1	1 '	1	1 '			1	1 '	'	1			!
	15-	(solut		'	1 '	'	1 '	1 '	1	1	1 '	1	1 '			1	1 '	'	1			!
	C00-	ion) Vial		'	1 '	'	1 '	1	1	1	1 '	'	1 '			1	1 '	'	1			!
	003	or		'	1 '	'	1 '	1 '	1	1	1 '	1	1 '			1	1 '	'	1			!
1		Filgra		'	1 '	'	1 '	1 '	1	1	1 '	'	1 1			1	1 '	'	1			!
		stim ۳۰۰		'	1 '	'	1 '	1	1	1	1 '	1 '	1 '	1		1	1 '	1 '	1			!
				'	1 '	'	1 '	1 '	1	1	1 '	1	1 '			1	1 '	'	1			!
1		mcg(30M U) /0.5		'	1 '	'	1 '	1 '	1	1	1 '	1 '	1 1	1 1		1	1 '	'	1			!
		U)		'	1 '	'	1 '	1	1	1	1 '	1 '	1 '	1		1	1 '	1 '	1			
1		/0.5		'	1 '	'	1 '	1 '	1	1	1 '	'	1 1			1	1 '	'	1			
1		ml or ofs		'	1 '	'	1 '	1 '	1	1	1 '	1 '	1 1	1 1		1	1 '	'	1			
		or pfs it's		'	1 '	'	1 '	1	1	1	1 '	1 '	1 '	1		1	1 '	1 '	1			
L	L			·	·	·		·					·	<u> </u>				ـــــ	·		4	



 	 		200		 	 	 	 r	 	 	 	 	
	ł	appro ved biosi milar بالنسبة											
		بالنسبة للرمز الوطني (٥٥- (003 يتم اختيار											
		اختيار احدى المادتين اما ال											
	(refere (nce او											
	(biosi (milar وحسب التنافس السعري											
	i	مع اللرمز - ۱۵) C00- (009											
	ĩ	وحسب قاعدة اقل الاسعار ج/											
	l t	Leno grast im											
	15- C00- 009 f	pow der for											
	1	reco nstit ution											



				200	1		 	 	 	 			r	
		, 33.6 milli on IU (263 µg) vial (with 1 ml prefil led syrin ge wate r for injec tions) code 15- C00- 003 يتخت الار الار يقا يقا روما الار الار الار الار الار الار الار ال												
	16- B00- 002	Anti D imm unog lobul in (500 IU												



)sol.	
	for	
	Injec	
	tion	
	(IM	
	/ IV)	
	(Ву	
	nano	
	filter	
	ation	
	&	
	SDF	
	met	
	hod)	
	تکون	
	ة لكافة	
	المتطل	
	بات	
	والموا	
	صفات	
	العالم	
	ية	
	المتعل	
	قة	
	بالنقارة	
	وخلوه	
	ا من	
	الفايرو سات	
	Anti	
16-	D imm	
B00-	unoa	
004	unog Iobuli	
	n (1500	
	1500	



	200			
IU) sol.				
sol.				
for				
lion				
or(
IM)				
يتم*				
استير اد				
استدفائه				
لشرط				
for inject ion IV or(IV/ IM) * متع استيفائه استيفائه تقديم شهادا				
شبهادا				
التحليل بالمراح				
والشدر				
ستهدا ت التحليل والسلا مة الأصلي ة				
5				
الخاصد ة				
بمصدر				
الدم				
الذي تم				
تصنيعه				
منها				
مع)				
الاسارة				
أرقام				
الوجبا				
ت)				
بالأضا				
بمصدر بلازما الذم الذي تم مع مع) منها الاشارة الاشارة الاشارة الوجبا نالأضا بالأضا بالأضا بالأضا على التي على				
التي				
يتم				
أجرائها				
على				



 			200	 	'						
		المنتوج النهائي (۲۳٦)) (By nano filter ation & SDF meth od) - - نكون خاضع تكون المتطل والموا بات والموا بالتاوة العالمية منات وخلوها سات									
	16- B00- 033	Hum an nor mal imm unog lobul in 5% prot ein (200 ml) OR									



				200											
		10%													
		prot													
		ein													
		(100													
		ml) (
		10													
		gm /													
		cont													
		ainer													
).													
		مراعاة													
		الشرك													
		õ													
		المصد													
		عة													
		بىوقىر ١١													
		بتوفير الشرو ط* انظر													
		ط ۲۰۰۰													
		الشر ه													
		الشرو ط													
		اسفل													
		القائمة													
		Sapr													\square
		opte													
		rin													
		dihy													
		droc													
		hlori													
	00	de													
	09 [.] H00														
	028)- mg 3 tab													
	020	milk	\vdash						$\left \right $				 	<u> </u>	\vdash
		form													
	09	- ula													
	Ebł														
	00	1 phe													
L	•							L	 		i	· · · · · · · · · · · · · · · · · · ·	0		



			200						-			1	 /
		nyke											
		tone											
		uria											
		(PK											
		Ú)											
		Ú) pati											
		ents											
		for											
		age											
		(
		from											
		birth											
		birtir											
		- 1ye											
		l ye											
		ar) Phe											
		Phe											
		nylal											
		anin											
		e											
		free.		 									
		milk											
		form											
		ula											
		for											
		phe											
		nyke											
		tone											
		uria											
		(PK											
		(PK U) pati											
		pati											
		ents											
		for											
		age(
		age(abo											
		ve1											
	09-	_											
	Ebh-	- 3ye											
	002	are)											
	002	ars)											\square



Phe P	 			 				 		 	-			_
anin a ree. - mik form ula form ula form phe nyke tone uria (PK U) pati ents for age (abo va3 - age age abit free. mix free. mix free. mix free. age age bybe age <td></td> <td></td> <td>Phe</td> <td></td>			Phe											
anin a anin a </td <td></td> <td></td> <td>nylal</td> <td></td>			nylal											
e e			anin											
Image: constraint of the constraint														
milk for ula for phe nyke una (PK U) pati ents for age (abo ve3 - - 8)ye ar Phe nyka tone una (PK U) pati ents for age (abo ve3 - - 8)ye ar Phe nyka tone una for age (bb) ve3 - - 8)ye ar Phe nyka tone una for age (bb) ve3 - - 8)ye ar Phe nyka tone ve3 - - 8)ye ar Phe nyka tone ve3 - - 8)ye ar Phe nyka tone ve3 - - 8)ye ar Phe nyka tone ve3 - - 8)ye ar Phe nyka tone ve3 - - - - - - - - - - - - - - - - - - -														
form ula for phe nyke tone uria (PK U) pati ents for age (abo ve3 - 8)ye ar Phe nytal 09- ents for age (abo 0 ve3 - 8)ye ar Phe nytal 0 0 0 0 0 0 0 0 0 0 0 0 0			milk											
ula ula i for phe nyke nyke una (PK U) pati ents for for age (abo ve3 - 8)ye ar Phe nytal phe 09- anin Ebh- e 003 free nyte tone ua for ua nik for nua 09- ain nytal nua 09- nik for nua ua nua 09- nik for nua ua nua nor nua nora nua <														
i i i for phe nyke nyke uria (PK U) pati ents for age (abo (abo ve3 - 8/ye ar nyla nyla nyla 09- ain e for age for nyla nyla 03 free. milk for nyla nyla nyla nula nyla nula nyla nula nyla nula nyke nula nyke nula nyke nula nyke nula nyke nula			ula											
phe nyke tone uria (PK U) pati ents for age (abo ve3 - 8)ye ar Phe nylal anin e Ebh- e 003 free.			for											
nyke nyke uria (PK U) pati ents for age (abo ve3 - 8)ye ar nylal - anin - Phe nylal o03 free. milk - yke - nyke - o03 free. milk - nyke - 003 for nyke - 004 - 005 free. - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - <td></td> <td></td> <td>phe</td> <td></td>			phe											
tone uria (PK U) pati ents for age (abo ve3 - 8)ye ar Phe nylal 003 milk for tone ula biol biol c biol c c biol c c biol c c c c c c c c c c c c c			, nyke											
uiria (PK U) uiria (PK U) uiria ents uiria for age (abo age (abo uiria ents uiria ents biye age (abo - biye ar - biye ar - biye ar - phe nylal - - 09- e anin Ebh- e - - 003 free. - - milk for phe nyke - - - 09- e uiria for phe - - 09- e - - - 003 for phe - - 09- e - - - 09- e - - - 003 for phe - - 09- e - - - 09- e - - - 003 for phe - - 09- e - - - 09- e - - - 09- e - - - 09- e - - -			tone											
Image: Construction of the second			uria											
U) pati ents for age (abo u ve3 - - <			(PK											
pati ents for age (abo ve3 - - - - - - - - - - - - - - - - - - -			Ù)											
ents age (abo ve3 - - 8)ye ar Phe nylal 003 ents for age (abo ve3 - - 8)ye ar Phe nylal e ents for age (abo ve3 - - 8)ye ar Phe nylal e ents for ape e ents for ar Phe e ents for ar free ents for ar free ents for ar free ents for ar free ents for ar for bhe nyle ents for ar for bhe nyle ents for ar for bhe nyle ents for ar for bhe nyle ents for ar for bhe nyle ents for bhe nyle ents for bhe nyle ents for bhe nyle ents for bhe nyle ents for bhe nyle ents for bhe for bhe ents for bhe for ents for bhe ents for for for for for ents for for for for for for for for for for			pati											
i i for age (abo ve3 i			ents											
age (abo ve3 age (abo ve3 age (abo ve3 age (bb) age (abo ve3 age (abo ve3 age op- Ebh- age op- e age			for											
ve3 - 8)ye ar Phe nylal 003 free.			age											
ve3 - 8)ye ar Phe nylal 003 free.			(abo											
- - - - - - - - 8)ye - 8)ye - 8)ye -			ve3											
ar Phe nylal 09- anin Ebh- e 003 free. milk form ula for phe nyke nyke none una for phe nyke tone uria (PK														
ar Phe nylal 09- anin Ebh- e 003 free. milk form ula for phe nyke nyke none una for phe nyke tone uria (PK			8)ye											
09- Ebh- 003 nylal anin e anin e anin e anin e anin e 003 free. milk form ula for phe nyke anin e anin e anin e anin e 09- phe nyke milk for phe nyke anin e anin e anin e anin e anin e anin e 09- Ebh- Ebh- milk for phe nyke anin e ani			ar											
09- Ebh- 003 nylal anin e anin e anin e anin e anin e 003 free. milk form ula for phe nyke anin e anin e anin e anin e 09- phe nyke milk for phe nyke anin e anin e anin e anin e anin e anin e 09- Ebh- Ebh- milk for phe nyke anin e ani			Phe											
09- Ebh- 003 anin e free. milk form ula for phe nyke tone milk form ula milk form ula milk form ula milk form ula milk form ula milk form ula milk form ula milk form ula milk form ula milk form phe nyke milk form ula milk form phe nyke milk form phe phe phe nyke milk form phe nyke milk form phe phe phe phe phe phe phe phe phe phe			nylal											
003 free. Image: state		09-	anin											
003 free. Image: state		Ebh-	е											
i form i		003	free.											
i form i			milk											
for phe nyke nyke tone 09- Uria Ebh- (PK)			form											
phe nyke tone 09- uria Ebh-			ula											
nyke nyke <th< td=""><td></td><td></td><td>for</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></th<>			for											
nyke nyke <th< td=""><td></td><td></td><td>phe</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></th<>			phe											
tone op- uria D9- Uria UPK			nyke											
Ebh- (PK			tone											
Ebh- (PK		09-	uria											
004 U)		Ebh-	(PK											
		004	U)											



pati for age (8)e ars and abo pati (9) (8)e ars and abo pati (9) pati (9) Pite Phe Phe free Peth udne Hd 50m peth		1		200	 1	 	1 1		-	1	 	
i i i for age (8ye ars and abo i </td <td></td> <td></td> <td>pati</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>			pati									
age (8ye ars and abo ve) ve) phe nylai anin e free Peth (file free Image: Second			ents									
(8)e ars and abo ve) Phe phe phe ree no 04- pre Holo som Som gmin Holo gmin (see ani Amp cost 15- glob 15- glob 088 e 15- glob												
(8)e ars and abo ve) Phe phe phe ree no 04- pre Holo som Som gmin Holo gmin (see ani Amp cost 15- glob 15- glob 088 e 15- glob			age									
ars and abo ve) Phe nylal are Preth nylal anin e e gene Preth nylal anin ars gene nylal anin anin e rece rece nylal anin anin e nylal anin anin e gene Peth Horo ginlin Jan Anint horo anin Jan Anint hype e glob anin Jan anin </td <td></td> <td></td> <td>(8ye</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>			(8ye									
abo ve) Phe nylai nylai e ree ree Peth g/ml Hold g/ml No			ars									
ve) Phe Nylal Nyl			and									
Phe P			abo									
Phe anin e free Phe me free Peth idine 04- HOO 010 Peth idine Hel Symm oule (see Peth Hel Symm (2mi) Amp oule (see Peth Hel Symm (2mi) (2mi) (2mi) (2mi) (2mi) (2mi) (2mi (2mi) (2mi) (2mi (2mi) (2mi) (2mi (2mi) (2mi (2mi) (2mi (2mi (2mi (2mi (2mi (2mi (2mi (2mi			ve)									
nylal anin e free nylal anin e free nylal anin e free nylal anin e free 0 04- Hoto Som gini, com and			Phe									
e ree Image: Constraint of the second s			nylal									
e ree Image: Constraint of the second s			anin									
Image: constraint of the constraint			е									
04- Hoo- 010 Peth idine Hd 50m (2mi)) Amp oule (see 4H) Peth Hd 50m (2mi)) Amp oule (see 4H) I <td></td> <td></td> <td>free</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>			free									
idine Hci 50m idine Hci 9/ml idine Hci 50m idine Hci id												
Hci Som g/ml Hoi O10 g/ml g/ml (2ml) Image: Comparison of the comparison of			Peth									
Hci Som g/ml HO: 010 g/ml g/ml (2ml) Hci Som g/ml (2ml) Image: Comparison of the comparison of t			idine									
04- H00- 010 g/ml inj., (2ml) Amp oule (see 4H) Amp oule (see 4H) Anit hym ocyt e Jantit hym ocyt e Jantit hym oc			Hcl									
04- H00- 010 g/ml inj., (2ml) Amp oule (see 4H) Amp oule (see 4H) Anit hym ocyt e Jantit hym ocyt e Jantit hym oc			50m									
H00- 010 inj., (2ml) Amp oule (see 4H) Image: Constraint of the second se		04-	g/ml									
i i <td></td> <td>H00-</td> <td>inj.,</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>		H00-	inj.,									
i i <td></td> <td>010</td> <td>(2ml</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>		010	(2ml									
oule (see 4H) Anti hym ocyt e Anti hym ocyt e Anti hym ocyt e Image: Comparison of the												
oule (see 4H) Anti hym ocyt e Anti hym ocyt e Anti hym ocyt e Image: Comparison of the			Amp									
Image: see state Image: see state <td< td=""><td></td><td></td><td>oule</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></td<>			oule									
4H) Antit hym Image: Antithym Image: Antithym Image:			(see									
15- B00- 088 300- equi ne 250 300- equi ne 10- e 10- e <td></td> <td></td> <td>4H)</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>			4H)									
hym ocyt - <td></td> <td></td> <td>Antit</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>			Antit									
15- B00- 088 glob ulin equi ne 250 15- e			hym									
e glob gl			ocyt									
15- B00- 088 glob ulin equi ne 250 ulin			е									
BO0- 088 ulin equi ne 250 ulin		15	glob									
		10- B00	ulin									
250 ne 250 ne 10 10 10 10 10 10 10 10 10 10 10 10 10		000-	equi									
250 mg		000	ne									
			250									
			mg									
			in 5									
			ml									



amp oule oule Image: I	
م العلاج فشل نخاع العظم المكذ	
ا ا ا ا ا ا ا ا ا ا ا ا ا ا ا ا ا ا ا	
العظم المكتر	
(Acq uire d apla stic	
mia	
الكمية المطلو	
بة من	
() على ان ان الجه الجه	



					200										,		 		1			-
Γ		·		المر		Γ '	Ţ I	·		_	,	Ē	r I	Γ I	- I			Γ	Γ	T	Γ	
		,		ضی	.	'	1 1	i	.		, I	i I	1 1		ı	.						
		,		الفعلي	.	'	1 1	i	.		, I	i I	1 1		ı	.						
		,		الفعلي	.	'	1 1	i	.		, I	i I	1 1		ı	.						
		,		وفق	.	'	1	i			, I	1 I	1 1		ı							
		,		وفق قاعدة		,	1 1	ı	.		, I	1 I	1 1		ı							
		,		البيانا	.	'	1	i			, I	1 I	1 1		ı							
		,		ت	.	'	1	i			, I	1 I	1 1		ı							
		·				· ·	1 1	ı			, I	1 I	1 1		ı							
		,		الرسم ية المتو فرة	.	'	1 1	ı			, I	i I	1 1		ı							
		,		ية		,	1 1	ı	.		, I	1 I	1 1		ı							
		,		المته	.	'	1 1	i	.		, I	i I	1 1		ı	.						
		,		ا ش م	.	'	1	i			, I	1 I	1 1		ı							
		,			.	'	1 1	i	.		, I	i I	1 1		ı							
		,		لدى	.	'	1 1	i	.		, I	i I	1 1		ı							
		,		الدوائر	.	'	1 1	i	.		, I	i I	1 1		ı							
		,		الدوائر اعلاہ	.	'	1	i			, I	1 I	1 1		ı							
		,		وحسد	.	'	1	i			, I	1 I	1 1		ı							
		,			.	'	1	i			, I	1 I	1 1		ı							
		,		ب ما جاء بتوصد	.	'	1	i			, I	1 I	1 1		ı							
		,		جاء		,	1 1	ı	.		, I	1 I	1 1		ı							
		,		بتوصد	.	'	1 1	i	.		, I	i I	1 1		ı							
		,		يات اللجنة	.	'	1	i			, I	1 I	1 1		ı							
		,		1 3 t. Th	.	'	1 1	i	.		, I	i I	1 1		ı							
		,		اللجنية		,	1 1	ı	.		, I	1 I	1 1		ı							
		,		الاست		,	1 1	ı	.		, I	1 I	1 1		ı							
		,		شارية	.	'	1 1	i	.		, I	i I	1 1		ı							
		,		لامرا	.	'	1	i			, I	1 I	1 1		ı							
		,				,	1 1	ı	.		, I	1 I	1 1		ı							
							1 1	i			, I	1	1		1							
				ض الدم			1 1	i			, I	1	1		1							
				السري		,	1 1	ı			, I	1	1 1			1						
				رية			1 1	i			, I	1	1		1							
		,		السريا رية ج٩٨٧	.	'	1 1	, I			, I	, I	1 1		, I							
├ ── ├	\rightarrow	·+	08-	Rec	. — [+'	ł	·+		\rightarrow	, 	 +	ł	\vdash	 	 	 			<u> </u>	<u> </u>	+
		,	00-		.	'	1 1	, I			, I	, I	1 1									
		,	C00-	omb	.	'	1 1	, I			, I	, I	1 1		, I							
		,	004	inan	.	'	1 1	, I			, I	, I	1 1		, I							
		,		t	.	'	1 1	, I			, I	, I	1 1		, I							
		,		hum	.	'	1 1	, I			, I	, I	1 ¹		, I							
		,			.	'	1 1	,			, I	, I	1 ¹		, I							
		,		an	.	'	1 1	, I			, I	, I	1 1		, I							
		,		eryt	.	'	1 1	, I			, I	, I	1 ¹		, I							
		,		hrop	.	'	1 1	, I			, I	, I	1 1		, I							
		,		oieti	.	'	1 1	, I			, I	, I	1 1		, I							
		,			.	'	1 1	, I			, I	, I	1 1		, I							
				n (alfa		,	1 1	ı			, I	1	1 1			1						
		.		(alfa		,	1 1	1 I			, I	1	1		1	1						



	200	
rh Epo) 400		
Epo)		
400		
0 IU		
per PFS		
or		
vial		
sol.		
For		
inj (Solu		
Solu		
tion		
with		
out		
hum		
an		
seru		
m I		
albu		
min		
e,H AS		
AS		
Free		
). Or		
its		
appr		
ove		
d		
biosi		
mila		
r (alfa		
(alfa		
or		
Zeta		
تقر () مادة		



etin zeta) نصن القائمة	
) i i i i i i i i i i i i i i i i i i i	
) i i i i i i i i i i i i i i i i i i i	
الإسا	
سية السية المالية المالي	
توى الاول	
الأول	
باحتيا	
ضمنى	
hrop hrop hrop hrop hrop hrop hrop hrop	
oieti	
ट १- ६१	
08- Rec 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6	
C00- omb	
001 inan	
eryt	
hrop oieti	
l (alfa l l l l l l l l l l l l l l l l l l	



	 	200						 	
	rh Epo) 200								
	Epo)								
	0 I.U								
	per								
	vial								
	or								
	PFS								
	sol.								
	for inj								
	with								
	out								
	hum								
	an								
	seru								
	m albu								
	min,								
	HAS								
	Free								
) Or								
	its								
	appr ove								
	d								
	biosi								
	mila								
	r								
	(alfa								
	or Zeta								
)								
	تقر '								
	تقر) مادة								
	Epo								
	etin								
	zeta								
	1								



																			 	_
		2	ضمز القائمة الاس																	
		2	سىية بالمس																	
			بوی توی الاول																	
		۱	باحتي																	
		4	خمني																	
			يم (eryt																	
			hrop pieti																	
			n alfa																	
)																	
			. 1 • £ 9																	
			· · · · ·																	
			ج٩٨٧																	
		ā	- 1 • 1 Y																	
		2	. . 																	
G	rand Total o	of Bid price: [Bidders may in	sert permiss	sible Curre	ency]		(In	figures)							(In v	words)	I	
	Delivery Period: [Bidder may insert quoted delivery period] as per INCOTERMS [®] current edition [Insert Incoterms]. Agent Name & Address: [Bidder may insert, if applicable]																			
A	gent Name	& Address: _									(B	Bidder	may i	inser	t, if app	olicable]			
A	gency Comr	mission:	[Bic	lder may ins	ert, if app	licable]														



Date: _____

206

 Name& Designation

 Business address

 Seal of the Bidder



3.B. Price Schedule for Goods to be imported from Abroad

							4													5				6 Total
							Count	ry origin	l										Unit	price (C IP)			Total Price (CIP)
Date of registratio nof offer submittin g company	Nameof offer submitti ng compan y	Origin of offer submitti ng compan y	Manufactur e company name	Certificates obtaine d	noof	manufactur	Compan yaddress	Compan yphone no	Com pany email	Company website	Nameof scientific bureau in Iraq that representi vethe company	Benefi ciary name	Bank name	Ban k add ress	Bank phone no	Acc ount no	Price per pack	Priceper unit (CIP)(A)	Cu ne ncy typ e	Secondary services as defined in table(B)	Free goods	Paym ent meth od	Price CIP {C=(A+ B)}	Total price CIP of the offered Qty. (CxQty.)
<u>Delive</u>	ry Peri	od:		[Bidde	er may i	nsert q	uoted d	elivery	perio	d] as per l	INCOTE	RMS®	[®] curr	ent eo	dition				icote	erms].	In woi	usj		
Agenc	y Comr	nissior	:		[Bidde	r may ir	nsert, if	applica	ble]															
																Name Busir	e& De ness ad	f Bidder_ signation dress Bidder					_	





4. Bid Security Form (Bank Guarantee)

[The Bank shall fill in this Bank Guarantee Form in accordance with the instructions indicated._____

[insert Bank's Name, and Address of Issuing Branch or Office]

Beneficiary: ______ [insert Name and Address of Contracting Entity] Date:

BID GUARANTEE No.:

We have been informed that [insert **name of the Bidder**] (hereinafter called "the Bidder") has submitted to you its bid dated (hereinafter called "the Bid") for the execution of [insert **name of tender/project**] under Invitation for Bids No. [insert **IFB number**] ("the IFB").

Furthermore, we understand that, according to your conditions, bids must be supported by a bid guarantee.

Ăt the request of the Bidder, we [insert **name of Bank**] hereby irrevocably undertake to pay you any sum or sums not exceeding in total an amount of [insert **amount in figures**] ([insert **amount in words**]) upon receipt by us of your first demand in writing accompanied by a written statement stating that the Bidder is in breach of its obligation(s) under the bid conditions, because the Bidder:

- (a) has withdrawn its Bid during the period of bid validity specified by the Bidder in the Form of Bid; or
- (b) having been notified of the acceptance of its Bid by the Contracting Entity during the period of bid validity, (i) fails or refuses to execute the Contract Form, if required, or (ii) fails or refuses to furnish the performance security, in accordance with the Instructions to Bidders.
- (c) has complained or appealed as per ITB clause 36 and it is decided by the competent authorities for this Bidder to compensate all damages resulting from delaying the contract signature for false or unjustified reasons.

This guarantee will expire: (a) if the Bidder is the successful bidder, upon our receipt of copies of the contract signed by the Bidder and the performance security issued to you upon the instruction of the Bidder; or (b) if the Bidder is not the successful bidder, upon the earlier of (i) our receipt of a copy of your notification to the Bidder of the name of the successful bidder and the bidder has not complaint or appeals to the Contracting Entity; or (ii) twenty-eight days after the expiration of the Bidder's Bid and the bidder has not complaint or appeals to the Contracting Entity.

Consequently, any demand for payment under this guarantee must be received by us at the office on or before that date.

This guarantee is subject to the Uniform Rules for Demand Guarantees, ICC Publication No.758. [signature(s)]



5. Manufacturer's Authorization

[The Bidder shall require the Manufacturer to fill in this Form in accordance with the instructions indicated. Thisletter of authorization should be on the letterhead of the Manufacturer and should be signed by a person with the proper authority to sign documents that are binding on the Manufacturer. The Bidder shall include it in its bid, if so indicated in the BDS.]

Date: [insert: date (as day, month and year) of Bid Submission]

IFB No.: [insert: number of bidding process]

To: [insert: complete name of Contracting Entity] WHEREAS

We [insert: complete name of Manufacturer], who are official manufacturers of[insert: type of goods manufactured], having factories at [insert: full address of Manufacturer's factories], do hereby authorize [insert: complete name of Bidder] to submit a bid the purpose of which is to provide the following Goods, manufactured by us [insert: name and or brief description of the Goods], and to subsequently negotiate and sign the Contract.

We hereby extend our full guarantee and warranty in accordance with Clause 15 of the General Conditions of Contract, with respect to the Goods offered by the above firm.

Signed: [insert: signature(s) of authorized representative(s) of the Manufacturer] Name: [insert: complete name(s) of authorized representative(s) of the Manufacturer]

Title: [insert: title

Duly authorized to sign this Authorization on behalf of: [insert: complete name of Bidder] Dated on ______ day of ______ [insert: date of signing]



6. Sample Form for Performance Statement

Contract placed by	Order No and date	Order placed on	Description of Goods	Quantity	Date if completion of Contract		Reasons of delay, if any	Are the goods supplied satisfactory?
					As per Contract	Actual		
1	2	3	4	5	6	7	8	9





PART 2 PROCUREMENT REQUIREMEN



128

SECTION VI SCHEDULE OF REQUIREMENTS

NOTES ON THE SCHEDULE OF REQUIREMENTS

The Schedule of Requirements provides a concise description of each product and the quantity required, along with any technical specifications unique to that item.





SCHEDULE OF REQUIREMENTS

130

Schedule: I List of Goods, Delivery Schedule and Terms of Delivery:

1				2			3	4	5	6
Schedule No.	Item No.	form, Ph	or Pharmaceu armacopoeia Equipment o	a Standard a	uct, Strength nd Unit pack cription of go	size. For	Quanti ty and physic al unit	Bid security amount in Iraqi Dinar [Note Insert Bid Security amount Schedule wise as one percent of Estimated Value]	Final Destination [Note Insert End- users" address]	Required Delivery period as per [insert Incoter ms® current edition]
[Incorf]	[Insert]	[Insert]	[Insert]	[Insert]	[Insert]	[Insert]	[Insert]	[Insert]	[Insert]	[Insert]
[Insert]	[Insert]	[Insert]	[Insert]	[Insert]	[Insert]	[Insert]	[Insert]	[Insert]	[Insert]	[Insert]
[Insert]	[Insert]	[Insert]	[Insert]	[Insert]	[Insert]	[Insert]	[Insert]	[Insert]	[Insert]	[Insert]

Terms of Delivery: The Bidders are required to quote prices as per the terms of delivery stipulated in Price Schedule in Section -IV



ScheduleII: Scope of Incidental Services:

[Insert:"**Nil**" for Health Sector Goods OR "Required Installation, Demonstration and onsite Training" for Medical Equipment]

ScheduleIV. Technical Specifications

The purpose of the Technical Specifications (TS) is to define the technical characteristics of the Goods and Related Services required by the Contracting Entity

Technical Specifications

1-the items offer should be stated by it's commercial name if it offer in it's scientific name should be stated in pharmacopoeia standards.
2-stat the shelf life.
3-stat the origin of a material.



Technical Specifications PHARMACEUTICALS

1. Product and Package Specification s

1.1 The Goods to be purchased by the Contracting Entity under this Invitation for Bids are included in Iraq's current national essential drugs list or national formulary. The required packing standards and labeling must meet the latest requirements of the World Health Organization (WHO) good manufacturing practices (GMP) standards in all respects. (These standards are contained in "Good Practices in the Manufacture and Quality Control of Drugs.")

- Product specifications indicate dosage form (e.g., tablet, 1.2 capsules. dry syrup, liquid, ointment. injectable. emulsion, suspension, etc.) and the drug content (exact number of mg or international units [IU] or % v/v, w/w or v/w acceptable range). The Goods should conform to standards specified in the following compendia: [The Contracting Entity should specify an acceptable pharmacopoeia standard from one of the following: the British Pharmacopoeia, the United States Pharmacopoeia, Pharmacopoeia, the French the Pharmacopoeia, International the European or Pharmacopoeia, the latter particularly for raw materials.] The standards will be the latest edition unless otherwise stated by the Contracting Entity or other if applicable. In case the pharmaceutical product is not included in the specified compendium, but included in the Iraq's national essential drug list, the Contracting Entity should clearly indicate acceptable limitsand the Bidder (Supplier), upon award of the Contract, must provide the reference standards and testing protocols to allow for quality control testing.
- Not only the pharmaceutical item, but also the packaging and labeling components (e.g., bottles, 1.3 closures, and labeling) should also meet specifications suitable for distribution, storage, and use in a climate similar to that prevailing in Iraq. All packaging must be properly sealed and tamper-proofand packaging components must meet the latest compendium standards and be approved for pharmaceutical packaging by the manufacturer's national regulatory authority (RA). The Contracting Entity should specify any additional special requirements.

Section VI. Schedule of Requirements

Republic of Irag

ىللە تك

- 1.4 All labeling and packaging inserts shall be in the language requested by the Contracting Entity or English if not otherwise stated.
- 1.5 Goods requiring refrigeration or freezing or those that should not fall below a certain minimum temperaturefor stability must specifically indicate storage requirements on labels and containers and be shipped in special containers to ensure stability in transit from point of shipment to port of entry.
- 1.6 Upon award, the successful Bidder(Supplier) shall, on demand, provide a translated version in the language of the bid of the prescriber's information for any specific goods the Contracting Entity may request.
- 2.1 The label of the primary container for each pharmaceutical and vaccine products shall meet the W210 GMP standard and include:
 - (a) The international nonproprietary name (INN) or generic name prominently displayed and above the brand name, where a brand name has been given. Brand names should not be bolder or larger than the generic name;
 - (b) dosage form, e.g., tablet, ampoule, syrup, etc.;
 - (c) the active ingredient "per unit, dose, tablet or capsule, etc.;
 - (d) the applicable pharmacopoeia standard;
 - (e) the Purchaser's logo and code number and any specific color coding if required;
 - (f) content per pack;
 - (g) instructions for use;
 - (h) special storage requirements;
 - (i) batch number;
 - (j) date of manufacture and date of expiry (in clear language, not code);
 - (k) name and address of manufacture;
 - (I) any additional cautionary statement.
- 2.2 The outer case or carton should also display the above information.
- 3.1 All cases should prominently indicate the following:
 - (a) Purchaser's line and code numbers;
 - (b) the generic name of the product;
 - (c) the dosage form (tablet, ampoule, syrup);
 - (d) date of manufacture and expiry (in clear language not code);
 - (e) batch number;
 - (f) quantity per case;
 - (g) special instructions for storage;
 - (h) name and address of manufacture;
 - (i) any additional cautionary statements.
- 3.2 No case should contain pharmaceutical products from more than one batch.
- 4.1 The Contracting Entity(Purchaser) shall have the right to request the Supplierto imprint a logo, if the quantity so justifies it, on thelabels of the containers used for packaging and in certain dosage forms, such as tablets,

3. Case Identification

4.

Unique

Identifiers

2. Labeling Instructions



and ampoules and this will be in the Technical Specifications. The designand detail will be clearly indicated at the time of bidding, and confirmation of the design of such logoshall be provided to the Bidder(Supplier) at the time of contract award.

- The successful Bidder (Supplier) will be required to furnish to the Contracting Entity:
 - (a) With each consignment, and for each item a WHO certificate of quality control test results concerning quantitative assay, chemical analysis, sterility, pyrogen content uniformity, microbial limit, and other tests, as applicable to the Goods being supplied and the manufacturer's certificate of analysis.
 - (b) Assay methodology of any or all tests if requested.
 - (c) Evidence of bio-availability and/or bio-equivalence for certain critical Goods upon request. This information would be supplied on a strictly confidential basis only.
 - (d) Evidence of basis for expiration dating and other stability data concerning the commercial final package upon request.
- 5.2 The Supplier (Bidder) will also be required to provide the Contracting Entity(Purchaser) with access to its manufacturing facilities to inspect the compliance with the GMP requirements and quality control mechanisms.]

5. Standards of 5.1 Quality Control for Supply



[Sample: Technical Specification VACCINES

- Product Qualification Requirements
 Option A
 The Goods to be purchased by the Contracting Entity under this Invitation for Bids must be produced under the control of a recognized, well-functioning National Control Authority (NCA) for biologicals, which performs all six critical functions as defined by the World Health Organization (WHO):
 - (a) licensing based on published set of requirements
 - (b) surveillance of vaccine field performance
 - (c) system of lot release for vaccines
 - (d) use of laboratory when needed
 - (e) regular inspections for Good Manufacturing Practices (GMP)
 - (f) evaluation of clinical performance

Or state the following: Option B

- 1.1 The Goods under this Invitation for Bids should be purchased from WHO-approved sources only.
- 1.2 The Goods to be purchased by the Contracting Entity under this Invitation for Bids must be produced in accordance with the GMP recommendations of WHO for biological products.
- 1.3 The Goods to be purchased by the Contracting Entity under this Invitation for Bids must be registered by the National Control Authority (NCA) of Iraq.
- 2.1 Dosage form (e.g.: oral or injectable; liquid or freeze dried with sterile diluents packed separately, etc.).
- 2.2 Type (e.g.: "live attenuated," "manufactured from purified inactivated (...) obtained from human plasma or manufactured using recombinant DNA technology," etc.).
- 2.3 Administration (e.g.: "intended for intramuscular injection," etc.).
- 2.4 Description of intended use (e.g.: "immunization of newborn infants," etc.).
- 2.5 Dosage size (if not restrictive), or expected immunogenic reaction (e.g.: each dose shall contain that amount of Hbsag protein with micrograms/ml specified by the manufacturer for newborn dosage, that when given as part of a primary immunization series [3 doses] is capable of producing specific humoral antibody [anti HBs] at a level of at least 10 milli international units in >-90 percent of recipients," etc.).
- 2.6 Dose package (e.g.: "5 infant dose sterile glass vials," etc.).
- 2.7 Filling volume (e.g.: "final product should contain 15% overfill," etc.).
- 2.8 Closures (e.g.: "vaccine vials shall be fitted with closures that conform to ISO standard 8362-2").
- 2.9 Storage temperature (e.g.: "2–8 degrees C. Do not freeze," or as appropriate, etc.).

2. Product Specification s



- 2.10 The product should remain stable up to the indicated test expiry date if kept according to the required storage temperature.
- 2.11 Standards (e.g.: "The vaccine should conform to standards established by Iraq or, where no standard has been adopted, meet current requirements published by the WHO Expert Committee on Biological Standardization, or requirements of an established body of equivalent stature such as the U.S. Pharmacopoeia, the British Pharmacopoeia, the French Pharmacopoeia, or the International Pharmacopoeia").
- 3.1 Each vial or ampoule shall carry the manufacturer's standard label in Iraqi language, if available at no extra charge; otherwise, the label shall be in English.
- 3.2 Each vial or ampoule label shall state the following:
 - (a) name of the vaccine:
 - (b) name of the manufacturer;
 - place of manufacture; (c)
 - (d) lot number;
 - (e) composition;
 - (f) concentration:
 - dose mode for administration;
 - (ġ) (h) expiration date;
 - (i) storage temperature;
 - (j) any other information that is appropriate.
- 3.3 All labeling shall withstand immersion in water and remain intact.
- 4.1 Inner boxes: Inner Boxes shall contain not more than (number) individual vials/ampoules and shall be constructed of sturdy white cardboard outfitted with individual segments for protecting and separating each vial/ampoules.
- 4.2 Printed materials: Each inner box shall contain at least (number) manufacturer's standard package inserts in the Iraqi language if available at no extra charge; otherwise, package insert shall be in English.
- 4.3 Over packing: Inner boxes shall be over packed so that the vaccine remains refrigerated as designated in Sub-Clause 2.9. The over packing must be suitable for export handling and be in accordance with WHO Expanded Program of Immunization (EPI) Guidelines on International Packaging and Shipping of Vaccines including all measures needed to maintain required temperatures for seventy-two (72) hours. It must have adequate insulation and sufficient refrigerant to ensure that the warmest storage temperature of the vaccine does not rise above that designated in Sub-Clause 2.9 when exposed to continuous outside temperature of +43 degrees C, nor fall below that specified of -20 degrees C during transit and for a period of at least twenty-four (24) hours after arrival at the airport destination. Additional cushioning shall be provided sufficient to protect the vials/ampoules from breakage during transit and handling.

Packing 4. Requirements

Labeling

Requirements

3.

Section VI. Schedule of Requirements

Republic of Iraq

ىللە تك

Product and printed 4.4 Exterior shipping cartons: materials, packaged as described above, shall be packed in weather-resistant, triple-wall corrugated fiberboard cartons with a bursting test strength of not less than 1,900 kPa. The overall dimensions of the exterior shipping cartons should be such that the product does not become damaged during transportation and storage.

No shipping carton should contain vaccine from more than one lot.

- 4.5 Cold chain monitor cards: Each insulated shipping container must include appropriate temperaturemonitoring devices designated by the Contracting Entity.
 - (a) At least two suitable cold chain monitor cards, as approved by the Contracting Entity, shall be packed in each transport case of vaccine.
 - (b) Freeze watch indicators shall be included in each transport case at the direction of Contracting Entity.
- 5.1 All containers and invoices must bear the following information:
 - (a) the name of the vaccine;
 - (b) expiration date of the vaccine;
 - (c) appropriate storage temperature.
 - 5.2 Inner boxes: The inner boxes containing vaccine vials or ampoules shall be marked with the following information in a clearly legible manner that is acceptable to the Contracting Entity:
 - (a) Generic name and trade name of the vaccine;
 - (b) Manufacturer's name and trade registered address;
 - (c) Manufacturer's national registration number;
 - (d) Lot or batch number;
 - (e) Composition and concentration;
 - (f) Number of vials contained in box;
 - (g) Expiration date (month and year in clear language, not code);
 - (h) Instructions for storage and handling;
 - (i) Place of manufacture (Made in _____).
 - 5.3 Exterior Shipping Cartons: The following information shall be stenciled or labeled on the exterior shipping cartons on two opposing sides in bold letters at least 30mm high with waterproof ink in a clearly legible manner that is acceptable to the Contracting Entity.
 - (a) Generic name and trade name of the vaccine;
 - (b) Lot or batch number;
 - (c) Expiration date (month and year in clear language, not code);
 - (d) Manufacturer's name and registered address;
 - (e) Manufacturer's national registration number;
 - (f) Destination airport and routing;
 - (g) Consignee's name and address in full;
 - (h) Consignee contact name and telephone number;

5. Marking 8 Requirements



- (i) Number of vials or ampoules contained in the carton;
- (j) Gross weight of each carton (in kg);
- (k) Carton #____ of ____
- (I) Instructions for storage and handling;
- (m) Contract number;
- (n) Place of manufacture (Made in____).
- 6. Quality Control for Supply
- 6.1 All goods must:
 - (a) meet the requirements of manufacturing legislation and regulation of vaccines in the country of origin;
 - (b) meet internationally recognized standards for safety, efficacy, and quality;
 - (c) conform to all the specifications and related documents contain herein;
 - (d) be fit for the purposes expressly made known to the Bidderby the Contracting Entity;
 - (e) be free from defects in workmanship and materials; and
 - (f) be certified by a competent authority in the manufacturer's country according to resolution WHA 28-65(2), of the WHO release certificate.
- 6.2 The Supplier will be required to furnish to the Contracting Entity with each consignment;
 - (a) A certificate of quality control and test results in conformity with the WHO release certificate.
 - (b) Assay methodology of any or all tests if required.
 - (c) Evidence of basis for expiration dating and other stability data concerning the commercial final package upon request.
- 6.3 Pre-shipment inspection and testing: The Supplier will be required to provide the Purchaser or his representative with access to the product as packed for shipment at the sellers' factory and/or warehouse at a mutually agreeable time prior to shipment of the product.
 - (a) The Purchaser may inspect and sample, or cause to be sampled, such product.
 - (b) The Purchaser may cause independent laboratory testing to be performed as deemed necessary to ensure that the Goods conform to prescribed requirements. The testing laboratory shall be of the Purchaser's choice and suitably equipped and qualified to conduct quality control test on biological products.



PART 3 CONDITIONS OF CONTRACT AND CONTRACT FORMS



SECTION VII. GENERAL CONDITIONS OF CONTRACT

NOTES ON THE GENERAL CONDITIONS OF CONTRACT

The General Conditions of Contract (GCC) in Section VII, read in conjunction with the Special Conditions of Contract (SCC) in Section VIII and other documents listed in the Contract Agreement, should be a complete document expressing all the rights and obligations of the parties.

GCC must remain unaltered. Contract-specific information, deletions, extensions, and modifications to the GCC shall be introduced only by the Contracting Entity through the SCC.



TABLE OF CLAUSES

- Definitions 1.
- Application 2.
- 3. Country of Origin
- 4. Standards
- 5. Use of Contract Documents and Information; Inspection and Audit
- Certification of Goods in Accordance with Laws of Republic of Iraq 6.
- 7. Patent Rights
- Performance Security 8.
- 9. Inspections and Tests
- 10. Packing
- 11. Delivery and Documents
- 12. Insurance
- 13. Transportation
- 14. Incidental Services & AMC
- 15. Warranty
 16. Payment
- 17. Prices
- 18. Change Orders
- 19. Contract Amendments
- 20. Assignment
- 21. Delays in the Supplier's Performance
- 22. Liquidated Damages
- 23. Termination for Default
- 24. Force Majeure
- 25. Termination for Insolvency
- 26. Termination for Convenience27. Settlement of Disputes
- 28. Limitation of Liability
- 29. Governing Language
- 30. Applicable Law
- 31. Notices
- 32. Taxes and Duties
- Withholding and lien in respect of sums claimed



1. Definitions

General Conditions of Contract

- 1.1 In this Contract, the following terms shall be interpreted as indicated:
 - (a) "The Contract" means the agreement entered into between the Contracting Entity and the Supplier, as recorded in the Contract Form signed by the parties, including all attachments and appendices thereto and all documents incorporated by reference therein.
- (b) "The Contract Price" means the price payable to the Supplier under the Contract for the full and proper performance of its contractual obligations.
- (c) "Day" means calendar day.
- (d) "Effective Date" means the date on which this Contract becomes effective pursuant to GCC Sub-Clause 6.2.
- (e) "End User" means the organization(s) where the goods will be used, as named in the Schedule of Requirements.
- (f) "GCC" means the General Conditions of Contract contained in this section.
- (g) "The Goods" means all of the pharmaceuticals including nutritional supplement and oral and injectable forms of contraception, vaccines, condoms and medical equipment that the Supplier is required to supply to the Contracting Entity under the Contract.
- (h) "The Purchaser" means the organization or the Contracting Entity purchasing the Goods, as **named in theSCC.**
- (i) "Registration Certificate" means the certificate of registration or other documents in lieu thereof establishing that the Goods supplied under the Contract are registered for use in the Iraq in accordance with the Applicable Law.
- (j) "SCC" means the Special Conditions of Contract.
- (k) "The Services" means those services ancillary to the supply of the Goods, such as transportation and insurance, and any other incidental services, such as installation, demonstration and onsite training at Endusers' site, and other such obligations of the Supplier covered under the Contract.
- (I) "The Site," where applicable, means the place or places of End-users' site as per Schedule of Requirements
- (m) "The Supplier" means the individual or firm supplying the Goods and Services under this Contract, as **named in the SCC.**
- (n) Fraud and Corruption :

The Purchaser defines Fraud and Corruption as per the relevant applicable Iraqi laws. For the purposes of this Sub-Clause, the Purchaser will be guided further by the definition of the terms as set forth here below:

- (i) "corrupt practice" is the offering, giving, receiving or soliciting, directly or indirectly, of anything of value to influence improperly the actions of another party;
- (ii) "fraudulent practice" is any act or omission, including a misrepresentation, that knowingly or recklessly misleads, or attempts to mislead, a party to obtain a financial or



other benefit or to avoid an obligation;

- (iii) "collusive practice" is an arrangement between two or more parties designed to achieve an improper purpose, including to influence improperly the actions of another party;
- (iv) "coercive practice" is impairing or harming, or threatening to impair or harm, directly or indirectly, any party or the property of the party to influence improperly the actions of a party;
- (v) "obstructive practice" is
- (aa) deliberately destroying, falsifying, altering or concealing of evidence material to the investigation or making false statements to investigators in order to materially impede a Purchaser's investigation into allegations of a corrupt, fraudulent, coercive or collusive practice in accordance with the applicable Iraqi laws; and/or threatening, harassing or intimidating any party to prevent it from disclosing its knowledge of matters relevant to the investigation or from pursuing the investigation, or
- (bb) acts intended to materially impede the exercise of the Purchaser's inspection and audit rights as per the applicable Iraqi laws and as per Sub-Clause 5.4.
- 2.1 These General Conditions shall apply to the extent that they are not superseded by provisions of other parts of the Contract.
- 3.1 For purposes of this Clause, "origin" means the place where the Goods were mined, grown, or produced, or from which the Services are supplied. Goods are produced when, through manufacturing, processing, or substantial and major assembly of components, a commercially recognized new product results that is substantially different in basic characteristics or in purpose or utility from its components.
- 3.2 The origin of Goods and Services is distinct from the nationality of the Supplier.
- 4.1 The Goods supplied under this Contract shall conform to the standards mentioned in the Technical Specifications and, when no applicable standard is mentioned, to the authoritative standards appropriate to the Goods' country of origin. Such standards shall be the latest issued by the concerned institution.
- 5.1 The Supplier shall not, without the Purchaser's prior written consent, disclose the Contract, or any provision thereof, or any specification, plan, drawing, pattern, sample, or information furnished by or on behalf of the Purchaser in connection therewith, to any person other than a person employed by the Supplier in the performance of the Contract. Disclosure to any such employed person shall be made in confidence and shall extend only as far as may be necessary for purposes of such performance.
- 5.2 The Supplier shall not, without the Purchaser's prior written consent, make use of any document or information enumerated in GCC Sub-Clause 5.1 except for purposes of performing the Contract.

2. Application

3. Country of Origin

4. Standards

5. Use of Contract Documents and Information; Inspection and Audit



- 5.3 Any document, other than the Contract itself, enumerated in GCC Sub-Clause 5.1 shall remain the property of the Purchaser and shall be returned (all copies) to the Purchaser on completion of the Supplier's performance under the Contract if so required by the Purchaser.
- 5.4 In accordance with the applicable Iraqi laws, the Supplier shall permit the Purchaser through the competent authorities to inspect the Supplier's offices and/or the accounts and records of the Supplier and its subcontractors relating to the performance of the Contract, and to have such accounts and records audited by auditors. The Supplier's attention is drawn to Clause 23, which provides, inter alia, that acts intended to materially impede the exercise of the Purchaser's inspection and audit rights provided for under this Sub-Clause constitute a prohibited practice subject to contract termination as well as to a determination of ineligibility pursuant to the Iraqi's prevailing sanctions procedures in Iraq.
- 6.1 If required under the Applicable Law, Goods supplied under the Contract shall be registered for use in the Iraq. The Purchaser undertakes to cooperate with the Supplier to facilitate registration of the Goods for use in the Iraq.
- 6.2 Unless otherwise **specified in the SCC**, the Contract shall become effective on the date ("the Effective Date") that the Supplier receives written notification from the competent authority in Iraq that the Goods have been registered for use in Iraq.
- 7.1 The Supplier shall indemnify the Purchaser against all third-party claims of infringement of patent, trademark, or industrial design rights arising from use of the Goods or any part thereof in Iraq.
- 8.1 Within 14 days, or twenty-nine (29) days in case of Complaints and Appeals raised by unsuccessful Bidders, of receipt of the notification of Contract award, the successful Bidder shall furnish to the Purchaser the performance security of 5% of Contract Price. If rules and regulations of Republic of Iraq grant exemption to Public Companies of State and Public Sector, they are accordingly exempted of submitting Performance Security.
- 8.2 The proceeds of the performance security shall be payable to the Purchaser as compensation for any loss resulting from the Supplier's failure to complete its obligations under the Contract.
- 8.3 The performance security shall be denominated in the currency or currencies of the Contractor in a freely convertible currency acceptable to the Purchaser and chosen from the list of currencies from which the Central Bank of Iraq quotes the rate of exchange to the Iraqi **Dinar.** The Security shall be an unconditional guarantee payable upon first demand and in one of the following forms:
- (a) A bank guarantee issued by accredited bank in Iraq in

6. Certification of Goods in Accordance with Laws of Republic of Iraq

7. Industrial owner ship or Patent Righ

8. Performance Security



accordance with the instructions of Central Bank of Iraq in the format provided in the Bidding Documents. In the case of a Bank Guarantee furnished from the banks located outside Iraq, it shall be endorsed and countersigned by an accredited bank in Iraq by way of back-to-back counter guarantee. Or

- (b) an irrevocable letter of credit or
- (c) Republic of Iraq bonds
- 8.4 The performance security will be discharged by the Purchaser and returned to the Supplier not later than thirty (30) days following the date of completion of the Supplier's performance obligations under the Contract, including any warranty obligations. The performance security shall be released after the final certificate regarding satisfactory completion of Supplier's performance obligations has been issued and final payment settlements have been done.
- 9. Inspections 9.1 The Purchaser or its representative shall have the right to inspect and/or to test the Goods to confirm their and Tests conformity to the Contract specifications. The SCC and the Technical Specifications shall specify what inspections and tests the Purchaser requires and where they are to be conducted. The Purchaser shall notify the Supplier in writing, in a timely manner, of the identity of any representatives retained for these purposes.

9.2 As specified in the SCC.

- 9.3 Nothing in GCC Clause 8 shall in any way release the Supplier from any warranty or other obligations under this Contract.
- 10.1 The Supplier shall provide such packing of the Goods as is required to prevent their damage or deterioration during transit to their final destination, as indicated in the Contract. The packing shall be sufficient to withstand, without limitation, rough handling during transit and exposure to extreme temperatures, salt, and precipitation during transit and open storage. Packing case size and weights shall take into consideration, where appropriate, the remoteness of the Goods' final destination and the absence of heavy handling facilities at all points in transit.
- 10.2 The packing, marking, and documentation within and outside the packages shall comply strictly with such special requirements as shall be expressly provided for in the Contract, including additional requirements, if any, **specified in the SCC** or Technical Specifications, and in any subsequent instructions ordered by the Purchaser.
- 11.1 Delivery of the Goods shall be made by the Supplier in accordance with the terms specified in the Schedule of Requirements. The details of shipping and/or other documents to be furnished by the Supplier are **specified** in the SCC.
- 11.2 For purposes of the Contract, "EXW," "CIF," "CIP," "DDP" and other trade terms used to describe the obligations of the parties shall be governed by the

10.Packing

11. Delivery and Documents



international rules for interpreting trading terms as prescribed in the current edition of INCOTERMS® published by the International Chamber of Commerce, Paris.

- 11.3 Documents to be submitted by the Supplier are **specified in the SCC.**
- 12.1 The Goods supplied under the Contract shall be fully insured in a freely convertible currency chosen from the list of currencies from which the Central Bank of Iraq quotes the rate of exchange to the Iraqi Dinar, against loss or damage incidental to manufacture or acquisition, transportation, storage, and delivery. Where delivery of Goods is required by Purchaser on a CIF or CIP basis, the supplier shall assure the insurance of an amount equal to 110 percent of the CIF or CIP value of the Goods from "warehouse" to "warehouse" on "All Risks" basis, including war risks and strikes.
- 12.2 Where delivery of the Goods is required by the Purchaser on a CIF or CIP basis, the Supplier shall arrange and pay for cargo insurance, naming the Purchaser as beneficiary. Where delivery is on an FOB or FCA basis, insurance shall be the responsibility of the Purchaser.
- 13.1 Where the Supplier is required under Contract to deliver the Goods FOB, transport of the Goods, up to and including the point of putting the Goods on board the vessel at the specified port of loading, shall be arranged and paid for by the Supplier, and the cost thereof shall be included in the Contract Price. Where the Supplier is required under the Contract to deliver the Goods FCA, transport of the Goods and delivery into the custody of the carrier at the place named by the Purchaser or other agreed point shall be arranged and paid for by the Supplier, and the cost thereof shall be included in the Contract Price.
- 13.2 Where the Supplier is required under Contract to deliver the Goods CIF or CIP, transport of the Goods to the port of destination or such other named place of destination in the Purchaser's country, as shall be specified in the Contract, shall be arranged and paid for by the Supplier, and the cost thereof shall be included in the Contract Price.
- 13.3 Where the Supplier is required under the Contact to transport the Goods to a specified place of destination within Iraq, defined as the Site, transport to such place of destination in Iraq, including insurance and storage, as shall be specified in the Contract, shall be arranged by the Supplier, and related costs shall be included in the Contract Price.
- 13.4 Where the Supplier is required under Contract to deliver the Goods CIF or CIP, no restriction shall be placed on the choice of carrier.
- 14.1 The Supplier shall provide such incidental services, if any, as are **specified in the Schedule of Requirements.**

12.Insurance

13. Transportation

14. Incidental Services & AMC



15.Warranty 16.Payment

- 14.2 The Supplier shall provide <u>Annual Maintenance</u> <u>Contract</u> (AMC), if any, after warranty period for number of years as specified in the Schedule of Requirements.
- 15.1 Warranty shall be as **specified in the SCC.**
- 16.1 The method and conditions of payment to be made to the Supplier under this Contract shall be **specified in the SCC.**
- 16.2 The Supplier's request(s) for payment shall be made to the Purchaser in writing, accompanied by an invoice describing, as appropriate, the Goods delivered and Services performed, and by documents submitted pursuant to GCC Clause 11, and upon fulfillment of other obligations stipulated in the Contract.
- 16.3 Payments shall be made promptly by the Purchaser, but in no case later than sixty (60) days after submission of an invoice or claim by the Supplier. In case of delay beyond 60 (sixty) days, the resolution of this delay shall be settled as **specified in the SCC**.
- When applicable, the advance security shall be payable upon an on demand and unconditional guarantee issued by an accredited bank in Iraq as per the official publication of the Iraqi Central Bank. If the security is issued by a Bank located outside Iraq, the issuer shall have a correspondent accredited financial institution located in Iraq to make it enforceable. In the case of a bank guarantee, the security shall be submitted using the Bid Security Form included in Section IX (Contract Forms) or in another substantially similar format with the prior approval of the Purchaser as per the applicable Iraqi laws.
- 16.4 Payment will be made in the currency or currencies in which the payment has been requested in the Supplier's bid.
- 16.5 Irrevocable non transferable and unconfirmed Letter of Credit (LC) shall be opened by the Purchaser in accordance with the applicable Iraqi regulations. However, if the Supplier requests specifically to open confirmed LC, the extra charges would be borne by the supplier. If LC is required to be extended and/or amended for reasons not attributed to the Purchaser, the charges thereof shall be borne by the Supplier. However, if the LC is amended to make LC as per Contract requirements then charges thereof shall be borne by the Purchaser.
- 17.1 Prices charged by the Supplier for Goods delivered and Services performed under the Contract shall not vary from the prices quoted by the Supplier in its bid, prices shall be fixed and firm for the duration of Contract.
- 18.1 No changes shall be introduced to the contract unless for the circumstances (a-e) listed herebelow. In such case, the Change should be limited to minimum and would be applicable for the following reasons:
- a) If the change is not introduced, a major damage will result economically and technically;
- b) If the change is not introduced, the Goods cannot be useful upon completion;

17.Prices

18. Change Orders



- c) If the change will realize savings in the cost of the Project;
- d) If the change does not result in a major modification to the pre-determined scope of supply;
- e) If the change will result in earlier time for completion but not to result in inferior technical specification or scope of supply
- The Purchaser may as per the applicable Iraqi laws, by a written order given to the Supplier pursuant to GCC Clause 31, make changes within the general scope of the Contract in any one or more of the following:
- (a) specifications, where Goods to be furnished under the Contract are to be specifically manufactured for the Purchaser;
- (b) the method of shipment or packing;
- (c) the place of delivery; and/or
- (d) the Services to be provided by the Supplier.
- 18.2 If any such change causes an increase or decrease in the cost of, or the time required for, the Supplier's performance of any provisions under the Contract, an equitable adjustment shall be made in the Contract Price or delivery schedule, or both, and the Contract shall accordingly be amended. Any claims by the Supplier for adjustment under this clause must be asserted within fifteen (15) days from the date of the Supplier's receipt of the Purchaser's change order.
- 19.1 Subject to GCC Clause 18, no variation in or modification of the terms of the Contract shall be made except by written amendment signed by the parties.
- 20.1 The Supplier shall not assign, in whole or in part, its obligations to perform under this Contract, unless specified otherwise in the SCC.
- 21.1 Delivery of the Goods and performance of Services shall be made by the Supplier in accordance with the time schedule prescribed by the Purchaser in the Schedule of Requirements.
- 21.2 If at any time during performance of the Contract, the Supplier or its subcontractor(s) should encounter conditions impeding timely delivery of the Goods and performance of Services, the Supplier shall promptly notify the Purchaser in writing of the fact of the delay, it's likely duration, and its cause(s). As soon as practicable after receipt of the Supplier's notice, the Purchaser shall evaluate the situation and may at its discretion extend the Supplier's time for performance, with or without liquidated damages, in which case the extension shall be ratified by the parties by amendment of Contract.
- 21.3 Except as provided under GCC Clause 24, a delay by the Supplier in the performance of its delivery obligations shall render the Supplier liable to the imposition of liquidated damages pursuant to GCC Clause 22, unless an extension of time is agreed upon pursuant to GCC Sub-Clause 21.2 without the application of liquidated damages.

19.Contract Amendments

20. Assignment

21. Delays in the Supplier's Performance



Section VII. General Conditions of Contract

22. Delay penalties	22.1 Subject to GCC Clause 24, if the Supplier fails to
(reduced according the	deliver any or all of the Goods or to perform the Services within the period(s) specified in the Contract, the
achievment	Purchaser shall, without prejudice to its other remedies
percentage	under the Contract, deduct from the Contract Price, as
	liquidated damages as per following formula:
	Total Contract Price X 10% - 25% = delay penalty per day
	Total validity contract (days)
	<u>OR could be deducted as followoing formula :</u> <u>Unperformed Contract Price</u> X 10% = Liquidated damages
	per day
	Delivery period (days)
	In the above formula the unperformed Contract Price
	applicable will be a sum equivalent to delivered price of
	the delayed Goods or unperformed Services until actual
	delivery or performance, up to a maximum deduction of
	the 10% percentage of Contract Price. Once the maximum is reached, the Purchaser may consider
	termination of the Contract pursuant to GCC Clause 23.
23. Termination for	23.1 The Purchaser, without prejudice to any other remedy
Default	for breach of Contract, by written notice of default sent to
	the Supplier, may terminate this Contract in whole or in
	part in accordance with the Iraqi applicable laws:
	(a) if the Supplier fails to deliver any or all of the Goods within the period(s) specified in the Contract, or within
	any extension thereof granted by the Purchaser pursuant
	to GCC Clause 21; or
	(b) if the Goods do not meet the Technical Specifications
	stated in the Contract within 30 days from date of
	receiving the wrriten notification issued by the purchaser;
	or (c) if the Supplier fails to provide any registration or other
	certificates in respect of the Goods within the time
	specified in the Special Conditions.
	(d) if the Purchaser determines as per the applicable Iraqi
	laws that the Supplier has engaged in corrupt, fraudulent,
	collusive, coercive or obstructive practices in accordance
	with GCC Sub-Clause 1.1.n, in competing for or in executing the Contract, then the Purchaser may, after
	giving 15 days notice to the Supplier, terminate the
	Supplier's employment under the Contract and cancel the
	contract, and the provisions of Clause 23 shall apply as if
	such expulsion had been made under Sub-Clause 23.1.
	(e) should any employee of the Supplier be determined to
	have engaged in corrupt, fraudulent, collusive, coercive, or obstructive practice in accordance with GCC Sub-
	Clause 1.1.n during the purchase of the Goods, then that
	employee shall be removed.
	(f) if the Supplier fails to perform any other obligation(s)
	under the Contract.

(g) if the supplier withdraw completely or partially rom the contract to another supplier or sign un-official contract with another supplier



	23.2 In the event the Purchaser terminates the Contract in whole or in part, pursuant to GCC Sub-Clause 23.1, the Purchaser may procure, upon such terms and in such manner as it deems appropriate, Goods or Services similar to those undelivered, and the Supplier shall be liable to the Purchaser for any excess costs for such similar Goods or Services. However, the Supplier shall continue performance of the Contract to the extent not terminated.
24. Termination for Insolvency	 The Purchaser may at any time terminate the Contract by giving written notice within 15 days to the Supplier if the Supplier becomes bankrupt or otherwise insolvent. Without retuning to the court as following cases : (a) if the supplier has been insolvency, poverty, or subjected to dissolution his assets or submit a request to become under Insolvency or poverty. (b) if the relevant court issued a judgment to put the supplier assets under the hand of Insolvency secretary . © if the supplier has agreed to carryout his contractual obligations under the observation of inspection committee consist of his creditors. (d) if the supplier assets have been holding (blocked) by the
	 In the supplier descert have been holding (blocked) by the relevant court which lead to inability to commit with his contractual obligations. In this case, the contract will be under determination without any compensation to the supplier & without exceed to the purchaser rights or compensations according to the contract or what are resulted beyond.
25. Force Majeure	 25.1 Notwithstanding the provisions of GCC Clauses 21, 22, and 23, the Supplier shall not be liable for forfeiture of its performance security, liquidated damages, or termination for default if and to the extent that it's delay in performance or other failure to perform its obligations under the Contract is the result of an event of Force Majeure. 25.2 For purposes of this clause, "Force Majeure" means an event beyond the control of the Supplier and not involving the Supplier's fault or negligence and not foreseeable. Such events may include, but are not restricted to, acts of the Purchaser in its sovereign capacity, wars or revolutions, fires, floods, epidemics, quarantine restrictions, and freight
	embargoes. 25.3 If a Force Majeure situation arises, the Supplier shall promptly notify the Purchaser in writing of such condition and the cause thereof. Unless otherwise directed by the Purchaser in writing, the Supplier shall continue to perform its obligations under the Contract as far as is reasonably practical and shall seek all reasonable alternative means for performance not prevented by the Force Majeure event.
26. Termination for	26.1 The Purchaser, by written notice sent to the Supplier,

26.1 The Purchaser, by written notice sent to the Supplier, Convenience (a) for general benefit. Section VII. General Conditions of Contract

- (b) in case there is no way to achieve the contract for anyreason agreed which are outside the will of the two parties, which lead to impossible supplying.
- For ,its convenience. The notice of termination shall specify that termination is for the Purchaser's convenience, the extent to which performance of the Supplier under the Contract is terminated, and the date upon which such termination becomes effective.
- 26.2 For the remaining goods, the Purchaser may elect:
- (a) to have any portion completed and delivered at the Contract terms and prices; and/or
- (b) to cancel the remainder and pay to the Supplier an agreed amount for partially completed Goods and Services and for materials and parts previously procured by the Supplier.
- 26.3 If the Contract is terminated for convenience of the Purchaser, the rights, duties and obligations of the parties, including all dues to the Supplier, shall be in accordance with the procedure set forth in Clause 27.
- 27.1 If any dispute or difference of any kind whatsoever shall arise between the Purchaser and the Supplier in connection with or arising out of the Contract, the parties shall make every effort to resolve amicably such dispute or difference by mutual consultation.
- 27.2 If, after thirty (30) days, the parties have failed to resolve their dispute or difference by such mutual consultation, then either the Purchaser or the Supplier may give notice to the other party of its intention to commence arbitration, as hereinafter provided, as to the matter in dispute, and no arbitration in respect of this matter may be commenced unless such notice is given.
- 27.2.1Any dispute or difference in respect of which a notice of intention to commence arbitration has been given in accordance with this Clause shall be finally settled by arbitration. Arbitration may be commenced prior to or after delivery of the Goods under the Contract.
- 27.2.2Arbitration proceedings shall be conducted in accordance with the rules of procedure **specified in the SCC**.
- 27.3 Notwithstanding any reference to arbitration herein,
- (a) the parties shall continue to perform their respective obligations under the Contract unless they otherwise agree; and
- (b) the Purchaser shall pay the Supplier any monies due the Supplier.
- 28.1 Except in cases of criminal negligence or willful misconduct, and in the case of infringement pursuant to Clause 7,
- (a) the Supplier shall not be liable to the Purchaser, whether in contract, tort, or otherwise, for any indirect or consequential loss or damage, loss of use, loss of production, or loss of profits or interest costs, provided that this exclusion shall not apply to any obligation of the Supplier to pay liquidated damages to the Purchaser

27. Settlement of Disputes

28. Limitation of Liability

29.1 The language of the Contract shall govern its

Section VII. General Conditions of Contract

Language	interpretation. All correspondence and other documents
	pertaining to the Contract that are exchanged by the
	parties shall be written in the same language.
30. Applicable Law	30.1 The Contract shall be interpreted in accordance with
	the Iraqi Law and guardianship of Iraqi judicial system.
31.Notices	31.1 Any notice given by one party to the other pursuant to
	this Contract shall be sent to the other party in writing or
	by cable (the term "cable" is deemed to include electronic
	mail, telex, or facsimile) and confirmed in writing to the
	other party's address specified in the SCC.
	31.2 A notice shall be effective when delivered or on the
	notice's effective date, whichever is later.
32. Taxes and	32.1 A Supplier supplying Goods from abroad shall be
Duties	entirely responsible for all taxes, stamp, duties, license
	fees, and other such levies imposed outside Iraq.
	32.2 A Supplier supplying Goods offered from within Iraq
	shall be entirely responsible for all taxes, duties, license
	fees, etc., incurred until delivery of the contracted Goods
	to the Purchaser. 32.3 The awarded company bears (the 2nd part that
	contracted with our company) all customs fees.
33. Withholding	33.1 Whenever any claim or claims for payment of a sum of
and lien in	money arises out of or under the Contract of Republic of
respect of	Iraq against the Supplier, the Purchaser shall be entitled
sums claimed	to withhold and also have a lien to retain such sum or
	sums in whole or in part from the security, if any,
	deposited by the Supplier and for the purpose aforesaid,
	the Purchase shall be entitled to withhold the said cash
	security deposit or the security, if any, furnished as the
	case may be and also have a lien over the same pending
	finalization of any such claim. In the event of the security
	being insufficient to cover the claimed amount or amounts
	or if no security has been taken from the Supplier, the
	Purchaser shall be entitled to withhold and have lien to
	retain to the extent of the such claimed amount or
	amounts referred to supra, from any sum or sums found
	payable or which at anytime thereafter may become
	payable to the Supplier under the same Contract or any
	other Contract with the Purchaser or the Republic of Iraq,
	pending finalization of any such claim and that The
	Supplier shall have no claim for interest or damages
	whatsoever on this account or on any other ground in
	respect of any sum of money withheld or retained under
	this clause and duly notified as such to the Supplier.



SECTION VIII. SPECIAL CONDITIONS OF CONTRACT

NOTES ON THE SPECIAL CONDITIONS OF CONTRACT

Similar to the Bid Data Sheet in Section II, the clauses in this Section are intended to assist the Purchaser in providing Contract-specific information in relation to corresponding clauses in the General Conditions of Contract (GCC).

The provisions of Section VIII complement the GCC included in Section VII, specifying contractual requirements linked to the special circumstances of thePurchaser Iraq, the sector, and the Goods purchased.

In preparing this section, the following aspects should be checked:

- (a) The correct version of the Special Conditions of Contract must be used as a base, dependent upon the type of Goods being procured.
- (b) Information that complements provisions of Section VII, GCC, must be incorporated
- (c) Amendments and/or supplements to provisions of Section VII, GCC, as necessitated by the circumstances of the specific purchase, must also be incorporated.}



Special Conditions of Contract

The following Special Conditions of Contract shall supplement the General Conditions of Contract. Whenever there is a conflict, the provisions herein shall prevail over those in the General Conditions of Contract. The corresponding clause number of the GCC is indicated in parentheses.

GCC 1.1 (h)	The Purchaser is: [Minstry of Health / Environment / The State Comany for Marketing Drugs and Medical Appliances (Kimadia)].
GCC 1.1 (m)	The Supplier is: [insert: name of Supplier].
GCC5	5.3 In addition to what has mentioned in ITB(instructions to bidders) the following will be added.
	1-Provide the second party with the official letters related to contract execution and first
	party will never be responsible about the results of these correspondences.
	2- adoption the original copy of the contract which is signed by the two parties and which is saved at the first party as it is the copy that will refer to in case of any misunderstanding.
	3- Submit the orginal commercial lists to the import department before shipment are sent for each shipment otherwise, the 1 st party will impose an import penity according to the text of article GCC 22
GCC6.2	The Effective Date of the Contract starts from date of signing the contract when
	1-Goods have already been registered. 2- excluded from registration
	It will be effective starting from the date of receiving the registration certificate if the goods to be submitted by the successful bidder upon signing the contract are not registered
GCC8	- Presentation of Performance bond:
	Submit the banking guarantee after the issuance of the letter of warding and keep
	valid all the period of the contract. The guarantee should not be cancelled unless
	there is a notification from Kimadia. A pledge should be submitted with the offer
	according to this matter.
	b-The Bank guarantee Should be issued by Iraqi governmental or private Iraqi Bank. These

Tender/Number: MED/ 3/2020 Contracting Entity:Ministry of Health / Environment / The State Company For Marketing Drugs Medical Appliances (kimadia)



reliable government banks do not have the right to issue bank guarantee to foreign company unless submitting a guarantee issued by foreign Bank (Back to Back) which has classification Issued by one of International classification organizations (Moody's standard and poor) and others or against monetary insurance not less than guarantee amount without the help of T.B.I . The guarantee should be in Arabic and English and the Arabic languages and the Arabic version should be the effective one. C-performance guarantee should be issued by the order of the company which contracted with or with its legal authorized person for issuing the guarantee in accordance with an official authenticated authorization submitted to the bank and included in the term of guarantee or attached letter issued by the issuing bank. d- The submission of the guarantee should be attached with an authentication letter of issuance (personal and confidential) send to kimadia by the bank who issued the guarantee. This guarantee should be unconditional and for the favor of (kimadia). Kimadia has the right to extend or confiscate the guarantee if required to do so, without any objection of correspondents or suppliers started from the first written claim e- The companies and scientific bureaus should take in consideration the following when issued the good performance guarantee:-1-The letters of guarantee should be issued by the name of the company which signed the contract exclusively. 2-Be sure that the contract no. is mentioned in the letter of guarantee. 3-the following statement should be written in the letter of guarantee (this guarantee is subject and explain in all matters according to the Iragi laws).

Tender/Number: MED/ 3/2020 Contracting Entity:Ministry of Health / Environment / The State Company For Marketing Drugs Medical Appliances (kimadia) Section VII. General Conditions of Contract

	4-The letter of guarantee should financially covered by the bank.
	5-Any letter of guarantee will not be received unless attaché with a formal letter issued
	by the bank who issued the letter of guarantee signed by the director of the bank
	or the one who represents him.
	6-The letter of guarantee should be written in (Arabic & English) and the Arabic language
	is the one to rely upon when having any dispute.
	7-It should be valid for one year from date of issuing.
	8-lt should not be direct or conditional.
	9- In case the supplier doesn't accept to make the modifications or extensions to the
	letters of performance guarantee or the supplier breaches, the amount of
	guarantee will be confiscated and deposit it in the account of our company.
	10-The letters of guarantee issued by the approved banks shall be received in
	accordance with a(bulletin —brochure) issued by central bank of Iraq.
	11-The letter of guarantee must be the same as the contract currency .
GCC8.3	The guarantee formula in item A of the general conditions of the contract is adopted , item (8.3) .
GCC9.1	In addition to what have been mentioned in the
	general conditions of the contract, the following
	are added:
	Receiving items will never be considered as confirmation for compliance to the
	specifications and technical conditions but it will relay on the results of laboratory tests
	issued by labs of Iraqi public health (National Center for control and medical research,
	Central Health Laboratory). After issuing the acceptance and testing decision by the
	central release committee formed for that purpose and not only the result of lab
	analysis.
	-Samples will be sent to national center for control and medical research, for test and

Contracting Entity:Ministry of Health / Environment / The State Company For Marketing Drugs Medical Appliances (kimadia) Republic of Iraq الله الكبر

Section VII. General Conditions of Contract

	evaluation and their results are reliable.
	-Standard analysis substances (i.e. B.P.C Rst U.S.P Rst E.U.C Rst) not working standard
	together with method and authenticated certificate of analysis are to be sent with the
	request to our national center for medicine control & research
	Any material or quantity that fails in the analysis as confirmed by our national center for control and medical research should be compensated by the supplier
GCC9.2	 "9.2.1. (a) Said inspection and testing is for the Purchaser's account. In the event that inspection and testing is required prior to dispatch, the Goods shall not be shipped unless a satisfactory inspection and quality control report has been issued in respect of those Goods. (b) The Supplier may have an independent quality test conducted on a batch ready for shipment. The cost of such tests will be borne by the Supplier. (c) Upon receipt of the Goods at place of final destination, the Purchaser's representative shall inspect the Goods or part of the Goods to ensure that they conform to the condition of the Contract and advise the Purchaser that the Goods were received in apparent good order. The Purchaser will issue an Acceptance Certificate to the Supplier in respect of such Goods (or part of Goods). The Acceptance Certificate shall be issued at the earliest within fifteen (15) days from the date of supplying material entrance to the place of supplying
	specified by the first party9.2.2. In case the supplier objection with the results of test carried out by the
	labrotatories referred to in pharagraph GCC9.1 the test shall be repeated at the centeral
	labrotatories of the public health and the results will be conclusive.
GCC10.2	Medical items should be shipped in a form of palette covered by nylon and placed on a wooden basis.
	- on the outside cover of the pack (pallet or big carton) the national code, order no.,
	and the quantity should be printed and on inside pack and small
	Pharmaceutical unit (ampoule or bottle or sheet) on good the mark of (MOH-Iraq),
	beneficiary name and shelf life(MF&Exp. Date) and to print (Batch no.) on all inside and
	outside packs as well as the smallest pharmaceutical unit.

Tender/Number: MED/ 3/2020 Contracting Entity:Ministry of Health / Environment / The State Company For Marketing Drugs Medical Appliances (kimadia)

-Pallets should be with the following dimension in order to facilitate the process of
receiving and storage of the arrived shipments.
*Length 1200 M.M
*Width 1000 M.M
*Height 1000 M.M (Including the height of pallet based(
*The weight of each pallet should be not more than 800 kilos
-All materials must be shipped in a cool condition and for all transporting ways till it
reaches MOH/Kimadia stores. The seller will be responsible for the compensation of any
material which fails in the analysis because of the unsuitable temperature degree during
the transportation
In addition to what mentioned, the following are added:
-All shipments should be attached with commercial shipping lists packing lists and a
true authenticated copy of certificate of origin.
-The supplier should submit the shipping documents before the arrival of the
consignment within a period not less than 15 days and be responsible for any shortage
or any delay caused by the lack of shipping documents.
-Delivery shall be as soon as possible within the period of credit validity and the shipping
schedule shall be as required of Kimadia
-Receiving the supplied items upon their arrival to MOH/ Kimadia stores and the
insurance of it (CIP) and not to be free from this obligation till organizing a formal minute
of finishing in the place of delivery agreed upon.
-The contract should be supplied with a limited number of lots and the quantity of each
lot should mentioned in the shipping list along with the manufacturing and expiry date.
-In case the item failed in the analysis of the national center for medicine control &

Section VII. General Conditions of Contract

research or any specialized party, the administrative charges will be added as equal to 15% from the total value of failed item with a delay fine in case the company will not ship the compensation item within the agreed period in the contract and with the agreed percentage.

- The supplier has to compensate the exp. QTY which are not used in stores of MOH and Kimadia stores at ratio 100% of the total QTY of exp. items.

-The seller should compensate the items failed in the analysis and the exp.. For technical reasons to the supplier at ratio 100% with 15% administrative charges from the total QTY of exp. items and impose a delay penalty in case not shipping the compensation QTY with same period and ratio which agreed upon in contract.

-The compensation for the expired materials shall be within aperiod determined by the order of the 1st party (the buyer / kim).

-Compensation for material failing to be analyzed shall be during the processing period & for the period stipulated in the contract from the date of notification thereof.

-The second party has to ensure the hidden defects or any failure in the product in duration parallel to shelf life of the product concerning the products subject for shelf life the and the products that do not subject for shelf life, the 2nd party has to ensure above defects for five years starting

from the date of receiving tests results.

-in case the company does not ship the compensation products within the same agreed period in the contract starting from the date of notifying him. The calculation of the shipping period per 2nd shipment will be started after the arrival of the compensated shipment if the contract was multiple shipments otherwise a delay penalty will be imposed according to the ratio that mentioned on the agreed penalties articles and in case the company has not compensate within the mentioned period, kimadia has the right to buy the products from another source on contractor expense and making him bear the difference in price and confiscate all insurance. In addition, it has the right to go to the concerned court in order to obtain its rights

-The seller is responsible to compensate the buyer for the defected items or shortage that appear after the distribution, usage of goods in the hospital and after the necessary checking and analysis and if it is due to a manufacturing defect.

-the seller should compensate the damaged , failed in analysis, missing, shortage items, and the items which not comply with specification required within delivery period stated in contract provided that the period starts from the date of notifying the company about the fail or shortage or missing taken into consideration that the period must be within the period of execution the contract and the other shipments must be shipped within the same shipping schedule from the date of shipping the compensation QTY otherwise the delay penalty will be imposed at the same percentage stated in penalties terms which agreed upon in case the company does not compensate within mentioned period, kimadia has the right to buy the products from another source on contractor expense and making him bear the difference in price and confiscate all insurance.

In addition, it has the right to go to the concerned court in order to obtain its rights.

-The seller must stamp the phrase (failed and not fit to consumption MOH-KIMADIA) on

the failure qty. or not compliance to specification in

MOH/ Kimadia stores on. The supplier shall bear all the expenses.

Any item or quantity that fails in analysis of the national center for medicine control & research is to be compensated by the manufacturer.

In case the item failed in the analysis or have been expired and the company does not respond for compensation within 15 days after sending a warning letter including the



	compensation & draw the failed or expired item, kimadia has the right to destroy the
	failed or expired items & dropping the right of the company for getting back the item or
	its value.
GCC 11.1	{ Sampleprovision (CIF/CIP/DDP terms) For Goods supplied from abroad:
& 11.3	 Upon shipment, the Supplier shall notify the Purchaser and the insurance company i writing the full details of the shipment including Contract number, description of th Goods, quantity, date and place of shipment, mode of transportation, and estimate date of arrival at place of destination. In the event of Goods sent by airfreight, th Supplier shall notify the Purchaser a minimum of forty-eight (48) hours ahead c dispatch, the name of the carrier, the flight number, the expected time of arriva and the waybill number. The Supplier shall fax and then send by express courier th following documents to the Purchaser, with a copy to the insurance company: (i) three originals and two copies of the Supplier's invoice, showing Purchaser as [enter correct description of Purchaser for customs purposes]; the Contract number, Good description, quantity, unit price, and total amount. Invoices must be signed i original, stamped, or sealed with the company stamp/seal; (ii) one original and two copies of the negotiable, clean, on-board through bill of ladin marked "freight prepaid" and showing Purchaser as [enter correct name c Purchaser for customs purposes] and Notify Party as stated in the Contract, with delivery through to final destination as per the Schedule of Requirements; (iii) four copies of the packing list identifying contents of each package; (iv) copy of the Insurance Certificate, showing the Purchaser as the beneficiary; in cas CIP, CIF. (v) one original of the manufacturer's or Supplier's Warranty Certificate covering a items supplied; and associated trading lists endorsed by the relevant Irac Commercial Agencies outside Iraq. For items originating from countries member ot the Arab Common Market, the certificates of origin and associated trading list endorsed by the competent country of origin authority shall be sufficient; (vii) original copy of the Certificate of Inspection furnished to Supplier by the nominate inspection agency and six copies (whe

Contracting Entity:Ministry of Health / Environment / The State Company For Marketing

Drugs Medical Appliances (kimadia)



Invoices must be signed in original and stamped or sealed with the company stamp/seal; two copies of delivery note, railway consignment note, road consignment note, (ii) truck or air waybill, or multimodal transport document showing Purchaser as [enter correct name of Purchaser] and delivery through to final destination as stated in the Contract; (iii) copy of the Insurance Certificate, showing the Purchaser as the beneficiary; four copies of the packing list identifying contents of each package: (iv) one original of the manufacturer's or Supplier's Warranty certificate covering all (v) items supplied; (vi) one original of the Supplier's Certificate of country of Origin covering all items supplied and associated trading lists endorsed by the relevant Iragi Commercial Agencies outside Iraq. Foritems originating from countries member of the Arab Common Market, the certificates of origin and associated trading lists endorsed by the competent country of origin authority shall be sufficient; original copy of the Certificate of Inspection furnished to Supplier by the nominated (vii) inspection agency and six copies (where inspection is required) (viii) other procurement-specific documents required for delivery/payment purposes. Note: In the event that the documents presented by the Supplier are not in accordance with the Contract, then payment will be made against issue of the Acceptance Certificate, to be issued in accordance with SCC 9 (GCC 9) above. GCC 15 15.1 "15.1 All goods must be of fresh manufacture and must bear the manufacture and expiry dates. The Supplier further warrants that all Goods supplied under this Contract unless otherwise specified by the contract, will have remaining a minimum of five-sixths (5/6) of the specified shelf life upon arrival to KIMADIA stores for goods with a shelf life of more than two years and the items with a shelf life of two years not more than 3 months (maximum) passed upon their manufacturing ; otherwise a financial penity will be imposed according to the ratios mentioned in pharagraph GCC22. 15.2 The Purchaser shall have the right to make claims under the above warranty for three months after the Goods have been delivered to the final destination indicated in the Contract. Upon receipt of a written notice from the Purchaser, the Supplier shall, with all reasonable speed, replace the defective Goods without cost to the Purchaser.



Section VII. General Conditions of Contract

	The Supplier will be entitled to remove, at his own risk and cost, the defective Goods
	once the replacement Goods have been delivered.
	15.3 Not applicable (In the event of a dispute by the Supplier, a counter analysis will be
	carried out on the manufacturer's retained samples by an independent neutral
	laboratory agreed by both the Purchaser and the Supplier. If the counter analysis
	confirms the defect, the cost of such analysis will be borne by the Supplier as well as the
	replacement and disposal of the defective goods. In the event of the independent
	analysis confirming the quality of the product, the Purchaser will meet all costs for such
	analysis.)
	 15.4 If, after being notified that the defect has been confirmed pursuant to GCC Sub-Clause 15.2 above, the Supplier fails to replace the defective Goods within the period for the replacement of defective goods of [insert period for replacement of defective goods], the Purchaser may proceed to take such remedial action as may be necessary, including removal and disposal, at the Supplier's risk and expense and without prejudice to any other rights that the Purchaser may have against the Supplier under the Contract. The Purchaser will also be entitled to claim for storage in respect of the defective Goods for the period following notification and deduct the sum from payments due to the Supplier under this Contract. 15.5 Recalls. In the event any of the Goods are recalled, the Supplier shall notify the
	Purchaser within fourteen (14) days, providing full details of the reason for the recall and promptly replace, at its own cost, the items covered by the recall with Goods that fully meet the requirements of the Technical Specification and arrange for collection or destruction of any defective Goods. If the Supplier fails to fulfill its recall obligation promptly, the Purchaser will, at the Supplier's expense, carry out the recall."
GCC16.1	 <u>{Sample provision:</u> The method and conditions of payment to be made to the Supplier under this Contract shall be as follows: <u>{In case the Supplier is a Public Entity (Public Sector Company)</u>, do not apply then the Contracting Entity may increase the Advance Payment to x% from the value of contract.and according to instructions } A. Payment for Goods supplied from abroad: Payment of foreign currency portion shall be made in [USD and ID]in special exception cases in the following manner: (i) Advance Payment: (not applied) section VIII (ii) On Shipment the purple of the purple
	(ii) On Shipment: the purchaser should pay to the supplier according to percent of the Contract Price of the Goods shipped shall be paid through irrevocable confirmed letter of credit opened in favor of the Supplier in a bank in its country, upon submission of documents specified in GCC Clause 11. Opening charges and charges

Tender/Number: MED/ 3/2020

Contracting Entity: Ministry of Health / Environment / The State Company For Marketing

Drugs Medical Appliances (kimadia)



	for amendment of the letter of credit at the request of or due to a fault or default of the Purchaser are for the account of the Purchaser. Confirmation charges and charges for amendment to letters of credit at the request of or due to a fault or default on behalf of the Supplier are for the account of the Supplier. - Payment terms:
	50% upon submitting shipping documents.
	- 50% after the arrival of materials to the warehouses of kimadia and acceptance.
	and release award
	shall be paid within [thirty (30)] days of receipt of the Goods upon submission of an invoice (showing Purchaser's name; the Contract number, description of payment and total amount, signed in original, stamped or sealed with the company stamp/seal) supported by the Acceptance Certificate issued by the Purchaser.
	B. Payment for Goods and Services supplied from within the Iraq: Payment for Goods
	and Services supplied from within Iraq shall be made in Iraqi Dinar, as follows upon
	receiving the financial allocation:
	1 -It is 100% after examination and acceptance and after financial allocation has been recieved
	2-the conditions which are mentioned above will be agreed on by the two parties as per
	kind of item & contract amount.
GCC16.3	The payment or payments will be settled as soon as possible after receiving the result of the laboratory tests according to the conditions of the announcement
GCC18	18.2 the contracting entity may increase the quantity of goods or materials or non- consulting services or amend its technical specifications which contracted upon by not more than 20% of the contract amount .
GCC19	19.1 - In addition to what have been mentioned in the general conditions of the contract,
	the following are added:
	any change is not allowed in contract by the supplier unless there is an agreement



	between the two parties otherwise the 2nd party considered a breach of his contractual
	commitments and kimadia has the right to take the legal procedures or impose penalty
	at ratio not less than 1% and
	not more than 5% for shipping quantity of the arrival item which not comply with our contractual conditions.
GCC 20.1	can not be waived of contract or apart of it
GCC21	21.2in addition to what mentioned in the general conditions of contract,
	the following reasons should be taken into consideration upon extension the contract:
	<u>First</u> :
	A. If any increase or change occurred in The required supplying quantity(qualitative,
	quantitative) which may effect the executing program which has been agreed upon as it
	can not be fulfilled within the agreed period in the original contract.
	B. If the delay of executing the contract related to reasons or procedures of the
	contracting party or any authorized legal party or to any reason of other contactors
	which the company owner used.
	C.If an exceptionable condition have occurred after contracting which is out of
	contractors control and which can't be avoided or expected upon contracting and
	which caused a delay in completing the works or supplying the required items
	according to the contract.
	<u>Second</u> :
	The application of the provisions of this article stipulated that the supplier should submit a written request for contracting party within 15 days started from the date of the cause arising which accordingly the extend has been requested indicating in it the accurate and complete details for any request to extend the period, Any request for extension will not be accepted if presented after issuing the primary receiving certificate mentioned in the



166

	contract conditions
GCC22	22.1 <u>First:</u> contract penalties:
	1- KIMADIA has the right to impose penity not less than 1% and not more than 5% from the amount of material shipped in case of :
	a-Any change in the contract by the supplier without the consent of the first party as mentioned in paragraph GCC 19.1
	b-In case of any shourtage in any document required from the supplier
	c-In case of contrary to paragraph 15.1 regarding to life of material
	d-In case of contrary to paragraph GCC10 regarding to packaging and shipment
	e- In case of contravention by the supplier (second party) need to impose penalty from the first party
	<u>second:</u> Delay penalties
	a- delivery in accordance with the scheduling of shipping and delivery
	mentioned in the paragraph of delivery and shipping and otherwise impose a delay day without prior notice and according to the following equation:
	Amount of contract (original amount of contract + any amendment in
	amount) / the total duration of contract (original duration of contract + any change in duration) x 10% = fine per day that does not exceed 10%from
	amount of contract . After the delay penalty reaches its maximum , legal
	actions can be used according to articles 10,3 from the instructions of implementing the governmental contracts no.(2) year 2014
	b-The delay penalty shall be deducted upon expiry of the original contract period with any additional period or upon desert in case of parial shippment
	c- Penalties are reduced according to the completion rates of the contractual
	obligation specified in the text of implementing the contracts which has a



Section VII. General Conditions of Contract

	certificate of first delivery according to the following equation :-
	The value of not implemented commitment /total duration of contract X
	10% =fine per day
	-When the contracted company hide any essential information which will be
	discovered later on , legal procedures will be taken or imposing a penalty at rate not less
	than 1% and not more than 5% of the quantity shipped for the arrived material and
	violated of our contractual conditions.
GCC23	23.1 In addition to what is stated in this item of the general condition: In case the supplier does not respond during the warning period and through the approved email which is written down in the contract the legal procedures shall be taken in accordance with the provisions of article 10 of the instruction of implementing the governmental contractno.2 in 2014 with respect to the confiscation or retention of legal insurance provided that the contract is executed on his expense according to the conditions of
	article 3 of the above instruction and according to the methods of implementation
GCC24	Item 24 G of the general conditions does not apply
GCC27.2.2	This cluse from general conditions contract it should be as:
	 for contracts with Supplier national of Iraq: "In the case of a dispute between the Purchaser and a Supplier who is a national of Iraq, the dispute shall be referred to conciliation or arbitration in accordance with the laws of the Iraqi Laws and guardianship of the Iraqi judicial system and according to adopted procedures."] -Any amount in the second party account which resulted from breaching any contractual
	commitment the first party has the right to claim the amount in the specialized court as
	well as the confiscation in case the requirements have been achieved
	- In case of the bidder has not complied with executing the conformed order and according to the agreed conditions a legal procedure will be taken against him.
GCC28	Deleted
GCC31.1	Kimadia email is: dg@kimadia.iq Insert :the supplier's address for the purpose of notifying and if by cable is acceptable provided that it should be followed by a written letter

	-The scientific bureau which represents the company and authorized representative of the company (Trade manager, manageretc) is the one to which the Judicial notifications will be sent. -email is considered one of the approved methods of directing warning
GCC32	 The Government debts are picked up in accordance with the Iraqi Law for collecting government debts No.56 of year 1977 The Contract is subject to Iraqi laws including laws of tax No. 113 for the year 1982, instruction of accounting tax of contracts between Iraqi contracting entry with foreign parties N02 for the year 2008, the stamp fee N071 for the year 2012, Notary fees and re-announcement charges. 1- Earning an amount of (100) hundred thousand Iraqi Dinars upon request for exchanging the border outlet. 2- Earning an amount of (25) twenty five thousand Iraqi Dinars for each unloaded and loading receipt for each shipment that arrived to the target store 3- Earning an amount of (10) ten thousand Iraqi Dinars for parking and parking overnight for the trucks that specified for transporting the drug and appliances to the stores of kimadia/Ministry of Health. 4- Earning an amount of (250) two hundred fifty thousand Iraqi Dinars for each objection request presented by the Scientific Bureau or company for any Importing status. - All bank charges (opening, issuing for L/C and amendments feesetc) inside and outside Iraq are on the seller expenses till reaching the company stores
) all customs fees.



Special Conditions of Contract PHARMACEUTICALS (Additional Clauses)

{ Note: The below of	data should be included in the Special Conditions of Contract used in
Bidding Documents	for the procurement of pharmaceuticals, otherwise, delete
GCC 11.1 & 11.3	For Goods supplied from abroad:
	(ix) One original of the Certificate of Pharmaceutical Product as
	recommended by the WHO for each of the items supplied.
	(x) Certificate of quality control test results in conformity with
	the World Health Organization "Certification Scheme on
	the Quality of Pharmaceutical Products Moving in
	International Trade" stating quantitative assays, chemical
	analysis, sterility, pyrogen content, uniformity, microbial
	limit, and other tests as appropriate to the Goods.
	(xi) Original copy of the certificate of weight issued by the port
	authority/licensed authority and six copies.
i	



	Special Conditions of Contract VACCINES (Additional Clauses)
GCC 11.1 & 11.3	 For Goods supplied from abroad: (ix) one copy of the Lot Release Certificate issued by the NCA of the country of manufacture for each lot shipped. (x) Certificate of quality control test results in conformity with the World Health Organization "Certification Scheme on the Quality of Pharmaceutical Products Moving in International Trade" stating quantitative assays, chemical analysis, sterility, pyrogen content, uniformity, microbial limit, and other tests as appropriate to the Goods. (xi) Original copy of the certificate of weight issued by the port authority/licensed authority and six copies. For Goods from within the Purchaser's country: (x) one copy of the Lot Release Certificate issued by the NCA of the country of manufacture for each lot shipped.
GCC 15.1	[Sample clauses: The Purchaser reserves the right to request evidence of bio- availability and/or bio-equivalence data and/or evidence of the basis for expiration dating and other stability data concerning the Goods to verify shelf life claimed for the Goods. If an adverse event following immunization (AEFI) occurs in the Purchaser's country and the cause of such event cannot be immediately established, the Purchaser will, with all urgency and in accordance with the procedures laid down by the NCA of the Purchaser's country, take steps to advise the Supplier in order that an investigation may be launched immediately. If the vaccine has been supplied through an agency of the United Nations, the most current procedures laid down by the WHO for such situations will be used.]
	The awarded company bears (the 2 ¹¹⁰ part that contracted with our company) all customs fees.



SECTION IX. CONTRACT FORMS

NOTES PREPARING THE CONTRACT FORMS

The Sample Contract Forms provided in this SSBD provide standard formats for a number of the key documents that the Purchaser and Supplier will exchange in the process awarding and implementing the Contract.

Form of Contract Agreement: Except as indicated by blanks and/or instructions to fill in information, the text of the Contract Agreement should be left unaltered in the Bidding Documents from how it appears in this SSBD. It would be at the time of Contract award when the Contracting Entity has an opportunity to add the final details needed in the Contract Agreement form, by making any necessary insertions or changes to paragraph 2.

Performance Security Form: Pursuant to GCC Sub-Clause 8.1, the successful Bidder is required to provide the performance security within fourteen (14) daysof notification of Contract award, or twentynine (29) days in case of Complaints and Appeal as per ITB 36.1.

Advance Payment Bank Guarantee: Pursuant to GCC Sub-Clause 16.1, the successful Bidder is required to provide a bank guarantee securing the advance payment, if SCC related to GCC Sub-Clause 16.1 requests for one.



CONTRACT FORMS

- 1. Form of Contract Agreement
- 2. Performance Security Bank Guarantee
- 3. Bank Guarantee Form for Advance Payment



1. Form of Contract Agreement

THIS CONTRACT AGREEMENT is made

the [insert: **number**] day of [insert: **month**], [insert: **year**].

BETWEEN

(1) [The State Company For Marketing

Drugs Medical Appliances represent by the general manager and chairman of the board in addition to his job], a [insert: **description of type of legal entity**, for example, an agency of the Ministry of of the Government of Iraq, or corporation incorporated under the laws of Iraq and having its principal place of business at [insert: **address of Purchaser**] (hereinafter called "the Purchaser"), and

(2) [insert: name of Supplier], a corporation incorporated under the laws of [insert: country of Supplier] and having its principal place of business at [insert: address of Supplier] (hereinafter called "the Supplier").

WHEREAS the Purchaser invited bids for certain goods and ancillary services, viz., [insert: brief description of goods and services] and has accepted a bid by the Supplier for the supply of those goods and services in the sum of [insert: contract price in words and figures] (hereinafter called "the Contract Price").

NOW THIS AGREEMENT WITNESSETH AS FOLLOWS this agreement confirm that the two parties are agreement as follow :

- 1. In this Agreement words and expressions shall have the same meanings as are respectively assigned to them in the Conditions of Contract referred to.
- 2. The following documents shall constitute the Contract between the Purchaser and the Supplier, and each shall be read and construed as an integral part of the Contract:
 - (a) This Contract Agreement
 - (b) Special Conditions of Contract
 - (c) General Conditions of Contract
 - (d) Technical Requirements (including Technical Specifications)
 - (e) The Supplier's bid and original Price Schedules
 - (f) Schedule of Requirements
 - (g) The Purchaser's Notification of Award
 - (h) [Add here: **any other documents**]
- 3. In consideration of the payments to be made by the Purchaser to the Supplier as hereinafter mentioned, the Supplier hereby covenants with the Purchaser to provide the Goods and Services and to remedy defects therein in conformity in all respects with the provisions of the Contract.
- 4. The Purchaser hereby covenants to pay the Supplier in consideration of the provision of the Goods and Services and the remedying of defects therein, the Contract Price or such other sum as may become payable under the provisions of the Contract at the times and in the manner prescribed by the Contract.

For and on behalf of the Purchaser Signed:

in the capacity of [insert: title or other appropriate designation]

in the presence of _

For and on behalf of the Supplier

Signed:

in the capacity of [insert: **title or other appropriate designation**] in the presence of



CONTRACT AGREEMENT Dated the [insert: number] day of [insert: month], [insert: year] BETWEEN [Insert: name of Purchaser], "the Purchaser" and

[insert: name of Supplier], "the Supplier"



2. **Performance Security Bank Guarantee**

[The Bank shall fill in this Bank Guarantee Form in accordance with the relevant conditions of Contract.] & it prefer us the central Iragi Bank form .

[insert: Bank's Name and Address of Issuing Branch or Office] Beneficiary: _____ [insert: Name and Address of Purchaser]

Date: ____

PERFORMANCE GUARANTEE No.:

We have been informed that [insert: name of Supplier] (hereinafter called "the Supplier") has entered into Contract No. [insert: reference number of the contract] dated ______ with you, for the supply of [insert: description of goods] (hereinafter called "the Contract").

Furthermore, we understand that, according to the conditions of the Contract, a performance guarantee is required.

At the request of the Supplier, we [insert: name of Bank] hereby irrevocably undertake to pay you any sum or sums not exceeding in total an amount of [insert: amount in figures] (____) [insert: amount in words] upon receipt by us of your first demand in writing accompanied by a written statement stating that the Supplier is in breach of its obligation(s) under the Contract, without your needing to prove or to show grounds for your demand or the sum specified therein.

This guarantee shall expire no later than the ____ day of month _ , 2____, and any demand for payment under it must be received by us at this office on or before that date.

This guarantee is subject to the Uniform Rules for Demand Guarantees, ICC Publication No. 458, except that subparagraph (ii) of Sub-article 20(a) is hereby excluded.

[signature(s)]



3. Bank Guarantee Form for Advance Payment

[The Bank shall fill in this Bank Guarantee Form in accordance with the relevant conditions of Contract.] & it prefer us the central Iraqi Bank form .

[insert: Bank's Name and Address of Issuing Branch or Office] [insert: Name and Address of Purchaser]

Beneficiary: ____ Date:

ADVANCE PAYMENT GUARANTEE No.:

We have been informed that [insert: **name of Supplier**] (hereinafter called "the Supplier") has entered into Contract No. [insert: **reference number of the contract**] dated ______ with you, for the supply of [insert: **description of goods**] (hereinafter called "the Contract").

Furthermore, we understand that, according to the conditions of the Contract, an advance payment in the sum [insert: **amount in figures**] (_____) [insert: **amount in words**] is to be made against an advance payment guarantee.

At the request of the Supplier, we [insert: **name of Bank**] hereby irrevocably undertake to pay you any sum or sums not exceeding in total an amount of [insert: **amount in figures**] (____) [insert: **amount in words**] upon receipt by us of your first demand in writing accompanied by a written statement stating that the Supplier is in breach of its obligation under the Contract because the Supplier used the advance payment for purposes other than toward delivery of the goods.

It is a condition for any claim and payment under this guarantee to be made that the advance payment referred to above must have been received by the Supplier on its account number ______ at ______ [insert: name and address of Bank].

This guarantee shall expire, at the latest, upon our receipt of copy (ies) of _____1, or on the ____ day of _____, 2___,² whichever is earlier. Consequently, any demand for payment under this guarantee must be received by us at this office on or before that date.

This guarantee is subject to the Uniform Rules for Demand Guarantees, in Iraq

[Signature]

¹ Insert documents establishing "delivery" of the goods in accordance with the particular INCOTERMS® selected. (See SCC 11.)

² Insert the delivery date stipulated in the original delivery schedule. The Purchaser should note that in the event of an extension of the time to perform the Contract, the Purchaser would need to request an extension of this guarantee from the Guarantor. Such request must be in writing and must be made prior to the expiration date established in the guarantee. In preparing this guarantee, the Purchaser might consider adding the following text to the form, at the end of the penultimate paragraph: "The Guarantor agrees to a one-time extension of this guarantee for a period not to exceed [six months/one year], in response to the Purchaser's written request for such extension, such request to be presented to the Guarantor before the expiry of the guarantee."